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Anatomy and physiology of the human skin 
The skin is the largest organ of the human body. It has many functions beyond the primary vital 
function of being a protective barrier between the internal body and the external environment. 
The skin also has important roles in temperature regulation, endocrine, immunological and 
sensory functions, and ultraviolet (UV) radiation protection. The composition of the skin is 
characterized by several distinctive structural layers. The outer layer, the epidermis, is a stratified 
epithelium. The epidermis is supported by a layer of connective tissue, the dermis. Underneath the 
dermis is a layer of subcutaneous fat, also called hypodermis. The interface between the dermis 
and the epidermis shows dermal projections into the epidermis, forming dermal papillae and 
epidermal rete ridges (Figure 1). The total thickness of the epidermis varies between 50 and 150 
μm, depending on the anatomical location, whereas the dermal thickness varies between 1.5 mm 
and 4 mm.  
The dermis is mainly composed of collagen. In addition, this supporting matrix of the epidermis 
contains elastic fibers (elastin) and glycoproteins and glycosaminoglycan/proteoglycan 
macromolecules. Collagen represents approximately 80–85% of the dry weight of the dermis and 
is responsible for the great tensile strength of the skin. Collagen type I is the most abundant type 
of collagen in the dermis, whereas collagen type IV is essentially located in the basement 
membrane of dermis-epidermis junction.2,3 Glycosaminoglycan and proteoglycan macromolecules 
in the dermis are responsible for the significant ability of this layer to retain water.2 The dermis has 
 
Figure 1. Schematic cross section of skin. Adapted from 1. 
10 | C h a p t e r  1  
 
a very rich blood supply, presenting a superficial and a deep vascular plexus and a rich network of 
lymphatic vessels. The two vascular plexus are interconnected by vertical vessels and have 
branches to vascularize the dermal papillae.4  
The epidermis contains different types of cells: (1) keratinocytes, the generic cell type of the 
epidermis that are dynamically regenerative; (2) melanocytes, which are responsible for the 
production of melanin, the natural pigment of the skin; (3) Langerhans’ cells, which are antigen-
presenting cells and have a role in immune response in the skin; and (4) Merkel cells, which act as 
sensory mechanoreceptors.5,6  
The epidermis is not vascularized. This layer is under constant renewal, with a cycle time of 
approximately 30 days. Renewal of the epidermis involves a continuous process of generation, 
terminal differentiation and desquamation of keratinocytes. These are the generic cell type of the 
epidermis. Keratinocytes produce keratin and the major cellular constituent of the epidermis. The 
epidermis has morphologically different sub-layers reflecting the state of differentiation, as shown 
in Figure 2. Keratinocytes originate from stem cells located in the lowermost cell layer of the 
epidermis, the basal layer (stratum basale). In a process of maturation, keratinocytes migrate 
upward from the stratum basale, where keratinocytes are cuboid cells that have large, dense nuclei 
and an high mitotic rate. It usually constitutes a single cell layer. As the keratinocytes progress 
upward in their differentiation process, they show an increasing number of bundles of keratin 
filaments. Those filaments are extended, forming desmosomes, to bound to surrounding 
keratinocytes, what confers the spiny aspect of these cells in the stratum spinosum layer.2,4 Upward, 
there is the stratum granulosum that is characterized by few layers of flattened polygonal cells 
filled with keratohyalin granules, a precursor of insoluble keratin.4,7 The outermost layer of skin, the 
stratum corneum, is composed by many layers of corneocytes, flattened non-nucleated keratinized 
cells without cytoplasmatic organelles. In these cells, there is an increase of cellular compaction 
and crosslinking of keratin with transglutaminases to form an insoluble keratin matrix that, 
together with lipids (fatty acids, sterols, ceramides) and cornified-envelope proteins form the 
stratum corneum.2,8 This cornified cells and its surrounding intracellular substances are responsible 
for the permeability characteristics of the skin.2 
Melanocytes are mostly located in the basal layer. Apart from producing melanin, they use their 
dendrites to distribute this pigment to the surrounding keratinocytes.2 Their dendrites extend to 
the upper layers of the epidermis, into the interstices, establishing contact with keratinocytes.4,9 
Each melanocyte is associated with approximately 30-36 keratinocytes, forming the epidermal 
melanin unit.9,10 The production and storage of melanin occur in the melanosome, an intracellular 
lysosome-like structure.11,12  
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Figure 2. Schematic representation of the epidermal layers. 
 
The process of melanin synthesis is regulated by tyrosinase, which is an enzyme that converts 
tyrosine firstly into 3,4-dihydroxyphenylalanine, then into dopaquinone, which is then converted 
into melanin after a series of transformations.5 Once mature, the highly dense melanin granules 
migrate within the melanocytes dendrites to be transferred to nearby keratinocytes. Inside the 
keratinocyte, melanin accumulates in the supranuclear region of the cytoplasm, thereby 
protecting the DNA in the nucleus from the damaging effects of UV radiation.4 One of the most 
important functions of the skin is to protect the body from the UV radiation. The hazard of UV 
radiation in human skin cells is due to the propensity of DNA to absorb UV radiation, which can 
result in DNA damage and lead to the formation of mutations in the highly mitotic active cells of 
the epidermis.9,11 The synthesis of melanin by melanocytes is stimulated by UV radiation.13 Melanin 
scatters and absorbs a wide spectrum of UV radiation and specifically protects the nucleus, which 
harbors the cell’s DNA.  
There are a multitude of lesions that can appear in the skin. Skin lesions can have several origins, in 
different types of cells. In this thesis, we confine on the pigmented skin lesions that have their 
origin in the melanocytes.  
 
Melanocytic lesions 
Melanocytic lesions are lesions with origin in the proliferation of melanocytes. They can vary 
between benign lesions, also termed melanocytic nevi, to malignant lesions, termed melanomas.13  
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Benign melanocytic lesions: nevi 
Benign melanocytic nevi, commonly called moles, can be congenital or acquired.14 Acquired nevi 
are the most common form of benign melanocytic lesions, which tend to appear during childhood 
or teenage years and appear more often in sun-exposed areas of the body.13 It is known that sun 
protection measures can reduce their incidence, which implies that exposure to UV-radiation can 
be a pathogenic factor for melanocytic nevi formation.13 Mutations in the BRAF gene (gene 
responsible for encoding the BRAF protein, from the RAF protein family, whose role is cell growth 
control), can be found frequently both in acquired benign and malignant melanocytic lesions. This 
mutation has an important role in the initial proliferation of melanocytes in melanocytic lesions.15  
Dysplastic melanocytic nevi are melanocytic lesions that present clinically or histologically some 
degree of irregularity or architectural disorder at the cell level.16-18 The term dysplastic is used as 
histological description whereas atypical nevus is a clinical description.19 Sometimes the terms can 
be used interchangeably. In recent literature, dysplastic nevi are also termed as intermediate 
neoplasms.13 A clinically atypical melanocytic nevus is a lesion larger than 5 mm showing irregular 
border and irregular pigmentation with a degree of inflammation. The histopathological 
description of a dysplastic nevus includes a description of an architectural disorder with individual 
or clustered melanocytes distributed at all levels within the epidermis and possibly from the 
papillary dermis into the lower dermis and elongation of epidermal rete ridges.19,20 There is debate 
among the field about whether dysplastic nevi are biologically intermediate lesions between 
common nevi and unequivocal melanoma.13  
Very often the clinical differentiation between benign melanocytic lesions and melanoma can be 
challenging, even for experienced dermatologists. 
 
Malignant melanocytic lesions: melanoma 
Epidemiology 
Melanoma is the most fatal form of skin cancer. Yearly 232,000 new cases of melanoma are 
diagnosed worldwide and 55,488 deaths are reported.21 The melanoma incidence has been 
steadily increasing in the last decades. The incidence varies significantly worldwide, with the 
Caucasian population affected most and the dark-skinned and Asian populations with the lowest 
incidence.21 Although it is not the most common type of skin cancer, melanoma is the most 
aggressive and lethal form of skin malignancy. It is preferably diagnosed at an early stage because 
of the high risk of metastasis at a later stage. In more advanced stages melanoma is in almost all 
cases incurable.22-24 Even though normal melanocytes can be found in non-cutaneous tissues (e.g. 
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in the eye) and in mucosal tissues (oral cavity, esophagus, nasal cavity and sinuses, genitals, and 
anus),25 this thesis focuses on cutaneous melanoma only.  
Melanomas may arise without having any pre-existing lesion (de novo) or can result from an 
evolution of an already existing lesion, usually from a melanocytic nevus (in approximately 25% of 
the cases).26 
Melanomas can be categorized in: (1) those originated in skin that is chronically damaged by long-
term exposure to UV radiation (chronic sun damage, CSD melanomas), or (2) those arising in 
intermittently sun-exposed skin but not chronically damaged by UV radiation (non-CSD 
melanomas).13,27 CSD melanomas appear mainly in the head and neck region and on the dorsal 
side of distal extremities, and is more common in individuals >55 years.13,27 On contrast, non-CSD 
melanomas commonly arise on the trunk of proximal extremities in younger individuals.13,27 This is 
the most common subtype of melanoma in the Caucasian population.27 
 
Risk factors 
The risk of developing melanoma is determined by a combination of environmental risk factors, 
most importantly exposure to UV radiation, number of sunburns at a young age, and host risk 
factors.  
Genetic predisposition is an important host risk factor and several specific mutations have been 
identified which significantly increase the risk of developing melanoma.13,14,28 Most of the non-CSD 
melanomas are BRAF-mutant. Several studies on genetics of melanoma report that BRAF-mutant 
melanomas are more likely associated with the presence of multiple melanocytic lesions than non-
BRAF-mutant melanomas, suggesting that this mutation is per se insufficient to contribute to 
melanoma development.27,29-31 A family history of melanoma is also related to an increased risk of 
developing melanoma, especially in first-degree relatives. Several genes are associated with the 
higher predisposition in melanoma families.32 
The number and type of nevi are another host risk factors. A meta-analysis performed by Gandini 
et al. on risk factors for cutaneous melanoma based on 46 studies, concluded that subjects that 
have more than 100 common nevi have up to seven times increased risk of melanoma compared 
with subjects with a lower number of common nevi (<15).33 Individuals that present multiple 
atypical/dysplastic melanocytic nevi, usually more than 50, especially in conjunction with a family 
history of melanoma, are at an even greater risk of developing melanoma.28 Although high-grade 
dysplastic nevi are associated with an increased risk of developing melanoma, 19,20,34 there is still 
debate whether dysplastic nevi are precursors of melanoma.17,18 This is reflected in a lack of clinical 
management agreements about excision of dysplastic lesions. 35,36  
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Melanoma stages 
Melanoma typically develops in three histological stages. In an earlier stage, the neoplastic 
melanocytes are confined to the epidermis (melanoma in situ). In a melanoma in situ, the 
melanocytes can be distributed across the full thickness of the epidermis (pagetoid spread). Some 
malignant cells can start spreading horizontally within the epidermis (radial growth phase).19 In an 
early stage, the melanoma cells still do not spread into the dermis (melanoma in situ). In a later 
stage, the spreading of malignant cells proliferates into the dermis (vertical growth phase), which 
is the start of the invasive stage in which tumor cells can invade vessels and metastasize.19,23,24 
Invasive melanoma can be potentially lethal.  
Breslow thickness is the most important prognostic factor because it strongly correlates with the 
metastatic propensity. It is defined as the distance between the stratum granulosum of the 
epidermis and the deepest melanoma cell. The staging of melanoma relies on the Breslow 
thickness.37-39 
According to the 8th edition of the American Joint Committee on Cancer, melanomas with a 
Breslow thickness < 0.8 mm can be treated surgically with a high cure rate and 5-year survival of 
97-99%.40 In contrast, the 5-year survival rate decreases rapidly to approximately 69% for 
melanomas with a Breslow thickness of 4 mm.40 Patients with thicker melanomas and signs of 
distant metastasis have a 5-year survival rate < 30%.40  
 
Classification of melanoma  
The historical classification of melanoma is based on its clinical and histological characteristics,22,23 
comprising superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma, nodular 
melanoma and other less common melanomas in mucosal sites.  
Superficial spreading melanoma (SSM) is the most common type of cutaneous melanoma, 
especially among fair-skinned individuals. It is most often seen on the trunk of men and on the 
legs of women.25,41 The main clinical features of the SSM consist of an irregularly pigmented 
macula with well-defined but irregular borders, and sometimes a raised plaque. Histologically, 
SSM is characterized by spreading of malignant melanocytes across the full depth of the 
epidermis, with an irregular distribution of either single malignant cells or nests of cells.22,23  
Lentigo Maligna is a subtype of melanoma in situ and is seen most frequently on sun-exposed skin, 
especially in head and neck regions. Lentigo maligna is the precursor of a histological subtype of 
melanoma, the Lentigo Maligna Melanoma. In clinical evaluation, lentigo maligna is typically 
recognized by a varying brown macula with irregular borders and located on regions of severe sun 
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damaged skin. The main histological characteristic of lentigo maligna is a spread of atypical 
melanocytes along the dermal-epidermal junction. When lentigo maligna is invasive it is called 
lentigo maligna melanoma.23  
Acral Lentiginous Melanoma shows histological similarity to lentigo maligna melanoma, with the 
distinguishing difference that acral lentiginous melanoma is located on non-hair bearing regions 
such as palms, soles or subungual sites. The acral lentiginous melanoma can show both a radial 
and a vertical growth phase. The most common clinical features are very irregular borders of a 
pigmented macula, varying colors of the macula, and an elevated nodule with or without 
ulceration.23 Histological features are characterized by large and atypical melanocytes with long 
dendrites and aberrant?nuclei disposed along the basal layer. Not uncommon is the migration 
upwards of nests of malignant cells towards the stratum corneum. 
The Nodular Melanoma is the only class of melanoma that has a minimal radial growth phase and 
an extensive vertical growth phase.19,20,23 Clinically, this type of melanoma presents a rapid 
growing nodule, which is usually well-defined and symmetrical. It may present black or blue color. 
The histological features include a dense invasion into the dermis with the radial growth not being 
wider than the width of three dermal papillae.23,42  
Figure 3 depicts the clinical presentation of the different classes of melanomas described above.?
 
The problem: diagnosis of suspicious melanocytic lesions 
The earliest possible clinical diagnosis of melanoma is of utmost importance for a good prognosis 
for the patient, to dramatically reduce the risk of dying from this disease. Nevertheless, 
discrimination of melanoma from benign melanocytic lesions can be challenging, even for 
experienced dermatologists. The first examination and clinical diagnosis of melanoma is based on 
visual inspection and recognition of its most common morphological characteristics, sometimes 
aided by dermoscopy. There are a variety of different algorithms that list and score the most 
common morphological characteristics of melanoma. Such algorithms and lists are used by 
dermatologists to recognize structures and help to establish a clinical diagnosis.  
One of the most known algorithms is the ABCDE rule, which describes the following clinical 
characteristics of melanomas: (A) Asymmetrical shape, (B) irregular Borders, (C) irregular 
pigmentation (Colour), (D) Diameter often > 5 mm, and (E) Evolution of lesion over time. Other 
algorithms may include the presence of irregular dots, the possible presence of regression 
structures and atypical vascular pattern.22-24,43,44 However, some melanomas lack common clinical 
features and therefore, are difficult to diagnose.45  
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Figure 3. Examples of clinical presentation of melanomas. a-b) superficial spreading melanoma, c-d) lentigo 
maligna melanoma, e-f) acral lentiginous melanoma, g-h) nodular melanoma. (photographs kindly supplied 
by dr. R. van Doorn, LUMC, The Netherlands). 
Because the clinical distinction between melanoma and benign pigmented lesions can be so 
difficult, and because of the severe consequences for the patient if an early melanoma is 
misdiagnosed, all suspicious lesions are excised for histopathological diagnosis to avoid the risk of 
missing a melanoma. The fact that most melanomas closely resemble benign melanocytic lesions 
and that clinical diagnosis is done by visual inspection of morphologic aspects results in a far-
from-perfect diagnosing accuracy.46?
The clinical accuracy depends on: (1) the detected true positive (TP) cases, (2) the missed true 
melanoma cases that were not identified during the clinical diagnosis (false-negatives, FN) and (3) 
the excised suspicious lesions that turn out benign after histopathological evaluation (false-
positives, FP).  
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The number needed to treat (NNT) that is the number of benign pigmented lesions excised to 
detect one melanoma, varies between 4-15 for melanoma diagnosis by dermatologists and 
between 20-30 for general practitioners.47-55 The NNT can be even higher in a population of young 
patients with less than 30 years (NNT = 75) or in high-risk populations (e.g. familial melanoma).49-
53,55 These numbers mean that out of all excised skin lesions suspected of melanoma, only 7-23% 
turns out to be a melanoma after histopathological diagnosis for dermatologists.53 It is reported 
that for biopsy or referral accuracy, among general practitioners the sensitivity varies between 70-
88%, and among dermatologists between 82-100%, and the specificity varies between 70% to 
87% among general practitioners and between 70%-89% among dermatologists.56 This implies 
that, according to those numbers a substantial number of early-stage melanomas goes unnoticed 
and will progress to the metastatic stage before being diagnosed. Obviously, the underdiagnosis 
of such fatal disease must be avoided. On the other hand, there is ample room to reduce the 
amount of (unnecessary) excisions because 77-93% of excised lesions did not have to be excised 
after all.54  
?
Room for improvement 
It is obvious that there is room for improvement in the clinical diagnosis of melanoma. By 
improving the accuracy of early melanoma diagnosis, not only the risk of lethal metastatic 
progression would be decreased, but it also would reduce the number of unnecessary surgical 
removals of benign skin lesions. In this way, new and accurate methods are needed to improve the 
specificity (probability of a clinical melanoma diagnosis, given that the patient has melanoma) and 
sensitivity (probability of a negative result, given that the patient does not have melanoma) of 
melanoma diagnosis.  
 
Morphology-based techniques 
Currently, the most used tool in the current practice by the clinicians worldwide for the 
examination of suspicious pigmented lesions and clinical recognition of melanoma is the 
epiluminescence microscopy, also known as dermoscopy. It consists of a magnifier and a polarized 
light source. It is used in combination with an oil medium, so that the light reflections on the skin 
surface can be reduced, which makes pigmented structures in the epidermis and dermal-
epidermal junction visible.43 Usually, the images are digitalized for further inspection and to check 
at a follow-up if the lesion has evolved.  
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Several studies report that the use of dermoscopy can improve the accuracy of detection of 
melanoma as compared to the unaided eye. However, this improvement is only seen when the 
dermoscopy is used by trained clinicians, implying that the learning curve for dermatologists to 
become experts in the interpretation of dermoscopic images is possibly lengthy.57-59 The 
limitations of dermoscopy are confirmed by the relatively low clinical diagnostic accuracy (correct 
clinical diagnosis) for melanoma,44 ranging between 56% and 80% for non-experienced and highly 
experienced dermatologists respectively.60 As referred, these values depend on the training 
experience of the clinician, but not only. The high intra-observer variability among clinicians and 
the difficulty to an effective assessment are set by the fact that the dermoscopic images show 
many different structures with various different algorithms for interpretation. Besides, there are 
difficult cases where some lesions mimic melanoma morphologic features and vice-versa.  
Other approaches are used to improve the diagnosis of early melanoma. Examples are total body 
photography, which enables assessment of changes in morphology of multiple pigmented skin 
lesions, and comparison of digital dermoscopy images taken at different time points (serial 
dermoscopy). These approaches aim at providing additional accuracy over unaided eye 
examination with dermoscopy, however, scientific evidence for the effectiveness of these more 
time-consuming methods is limited.61 
 Various methods have been investigated to objectively diagnose melanoma, almost all of which 
rely on image analysis and the detection of morphological differences. Examples of such methods 
are reflectance confocal microscopy,62-64 confocal microscopy,65,66 multispectral imaging 67,68 and 
automated dermoscopy image analysis.69 Incremental improvements in diagnostic accuracy are 
feasible through optimization of these morphology-based methods. However, these technologies, 
the discrimination between melanoma and benign melanocytic lesions are again (as in the case of 
dermoscopy) based on morphological criteria that is subjective.  
Even though electrical impedance spectroscopy is not an image-based technique, it evaluates 
morphological changes by measuring tissue impedance.70,71 It can detect changes in cell shape, 
size and membrane composition.72-74 
In the last years, automated image analysis based on deep learning algorithms has evolved largely. 
Applications for smartphones using these algorithms dedicated to dermatologists or to the public 
have flourished. Those algorithms can be fed with millions of images of lesions correlated to their 
clinical or histopathological diagnosis.75-77 Although artificial intelligence algorithms have proved 
to help separate skin lesions classes, it is still necessary to evaluate its performance in clinical 
settings.75 Besides, the diagnosis of skin lesions is also based in other contextual factors beyond 
visual inspection, like host factors. The interpretation of the visual inspection (digitally or not) by 
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dermatologists can be complemented by objective methods with an insight over the biochemical 
composition of the lesions.  
Biochemical composition-based techniques 
A promising approach is the analysis based on biochemical and genetic differences. It is known 
that these differences are greater and more specific than those in morphological appearance.78,79 
Research in proteomics and genomics have revealed that melanoma and benign melanocytic 
lesions demonstrate marked differences with respect to their biomolecular composition.80-84 On 
the DNA, RNA and protein level thousands of melanoma-specific alterations have been identified 
in tumor tissue and cultured cells.85-88 Methodologies that aim to identify characteristics of the 
biomolecular composition of the pigmented skin lesions are more promising to provide a major 
step towards the improvement of melanoma diagnosis, since the molecular specificity enhances 
the specificity of the diagnosis. With molecular-based technologies, the discrimination of 
melanoma would not be dependent on the clinician's experience in recognizing morphological 
features, but on the molecular composition of the lesion itself. Besides enhanced sensitivities, 
specificities and positive predictive values of diagnosis, such methods would potentially enable 
diagnosis at an earlier stage of disease, which would enable improvement of treatment efficiency 
and survival rates.  
 
Raman spectroscopy  
Raman spectroscopy is an optical technique, based on the inelastic scattering of light. It enables 
the non-invasive analysis of tissue composition due to specific vibrations of the molecules 
comprising the tissue. This technique has been extensively used in many oncological applications, 
including in skin cancer diagnosis.89-93  
The principle of Raman scattering  
Raman scattering was discovered simultaneously and independently by L.I. Mandel’shtam and G.S. 
Landsberg in the USSR and by the Indian physicist Sir Chandrasekhara Venkata Raman in 1928. 
Raman was the person who was rewarded with the Nobel Prize of Physics in 1930 for this 
discovery and the person the phenomenon was named after. 
Raman scattering is a process of inelastic scattering of light upon interaction with matter. When 
photons interact with molecules, they polarize the molecule’s electron cloud, raising the vibration 
energy of the molecule to a so-called ‘virtual energy state’ (Figure 4). After an extremely short 
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time, commonly about 10-14 seconds, the molecule drops back to its vibrational ground state. In 
elastic scattering, also known as Rayleigh scattering, the molecule returns to the original ground 
state and thereby emits a photon in a random direction. This photon has the same energy as the 
incident photon, i.e. the wavelength of the emitted photon is the same as the wavelength of the 
incident photon (Figure 4).  
It is also possible that an excited molecule falls back to an energy state different from the original 
state. This process is called inelastic scattering of light, also known as Raman scattering. The 
emitted photon has a slightly higher or lower energy than the original photon. This energy shift 
exactly matches the energy difference between the vibrational states. An observer can measure 
such energy shifts of scattered photons determine the vibrational energy levels of the molecules 
involved. When the molecule returns to an excited vibrational state, the energy of the emitted 
photon has decreased. This is called Stokes Raman scattering. When the molecule was in a 
vibrational state and returns to the ground state, the emitted photon has increased. This process is 
called anti-Stokes Raman scattering (Figures 4 and 5). The shift in energy between the incident 
and scattered photons can be observed as wavelength shifts. Stokes scattering results in a shift to 
a longer wavelength and anti-Stokes scattering results in a shift to a shorter wavelength. Rayleigh 
scattering is about 106 to 108 times more common than Raman Scattering, meaning that Raman 
signal is relatively weak when compared to the elastic scattering. At room temperature, the 
majority of molecules is in their ground state. As a result, elastic scattering is predominantly 
attributed to Stokes Raman scattering.  
 
 
Figure 4. Diagram of energy states of a molecule in elastic scattering of light (Rayleigh) and in inelastic 
scattering of light (Raman). Adapted from 94. 
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Figure 5. Schematic representation of a Raman spectrum with the respective Stokes and anti-Stokes shifts 
around the laser wavelength (in this example, 976 nm). Adapted from 95,96. 
A Raman spectrum is a plot of the intensity of the elastically scattered light versus the Raman 
frequency shift. As illustrated in Figure 6, Stokes and anti-Stokes shifts are symmetrically 
positioned around the Rayleigh scattered light. At room temperature, Stokes-shifted Raman peaks  
are much more intense than the anti-Stokes-shifted Raman peaks. In the research described in this 
thesis, only Stokes-shifted Raman signal was investigated. 
The position of a peak in the Raman spectrum corresponds to the energy required to excite a 
molecule to a certain energy level. Each peak in a Raman spectrum corresponds to a well-defined 
molecular vibration. Thus, a Raman spectrum provides specific information about the vibrational 
energy levels of a molecule, which are dependent on its molecular structure and which are a 
unique characteristic of that molecule. Raman shifts are commonly described in wavenumbers, 
which directly relate to energy. Conversion between wavelength and wavenumbers is done with 
the equation, 
 
?? ? ? ?
??
? ?
??
?                                                                    (1.1) 
where ?? is the Raman shift expressed in wavenumbers (cm-1), ?? is the initial wavelength of the 
excitation light (expressed in cm) and ?? is the wavelength of the Raman scattered photons 
(expressed in cm). 
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A Raman spectrum can be divided into two distinct spectral regions: the fingerprint region and the 
high-wavenumber (HWVN) region. The fingerprint region is typically defined as the range 400-
1800 cm-1 and contains more spectral detail than the HWVN region, which ranges from 2500 to 
4000 cm-1. The HWVN Raman spectrum of tissue is dominated by the stretching vibrations of the 
chemical CH groups (Carbon- Hydrogen bond) and OH groups (Oxygen-Hydrogen bond).  
 
Raman instrumentation 
The functional components of a Raman instrument are simple. A Raman instrument contains a 
light source, delivery and collection optics, a spectrometer and a detector. However, because of 
the fundamentally extremely low intensities of Raman signals and the requirement to accurately 
measure wavelength shifts, an actual Raman instrument can be a rather complex device. 
Lasers are the light sources of choice for Raman spectroscopy because they can provide intense 
monochromatic light of a stable and narrow wavelength. For applications involving Raman 
measurements on pigmented samples, as in the case of melanoma, intense laser light can induce 
tissue auto-fluorescence. The intensity of the fluorescence can be orders of magnitude stronger 
than the intensity of the weak Raman scattered light, and poses a major problem to obtain good 
quality Raman spectra. The use of lasers with longer wavelengths can diminish this problem to a 
level where good quality Raman spectra can be obtained from pigmented tissues (Chapter 2 of 
this thesis). The delivery of light from the laser unit to the sample can be done in various ways 
depending on the specific application. For instance, for in vivo medical applications, the most 
convenient solution is delivering light through a flexible fiber-optic probe, which enables Raman 
measurements on different parts of the patient’s body.  
The spectrometer, or spectrograph, is the element used to disperse the Raman photons into their 
different wavelengths.  
The detector is the component that detects the Raman scattered photons. Because the intensity of 
Raman signals is extremely low, typically tens to hundreds of photons per second, the detector 
must be sensitive and produce extremely little noise. The choice of detector also depends on the 
wavelength range. For visible to near-infrared wavelengths (up to 785 nm) the state-of-the-art 
detector is a cooled silicon-based Charge Coupled Device (CCD) detector, which combines very 
low noise levels with high sensitivity for wavelengths up to 1100 nm. For longer wavelengths, 
detector types other than silicon-based should be used. Examples are germanium, indium-gallium, 
indium-gallium-arsenide detectors. Such detectors are characterized by their inherently high noise 
levels. 
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Raman spectroscopy for diagnosis of melanoma 
Over 20 years Raman spectroscopy has been investigated as candidate technique for in vivo 
characterization of biological tissue and, more specifically for noninvasive diagnosis of non-
melanoma skin cancer. Non-melanoma skin cancers do not have their origin in melanocytes and 
are therefore usually not pigmented. Examples of non-melanocytic skin cancers are basal cell 
carcinoma and squamous cell carcinoma. Many studies have reported good results of Raman 
spectroscopy in discriminating between non-melanoma skin cancer and benign lesions or healthy 
skin.89-93 Specific characteristics that make Raman spectroscopy especially interesting for 
diagnostic applications in dermatology are the potentially high discriminating sensitivity and 
specificity and the ability to be used in vivo, directly on the skin of the patient. Such Raman 
spectroscopic measurements are painless, do not require tissue preparation and do not require 
(histochemical) staining or labeling or use of reagents. These are important characteristics to 
facilitate translation to the clinic. 
Hurdle of applying Raman spectroscopy for diagnosis of pigmented lesions  
However, the application of Raman spectroscopy for the analysis of pigmented biological samples, 
such as melanocytic lesions, presents a major hurdle. When using visible or near-infrared laser 
excitation wavelengths up to about 850 nm, the absorption of light by melanin in pigmented skin 
lesions results in strong laser-induced tissue fluorescence. This fluorescence signal is generally 
much more intense than the Raman signal from the tissue, to a point where the Raman spectral 
features are completely masked by the interfering fluorescence. This makes difficult, if not 
impossible, to obtain high-quality Raman spectra from pigmented tissues.  
Several strategies have been developed to reduce the interference from fluorescence. However, 
these solutions have insufficiently resolved the problem for Raman spectroscopy of pigmented 
tissues. Frequent problems were insufficient reduction of interference from fluorescence, too 
complex measurement setups for use outside the laboratory environment and insufficient 
perspective for application in vivo. Many efforts to solve the fluorescence interference problem 
have focused on a correction of the detected signal for fluorescent backgrounds. These inevitably 
result in spectral artifacts, in particular with a Raman signal that is weak compared to the 
fluorescence background. Other strategies resulted in long acquisition times incompatible with 
the clinical application. 
The solution, as described in this thesis, aimed at avoiding the generation of fluorescence at the 
source, by using a laser with a longer wavelength well into Short Wave Infrared range, in 
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combination with the employment of a novel low noise multi-channel detector to enable 
recording of high quality Raman spectra in short signal collection times. 
The research described in this thesis was performed in the framework of the RASKIN project, 
funded by Innovatiegerichte Onderzoeksprogramma (IOP) Photonic Devices and managed by 
AgentschapNL, Ministry of the Economic Affairs from The Netherlands. The RASKIN project was 
comprised by a consortium that involved expertise from research, clinical and company-oriented 
partners: (1) the Raman group at the Center for Optical Diagnostics and Therapy (CODT) of the 
Erasmus University Medical Center; (2) Leiden University Medical Center; (3) Philips Lighting B.V.; 
(4) RiverD B.V; (5) the Netherlands Organization for Applied Scientific Research (TNO); (6) Delft 
University of Technology, and (7) Avantes B.V.. This project had as final goal the development of a 
low-cost, easy-to-use Raman spectroscopic device for use by dermatologists and primary care 
physicians, for objective, rapid identification of suspicious pigmented skin lesions.  
 
Aims of this thesis 
High-quality Raman signals from melanocytic lesions compatible with a possible clinical 
application have not been demonstrated yet. The objectives of the work described in this thesis 
were: 
I: The development of a Raman spectroscopic prototype for objective and fast assessment of 
melanocytic skin lesions clinically suspicious for melanoma;  
II: Identification of the main spectroscopic features of melanoma and benign melanocytic lesions 
suspicious for melanoma; 
III: Assessment of the feasibility of Raman spectroscopy as an adjunct technique to improve 
clinical diagnosis of melanocytic skin lesions. 
Outline of this thesis 
Chapter 2 describes the developed Raman instrument based on a low-noise InGaAs imaging 
camera. In this study, we demonstrate the application of a novel imaging camera as a 
spectroscopic detector in Raman spectroscopy. Results are presented of high-quality HWVN-
Raman spectra with low fluorescence background of samples, which would not be possible with 
CCD-based instruments. The feasibility of using this detector for Raman spectroscopy was 
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demonstrated by shot-noise limited multichannel Raman spectroscopic measurements of 
pigmented biological samples in the SWIR region. 
Chapter 3 describes an alternative laser source developed within the RASKIN project. A 986-nm 
CW electrically pumped VECSEL is characterized and implementation in the SWIR multi-channel 
Raman spectroscopy instrument has been investigated. This study tests the suitability of the 
VECSEL for Raman spectroscopy applications. Vertical-external-cavity surface-emitting lasers 
(VECSELs) are an interesting 
alternative laser source for Raman spectroscopy. VECSELs offer a narrow linewidth, high power 
stability, good power efficiency and circular beam profile characteristics, and their wavelength can 
be engineered over a broad range in the near-infrared. In addition, they offer the potential of low-
cost mass production, and they are small in size. The VECSEL was characterized in relation to the 
requirements set by this biomedical application. For the first time, Raman spectra of pigmented 
skin lesions with a VECSEL in the SWIR region were demonstrated. The results show that the 
VECSEL fulfills the requirements of a laser source to be applied in Raman spectroscopy, opening 
the possibility of using VECSELs for low-cost compact hand-held Raman spectroscopy 
applications. 
In Chapter 4, the developed instrument was employed to obtain Raman measurements of freshly 
excised skin lesions clinically suspected of melanoma in an out-patient clinic that follow high-risk 
patients with familial melanoma. These are medically important use cases, with clinical relevance. 
The main objective was to explore whether there is spectroscopic information in the HWVN range 
(2800−3050 cm-1) to discriminate melanoma from benign melanocytic lesions. In total, 82 excised 
lesions were measured. The analysis was limited to include only histopathologically homogeneous 
lesions. This decision was based on the lack of point-to-point correlation between the Raman 
measurement location and the respective histopathology, which precluded a reliable gold 
standard for individual measurements on heterogeneous lesions. The results showed that the 
main spectral differences between melanoma and benign melanocytic lesions can be assigned to 
the symmetric CH stretching vibrations of lipids, with the Raman spectra of melanoma having an 
increased contribution from lipids compared to the other histopathological classes. In this study, a 
classification model was developed using PCA-LDA to investigate the discriminatory power of the 
CH region of HWVN Raman spectra. The model was optimized to discriminate melanoma from all 
the other lesion classes included in the analysis, with a leave-one sample-out cross-validation. Our 
preliminary classification model correctly classified all melanomas (sensitivity 100%) with a 
specificity of 45%. 
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Chapter 5 describes a development of a diagnostic model to discriminate melanoma from benign 
melanocytic lesions using multiple measurements within the lesion. This makes the method less 
sensitive to lesion heterogeneity. In order to have a representative Raman signal contribution, a 
filtering method of non-informative spectral contributions of keratin and collagen was developed.  
Chapter 6 provides an overview of the current status of the Raman technology towards clinical 
translation, using Technology Readiness Levels (TRL) for each Raman clinical study. The TRL is an 
index used to measure the maturity and usability of an evolving technology. The problems that 
need to be solved in order to bring the technique successfully to the end-users in the hospital 
setting are discussed. The importance of defining the clinical needs and requirements, for different 
applications, is also explored in this review.  
Chapter 7 presents the implementation of the simplest possible probe design, which is a single-
fiber probe, in the SWIR multi-channel Raman spectroscopy instrument. The purpose of this study 
was to characterize its sampling depth to test its viability for (early) melanoma diagnosis and to 
test the feasibility of the implemented single-fiber probe for in vivo Raman spectroscopy 
measurements on pigmented skin lesions. 
In Chapter 8 a general conclusion is drawn from the work developed and described in this thesis, 
as well as a discussion about the prospects of the implementation of Raman spectroscopy for 
improvement of clinical diagnosis of melanocytic skin lesions. 
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Implementation of a novel low-noise 
InGaAs detector enabling rapid near-
infrared multichannel Raman spectroscopy 
of pigmented biological samples 
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Abstract  
Pigmented tissues are inaccessible to Raman spectroscopy using visible laser light due to the high 
level of laser-induced tissue fluorescence. The fluorescence contribution to the acquired Raman 
signal can be reduced by using an excitation wavelength in the near infrared range around 1000 
nm. This will shift the Raman spectrum above 1100 nm, which is the principal upper detection 
limit for silicon-based charge-coupled device (CCD) detectors. For wavelengths above 1100 nm 
Indium Gallium Arsenide (InGaAs) detectors can be used. However, InGaAs detectors have not yet 
demonstrated satisfactory noise level characteristics for demanding Raman applications.  
We have tested and implemented for the first time a novel sensitive InGaAs imaging camera with 
extremely low readout noise for multichannel Raman spectroscopy in the Short-Wave Infrared 
(SWIR) region. The effective readout noise of 2 electrons is comparable to that of high quality CCDs 
and 2 orders of magnitude lower than that of other commercially available InGaAs detector arrays. 
With an in-house built Raman system, we demonstrate detection of shot-noise limited high quality 
Raman spectra of pigmented samples in the high wavenumber region, whereas a more traditional 
excitation laser wavelength (671 nm) could not generate a useful Raman signal due to high 
fluorescence.  
Our Raman instrument makes it possible to substantially decrease fluorescence background and 
to obtain high quality Raman spectra from pigmented biological samples in integration times well 
below 20 seconds. 
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Introduction 
Raman spectroscopy is widely used to characterize biological tissues and to detect the molecular 
changes associated with pathological processes, e.g. distinguishing malignant from non-
malignant tissue.1,2 However, the application of Raman spectroscopy in the analysis of highly 
pigmented biological samples presents a problem. When using laser excitation wavelength up to 
about 850 nm intense laser-induced tissue fluorescence often makes it difficult or impossible to 
obtain high quality Raman spectra. 
Several strategies to reduce the interference from fluorescence have been developed, such as time 
gated detection,3,4 photobleaching, 5,6 a confocal signal detection scheme, 7surface enhanced 
Raman spectroscopy (SERS) 8 and resonance Raman (RR) scattering. However, these solutions have 
insufficiently solved the problem for (in vivo) Raman spectroscopy of pigmented tissues because 
they are either not sufficiently effective, lead to complex measurement setups, and/or have not 
shown to be applicable in vivo. 
 Even though confocal Raman instruments can significantly reduce fluorescence background from 
out-of-focus regions, this reduction is insufficient for highly fluorescent samples. Also digital 
background subtraction techniques 9-12 are not an appropriate solution to the fluorescence 
problem because they may be able to subtract the background but not the shot noise that is 
generated by the fluorescence. Some studies have used 785 nm excitation to obtain spectra of 
several types of pigmented skin lesions in the so-called fingerprint region (500-1800 cm-1); 
baseline removal algorithms have to be employed to remove the very strong fluorescence 
background. 13 This inevitably results in spectral artifacts, in particular when the Raman signal is 
weak compared to the fluorescence background. Moreover, background subtraction cannot 
remove the shot noise that is added by the background. Nevertheless, using a large measurement 
volume (200 μm core diameter single fiber that illuminates a 3.5 mm diameter skin area), Lui et al. 
obtained useable Raman signals from excised pigmented tissues.13 
The most established approach to reduce sample fluorescence in Raman spectroscopy is the use 
of excitation wavelengths outside the visible range: either in the near infrared (NIR) region, far 
above 700 nm,14 or in the ultraviolet (UV), below 250-300 nm.15 For application on biological 
tissues in vivo UV laser excitation is not desirable, as it may cause cell and DNA damage.16 In 
addition, the penetration depth of UV light in tissue is only in the order of a few microns.16,17 
Several studies have suggested that using an excitation wavelength with a photon energy far from 
the energies of electronic transitions is most promising in this respect.14,16,18,19 
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Fourier-Transform (FT) Raman has been successfully used to obtain spectra of pigmented skin 
lesions.20,21 This proves that the problem of tissue fluorescence can be overcome by using a longer 
laser excitation wavelength (1064 nm in the case of FT-Raman). However, FT-Raman spectroscopy 
is a multiplexing single-channel technique for which signal integration times are typically several 
orders of magnitude longer than for multi-channel Raman spectroscopy. This is not compatible 
with in vivo medical applications. Patil et al. have reported dispersive Raman spectroscopy of 
tissues with strong auto-fluorescence using 1064 nm excitation in combination with an Indium-
Gallium-Arsenide (InGaAs) detector array.14 Laser-induced tissue fluorescence was significantly 
reduced as compared to laser in the visible wavelength range, but at the cost of much lower 
signal-to-noise ratio (SNR) due to the high detector noise of the traditional InGaAs detector 
technology. 
The ideal solution would be to use a higher wavelength laser excitation to reduce fluorescence in 
combination with low noise multi-channel Raman spectroscopy to enable short signal collection 
times.  
Further reduction in interference from tissue fluorescence is seen in the high wavenumber (HWVN) 
spectral range (ca. 2500-4000 cm-1), which is the part of the Raman spectrum with the largest 
Stokes-shift from the laser line and thereby in most cases also away from the spectral region with 
the highest tissue fluorescence intensity.  
Although the HWVN spectral region is not as rich in spectral features as the fingerprint region, it 
has been shown to provide clinical diagnostic information just like the more commonly used 
fingerprint region (400-1800 cm-1), enabling the distinction of malignant and healthy tissue. Ample 
evidence supports the presence of sufficient spectral features required for demanding biomedical 
applications, such as a diagnostic tool for tissue malignancies.1,2,22,23 In addition, in this spectral 
range the interfering Raman signal from fused silica in optical elements such as lenses and optical 
fibers is virtually absent, enabling very simple fiber optic probe construction.24 
Until now the detection of Raman signals in the SWIR region (>1100 nm) was constrained by 
limitations of the detector technology. For visible to NIR excitation the state-of-the-art detector is 
the cooled Charge Coupled Device (CCD) detector, which combines very low readout noise and 
very low dark current with high quantum efficiency. However, light with wavelength above 1100 
nm cannot be detected due to the band gap of silicon. An alternative in this spectral range are 
InGaAs detectors, which enable detection at wavelengths well above 1100 nm.  
During the past years there has been an increasing demand for low-noise dispersive spectroscopy 
solutions in the SWIR wavelength range. Dispersive spectroscopy allows multichannel detection. 
This, in contrast to for instance FT-Raman, enables simultaneous detection of Raman signal over a 
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range of wavelengths, reducing the total integration time. Several companies have recently 
moved towards the SWIR range and have introduced InGaAs-based Raman devices. However, as 
mentioned above, InGaAs detectors show a very high inherent readout noise in comparison with 
CCD detectors. Also, the dark current is orders of magnitude higher than in CCD’s, even when 
cooled to 77 K with liquid nitrogen. As a result of the relatively poor noise characteristics of InGaAs 
detectors the SNR of the Raman signal is limited by the detector noise of the InGaAs detector and 
not by shot noise of the Raman signal, which is typical for CCD-based Raman spectroscopy. This is 
not ideal for demanding Raman applications such as Raman spectroscopy of biological tissues.  
A new type of deep-cooled InGaAs detector for SWIR imaging applications has recently been 
introduced by Xenics (Leuven, Belgium). This detector exhibits extremely low noise characteristics, 
approaching those of high-end CCD detectors, combined with a high quantum efficiency (>90%) 
up to 1570 nm. 
We have developed a Raman instrument based on this novel low-noise InGaAs imaging camera. 
We show how it can be used for Raman spectroscopy and provide examples of its performance in 
obtaining high quality HWVN-Raman spectra with low fluorescence background of samples that 
are difficult to obtain using CCD-based instruments. In this paper we test the feasibility of this 
detector for Raman spectroscopy and demonstrate shot-noise limited multichannel Raman 
spectroscopy of biological samples in the SWIR region.  
Materials and Methods 
SWIR multichannel Raman instrument. A SWIR multichannel Raman instrument was constructed 
in-house (Figure1). The excitation light source was a single-mode continuous wave diode laser 
with a wavelength of 976 nm and an output power of 150 mW (Model R-type, Innovative Photonic 
Solutions, Monmouth Junction, NJ, USA).  
The collimated light from the diode laser was expanded to a beam of 7.8 mm in diameter using 
two achromatic lenses (f = 9 mm, Ø6 mm and f = 100 mm, Ø25 mm, Edmund Optics Barrington, 
NJ, USA) and focused in the sample to a Gaussian spot with a diameter of ~6 μm using an 
achromatic lens (f = 35 mm, NA 0.36, Edmund Optics Barrington, NJ, USA). The backscattered 
Raman signal is collected by the same lens and focused onto the entrance slit (25 μm) of the 
spectrometer using an identical achromatic lens (f = 35 mm, NA 0.36). The achromatic lenses used 
in this setup have an anti-reflection coating (<0.5% reflection in the SWIR region of 900-1700 nm). 
Two long pass edge filters (OD>6.0, cutoff at 1064 nm, Model Raman Edge Filter, Edmund Optics, 
Barrington, NJ, USA) were used for laser light suppression in the signal detection path in front of 
the spectrometer. The f/#2 spectrometer, has an entrance slit with a width of 25 μm and a 5 cm-1 
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spectral resolution and was customized to cover the spectral range between 1300-1550 nm 
(BaySpec Inc., San Jose, CA, USA). 
The detector for the Raman signal is a Cougar-640 InGaAs imaging camera (Xenics, Leuven, 
Belgium) with an InGaAs focal plane array sensor with 512 x 640 pixels, cooled with liquid nitrogen 
to 77 K. The Cougar-640 camera offers two distinct readout modes. In the classical Integrate-Then-
Read mode, the photo-electrons are collected for a fixed exposure time after which the 
accumulated charge is probed and the buffering capacitors are reset. This scheme results in a 
relatively high capacitor-reset noise. The second scheme uses the Read-While-Integrate (RWI) 
mode. In this scheme the accumulating photo-electrons are probed non-destructively during the 
integration period without resetting the buffering capacitors. In combination with a noise level 
that is already low for a single readout, the non-destructive sampling option can be used to 
virtually eliminate the effective readout noise of the detector. This will be explained in more detail 
in the section Data pre-processing.The captured spectral range of 1340-1540 nm corresponds 
approximately to a Raman spectrum from 2780 to 3750 cm-1. The Raman spectrum is imaged on 
512 pixels. The direction of the pixel readout process of the InGaAs-chip is perpendicular to the 
spectral direction, which avoids possible cross-talk effects between adjacent pixels. 
A custom-made sample cartridge was used to hold an excised skin sample between two fused 
silica windows (Figure 2). For Raman measurements the cartridge was inserted inside an anodized 
aluminum cartridge holder that was mounted perpendicularly to the laser beam (Figure 2). The 
skin sample was placed in the laser beam and the focus position optimized on the Raman signal. 
 
 
Figure 1. Scheme of the SWIR Raman spectroscopy setup. L: lens; M: mirror; LPF: long pass filter; VPH: volume 
phase holographic grating. 
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Figure 2. Skin sample holder. a) The skin sample is held between two fused silica windows; b) The sample 
cartridge is inserted in the cartridge holder. 
 
State-of-the-art commercial Raman device. We used a commercial spectroscopic Raman device 
(Model 3510SCA Skin Analyzer, RiverD International B.V., The Netherlands), equipped with a 671 
nm laser to record Raman spectra in the high wavenumber region, to compare the high 
wavenumber Raman spectra obtained with a CCD-based Raman multichannel system to the 
spectra obtained with the new SWIR-Raman setup. The CCD detector was an air-cooled back-
illuminated CCD with 1024 x 128 pixels (Andor iDus type DU401A-BR-DD, Andor Technology Ltd., 
U.K.). The spectral range of this instrument is 2500 to 4000 cm-1, with a spectral resolution better 
than 5 cm-1.  
Data pre-processing 
The Cougar-640 InGaAs detector was originally designed for SWIR imaging. In order to use it for 
Raman spectroscopy software algorithms were developed and implemented to read and pre-
process the raw data that are generated by the camera using the RWI scheme.  
Non-destructive readout detection. The RWI mode has been described for low light level imaging 
in astronomy,25-28 and is also known in the literature as the up-the-ramp readout scheme. During 
the course of a single integration the electrons generated in each pixel are buffered on a capacitor 
with a fixed pixel clock frequency. The voltage across the capacitor is then probed without 
resetting the capacitors, at regular time intervals that can be chosen by the user. The total 
integration time is thus divided into N equidistant intervals. RWI operation starts with a 
simultaneous global reset of the buffering capacitors of the entire array, followed by multiple non-
destructive readouts which trace the evolution of the accumulating charge for each pixel (Figure 
3). Because the noise in the successive non-destructive readouts is uncorrelated, the effective 
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readout noise for the full signal integration time can be reduced by fitting a straight line through 
the successive readouts. To employ this readout scheme, the accumulating signal in each pixel 
was translated into a slope of a line fitted through all intermediate sampling points for that 
individual pixel. The counts in Analog-to-Digital converter Units (ADU) are then converted to the 
number of generated electrons, which equals the number of detected photons. The global 
conversion gain for the Cougar-640 camera is 0.168 photons per ADU. From the slope (number of 
detected photons per number of readouts) and the sampling rate (number of readouts per 
second), the signal intensity detected by each pixel was computed as the number of detected 
photons per second.  
Using N uniformly spaced readouts, the readout noise in the total acquisition ???? is given by 26 : 
???? ? ??????? (2.1) 
 
where ??? is the standard deviation of the residuals with respect the fitted line and defined by: 
 
??  = ?
? ????????????????????
?
 
(2.2) 
 
In this equation y(i) are the measured intermediate readouts and p(x(i)) are the values of the fitted 
line.  
 
Figure 3. Representation of signal accumulation process for a single pixel. The red dots represent intermediate 
non-destructive readouts of the charge accumulated by the pixel, during accumulation. The slope of the linear 
regression represents the average signal intensity in counts per second. 
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Linearization of pixels response. During the characterization of the camera the response showed 
progressive non-linear behavior after the accumulated signal exceeded a certain threshold. We 
identified a cutoff threshold for the linear behavior. An algorithm was implemented to correct for 
this non-linear response of the pixels above the threshold value. A first order polynomial was fitted 
to the linear range during the first part of the integration period (Figure 4b). The ratio between the 
fitted line (in blue, Figure 3) and the intermediate pixel readouts (red dots, Figure 3) were stored in 
a lookup table together with the corresponding pixel readout values. The lookup table was 
created from the averaged result of 10 ratios. Thus for each pixel readout the lookup table 
provided a correction factor by linear interpolation. The response for each pixel was then 
linearized by multiplying the readout by the corresponding correction factor from the lookup 
table. For each pixel a first order polynomial was fitted to the linearized data to determine the 
slope (see Figure 4b) which represents the number of photons detected per second (Figure 4c).  
Finally the slopes of the pixels in a region of interest of 12 pixels perpendicular to the spectral 
direction were co-added (Figure 4d) to result in a single detected intensity per super pixel for each 
spectral point.  
Calibration of Raman spectra. Raman spectra were corrected for wavelength-dependent 
detection efficiency of the setup, using a NIST calibrated glass (NIST, Gaithersburg, Maryland, USA). 
Since no standard reference material (SRM) was available for 976 nm excitation wavelength, we 
used an SRM for 830 nm excitation (SRM 2246, NIST, USA) and compared the spectra acquired with 
an 830 nm laser to the spectrum acquired with the default 976 nm laser. The relative difference 
was smaller than 6%. We decided that this difference would be sufficient to use the SRM 2246 with 
an excitation wavelength of 976 nm to correct for the wavelength-dependent detection efficiency 
of the setup with satisfactory accuracy. The theoretical curve for 830 nm excitation and the curve 
obtained with the 976 nm laser were divided to determine a correction curve. 
At the start of each measurement session a spectrum of the SRM 2246 was measured (with 976 nm 
excitation) to determine the wavelength dependent response of the instrument. All recorded 
Raman spectra in that session were corrected for this response. 
The relative wavenumber calibration was determined using a calibration neon-argon lamp. The 
exact wavelength of the laser was determined using cyclohexane as a Raman standard spectrum, 
and the laser line position was computed from the Raman bands at 2852.9, 2923.8 and 2938.3cm-1. 
The Raman background that originates from the optics was subtracted from all spectra. 
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Figure 4. Schematic overview of the RWI processing algorithm. a) Only 12 rows of pixels are used to record the 
spectrum. The readout direction is indicated in the figure. b) For each pixel, the response as a function of time 
is linearized and the slope is determined; c) the slopes for different pixels are then co-added in the readout 
direction as indicated in a); d) the final Raman spectrum is obtained. 
Sample preparation.  
Ex vivo human skin. Pigmented human skin lesions suspected of melanoma were excised in the 
dermatology outpatient clinic of the Leiden University Medical Center (LUMC) as part of the 
standard patient care. Skin samples were obtained from one female and from one male subject. 
This study was approved by the medical-ethical committee at LUMC (C13.06). Informed consent 
was obtained from the patients. 
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The freshly excised skin samples were rinsed with NaCl 0.9% solution, gently flattened between 
two fused silica windows and measured within a maximum of 30 minutes after surgery with the in-
house built SWIR Raman instrument. After measuring, the skin samples were put in a 
formaldehyde aqueous solution (4%) and sent to the pathology department for the routine 
diagnostic procedure. During this procedure it was also verified that no visual damage had 
occurred due to the measurements.  
Human hair. A dark brown hair was clipped from one Caucasian female subject and measured 
immediately after collection. No hair treatment such as dying, waving, or other styling methods 
were used. Spectra were collected on the first third of the total length of the hair, close to the hair 
root.  
Red wine. Dark red wine (grape type Aragonez, 13% alcohol) was obtained from a local store and 
measured in a fused silica cuvette of 1x1 cm diameter. The cuvette was placed in the sample 
holder and positioned in the laser focus. 
 
Results  
Readout noise and dark current 
Table 1 shows the detector readout noise for a single readout and the dark current with the 
detector operating in a room at 23˚ C. The readout noise (per single readout) was determined 
according to equation 2.2, described in Materials and Methods. 
 
Non-linearity in the detector response 
The detector response was measured for different pixels until the saturation level of 3.5x106 
detected photons was reached, using the Raman signal of cyclohexane (Figure 5a). Figure 5b 
shows the detector response of pixels exposed to different light intensities. The accumulated 
charge, expressed in number of detected photons, is shown as a function of time. With the time-
axis normalized on the time to reach detector saturation the response of pixels exposed to 
different light intensities overlap (Figure 5c). This demonstrates that the non-linearity in the pixel  
Table 1. Experimentally determined noise characteristics of InGaAs Cougar-640, Xenics® 
 
Noise source Electrons ± SD 
Readout noise (e- per single readout) 22.7 ± 5.9 
Dark current (e-/s/pixel) at room temperature 69.4 ± 4.5 
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response is a function of the total number of detected photons only and independent of the light 
intensity or rate at which photons are detected.  
Figure 6 shows two HWVN-Raman spectra obtained ex vivo of a skin sample and illustrates the 
effect of non-destructive readout. Both spectra were obtained using a signal collection time of 10 
seconds. The upper spectrum (spectrum a, Figure 6) was obtained using non-destructive readout 
at a sampling rate of 10 readouts/s (100 intermediate readouts in 10 seconds) and the bottom 
spectrum (spectrum b, Figure 6) was obtained with a sampling rate of 0.2 readouts/s (2 
intermediate readouts in 10 seconds).  
The readout noise given in Table 1 decreases significantly when more sampling readouts were 
performed during the integration time, in accordance with Equation. 1.1. Table 2 presents the 
 
 
 
Figure 5. a) Raman spectra of cyclohexane; b) response curve of three different pixels (shown in a) exposed to 
different light intensities during the signal integration period; c) accumulation of charge as a function of 
normalized time, i.e. integration time divided by the time to reach the intensity threshold of saturation. 
 
Figure 6. Raman spectra of ex vivo skin obtained with a signal integration time of 10s. The spectra are offset 
along the intensity axis for clarity. a) Spectrum obtained with a non-destructive readout rate of 10 readouts/s; 
b) Spectrum obtained with a nondestructive readout rate of 0.2 readouts/s. 
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readout noise (e-/pixel) and the signal intensity in generated electrons of the spectra shown in 
Figure 6, which were measured with a different number of readouts. The signal intensity is the 
maximum intensity in the CH band at 2938.3 cm-1. The readout noise was determined according to 
Equation. 1.1, (Materials and Methods). 
Figure 7a shows how the spectral noise develops with increasing signal collection time. All spectra 
are acquired at the same non-destructive readout rate of 10 readouts/s. The HWVN-Raman spectra 
were obtained ex vivo of a pigmented skin lesion using different exposure times of 0.5 s, 1 s, 2 s, 4 
s, 8 s and 16 s.  
Table 2. The effective readout noise of the Cougar-640 detector 
 
Number of 
intermediate readouts 
Signal intensity 
(e-/pixel/s) 
Effective readout noise 
(e-/pixel) 
Dark current at room 
temperature (e-/s/pixel) 
2 200 16.1 69.4 
100 200 2.27 69.4 
 
 
Figure 7. a) Ex vivo Raman spectra of pigmented human skin measured with different integration times with a 
non-destructive readout rate of 10 readouts/s. The spectra are offset along the intensity axis for clarity. 1) 16 s 
integration time; 2) 8 s integration time; 3) 4 s integration time; 4) 2 s integration time; 5) 1 s integration time; 
6) 0.5 s integration time. b) Measured spectral noise of the spectra shown in a) versus the theoretical shot 
noise. The dashed line indicates the level at which the empirical noise equals the theoretical noise. 
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Figure 7b shows the measured spectral noise plotted against the calculated shot noise defined as 
square root of the signal.29 The empirical noise in signal was determined after fitting a 2nd order 
polynomial to part of the OH-band (3360-3470 cm-1) and then calculating the standard deviation 
of the residual.  
To test the feasibility of acquiring Raman spectra of pigmented samples, we tested a number of 
samples which show high fluorescence when excited with visible light (red wine and dark brown 
human hair). This was done using 671 nm laser light and using 976 nm laser light (Figure 8).  
 
 
Figure 8. Raman spectra of pigmented biological samples. a) HWVN-Raman spectra of red wine obtained 
using 976-nm laser excitation and the SWIR Raman instrument built in-house. Signal collection time: 10 s; non-
destructive readout rate: 10 readouts/s; b) HWVN-Raman spectra of red wine obtained using 671-nm laser 
excitation and a CCD-based Raman instrument (Model 3510 SCA, RiverD International B.V., the Netherlands). 
Mean spectrum and spectral variance are shown (25 spectra measured with a signal collection time of 1 s 
each); c) HWVN-Raman spectra of a human brown hair obtained using 976-nm laser excitation, a 10-s signal 
collection time, and non-destructive readout rate of 10 readouts/s; d) HWVN-Raman spectra of a human brown 
hair obtained using 671-nm laser excitation. Mean spectrum and spectral variance are shown (25 spectra 
measured with a signal collection time of 1 s each). In all figures the solid line represents the mean spectrum, 
and the shadow area represents the spectral variance (eight repeated measurements). 
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Figure 9 presents two examples of HWVN Raman spectra of highly pigmented excised human 
melanocytic nevi using the 976 nm SWIR Raman instrument. The spectra were acquired from eight 
different locations of the pigmented lesions shown in Figure 9a and 9c. The spectra presented 
were intensity-normalized and offset along the intensity axis for clarity. 
Discussion  
The purpose of this in-house built SWIR Raman instrument was to enable rapid acquisition of high 
quality Raman spectra of freshly excised pigmented human skin lesions. For detection of the 
Raman signals a novel SWIR InGaAs imaging camera was employed and adapted to Raman 
spectroscopy. 
The choice of an excitation wavelength of 976 nm was guided by the requirement to collect signal 
in the 2780 - 3750 cm-1 spectral range with NIR excitation and by the 1570 nm sensitivity cut-off of 
the low-noise InGaAs detector. Using 976 nm excitation laser, the spectral range of 2780 - 3750cm-
1 corresponds to signal detection in the 1340 nm - 1540 nm wavelength range. This spectral  
 
Figure 9. Photographs and corresponding Raman spectra of freshly excised human pigmented skin lesions 
using 976-nm laser excitation and the SWIR Raman instrument. Exposure time: 10 s. a) and b) Melanoma in 
situ; c and d) benign melanocytic nevus. 
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interval covers the CH-stretching, NH-stretching and OH-stretching regions, which enables the 
detection of protein, lipid, NH and OH vibration bands. We have shown earlier that this 
wavenumber range provides diagnostic information to differentiate malignant tissue from benign 
tissue.1,2  
Noise characteristics SWIR InGaAs camera  
The RWI readout scheme was specially designed for low light intensity applications, which also 
makes this camera of special interest for application in Raman spectroscopy. This readout scheme 
is a novelty for Raman spectroscopy and enables virtual elimination of readout noise. The detector 
noise characteristics were experimentally verified and approach those of high-quality CCD 
detectors, which is unprecedented for InGaAs detectors (Table 1). For instance, in a 10 second 
exposure time with a frame rate of 10Hz, the effective readout noise is reduced to 2.27 electrons 
(Table 2), which is comparable to the readout noise levels found in cooled slow-scan CCD 
detectors used in spectroscopy.  
The experimentally determined dark current value (69.4 ± 4.5 e-/s/pixel) is about seven times 
higher than specified by the manufacturer (< 10 e-/s/pixel). In this manufacturer specification the 
dark current is measured in a cold room with an additional cold shield mounted in the detector 
housing, which significantly reduces the influence of thermal radiation from the environment. The 
dark current in this paper is determined under standard operational conditions without an internal 
cold shield and therefore reflects the effective dark current including collection of normal thermal 
radiation from the environment. The pixel reset of the InGaAs detectors introduce small variations 
in the pixel-capacitor values at the start of an integration. This results in a significant pixel-noise 
component, which could limit low-light applications. Using the RWI readout scheme, this reset 
noise component can be completely cancelled because the slope of the accumulated charge for 
each individual pixel is used, not the offset (Figures 3 and 4).  
During integration cycles with a constant light source the detector showed a strong non-linear 
response of accumulated pixel charge versus time. The characteristic curve resembles an S-shape 
and is due to a fundamental feature of the type of capacitors used in this detector (Figure 5). This 
non-linearity is essentially caused by the bias leakage in the pixel circuitry of the readout chip that 
decreases during the integration period, which results in decreasing sensitivity. In order to obtain 
a linear response of the Raman spectral intensities, a non-linearity correction was performed on 
the individual pixels. This was possible because we could verify that the non-linear response was 
dependent on the accumulated charge of a pixel and not on the intensity or photon flux, and did 
not vary between pixels. This means that a single lookup table could be used to convert the non-
linear scale of accumulated charge to the linear scale of number of detected photons for a given 
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integration time. The practical implication is that linearization of the detector response can easily 
be implemented on-line in the acquisition software and does not require much processing power. 
Shot noise or Poisson noise is associated with the particle nature of light and can be quantified by 
the square-root of the number of detected photons in a given time interval. For very strong signals 
the associated shot noise is generally the dominant noise factor but for weak signals, such as 
Raman signals from biological tissues, the detector noise can become a limiting factor. Ideally, the 
signal-to-noise ratio in a Raman spectrum is not limited by the detector noise but only by the 
unavoidable shot noise in the Raman signal. To test whether we could obtain quality shot-noise 
limited Raman spectra with the developed instrument we measured some biological samples that 
give low intensity Raman signals. Figure 6 illustrates that readout noise is drastically reduced by 
using the InGaAs detector in RWI mode with multiple non-destructive readouts during acquisition. 
Figure 7 shows how Raman signal evolves after 0.5, 1, 2, 4, 8, 16 s of acquisition. For shorter 
integration times the readout noise exceeds the signal shot noise. At high signal intensities the 
shot noise dominates other noise sources. The effective noise in the spectra approaches the 
theoretical shot noise values for exposures longer than 4 seconds, i.e., the noise in the spectra is 
determined by Poisson statistics and no longer by detector noise. The fact that the effective noise 
is slightly higher (about 9 photons) than the square root of the signal reflects the inaccuracy in the 
empirical determination of the effective noise in the spectra. It is clear from Figure 7 that, using the 
non-destructive readout scheme of this InGaAs detector (RWI), we were able to obtain shot-noise 
limited detection of weak HWVN-Raman signals from biological tissues with excitation and 
detection in the NIR and SWIR region.  
We present some example spectra of naturally highly pigmented samples, of which it is extremely 
difficult to obtain high-quality and low-background Raman spectra with visible laser excitation. In 
the first example (Figures 8a and 8b) of red wine it is evident that the spectrum acquired with the 
976 nm setup shows hardly any fluorescence background and a strong Raman signal is well 
visible, whereas the spectrum acquired with 671 nm excitation shows a very strong fluorescence 
background in comparison to the superimposed Raman signal. In the second example (Figures 8c 
and 8d), we could get a strong Raman spectrum from human brown hair, with the protein band 
and CH vibration features well perceptible on top a still noticeable fluorescence background. 
When measuring the same sample with 671 nm the background largely obscures the Raman 
signal, which that is only marginally noticeable on top of the strong background. The first 
measurements also show the feasibility of the in-house built instrument to obtain high-quality 
Raman spectra of biological pigmented samples in just few seconds of integration time. We also 
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presented two examples of high quality Raman spectra of pigmented human skin lesions 
measured in only 10 s (Figure 9). 
Now that technological limitation of multichannel detection above 1100 nm with extremely low 
noise levels is overcome, it is possible to use longer excitation wavelengths in Raman 
spectroscopy in order to decrease tissue fluorescence that would otherwise obscure the Raman 
signal. This detector enables low-fluorescence spectra from pigmented biological samples with a 
multichannel NIR detector.  
 
Conclusions 
In this paper, we describe a novel Raman instrument for obtaining high quality spectra from 
pigmented samples, using short signal integration times.  
The key element in this setup is the low-noise InGaAs detector. It enables near shot-noise limited 
signal collection and opens a wide field of demanding applications, e.g. in medical diagnosis, food 
quality control, or other fields in which high quality Raman spectra of pigmented samples are 
required. 
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Abstract 
Raman spectroscopy of pigmented samples can be problematic due to strong laser-induced auto-
fluorescence. Moving the laser excitation more into the near-infrared region (>900 nm) and 
detection to the short-wave infrared region (1200-1600 nm) significantly decreases laser-induced-
fluorescence for many pigmented samples. However conventional near-infrared (NIR) diode-lasers 
suitable for Raman Spectroscopy are expensive. Vertical-external-cavity surface-emitting lasers 
(VECSELs) are an interesting alternative laser source for Raman spectroscopy. VECSELs offer a 
narrow linewidth, high power stability, good power efficiency and circular beam profile 
characteristics, and their wavelength can be engineered over a broad range in the NIR. In addition, 
they offer the potential of low-cost mass production and they are small in size. We developed a 
986 nm VECSEL for a specific biomedical application (Raman measurements of pigmented skin 
lesions). We implemented and tested the feasibility of the novel 986 nm VECSEL in a short-wave 
infrared (SWIR) multi-channel Raman spectroscopy instrument. We have characterized the VECSEL 
in relation to the requirements set by this biomedical application and have demonstrated for the 
first time Raman spectra of pigmented skin lesion with a VECSEL in the SWIR region. Our results 
show that the VECSEL fulfils the requirements of a laser source to be applied in Raman 
spectroscopy. This opens the possibility of using VECSELs for low-cost compact hand-held Raman 
spectroscopy applications. 
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Introduction 
Dispersive Raman spectroscopy has been mainly restricted to using visible excitation wavelengths 
due to the band gap of silicon, which does not enable the use of charge coupled device (CCD) 
detectors for wavelengths above 1100 nm. When using visible laser excitation wavelengths up to 
about 850 nm on pigmented samples, intense laser-induced tissue fluorescence is generated, 
which overwhelms the Raman signal. Because of that, pigmented biological tissues are 
traditionally inaccessible for dispersive Raman spectroscopy using a CCD detector and visible 
wavelength lasers. The short-wave infrared (SWIR) region (wavelengths from 0.9 to 1.7 μm) is an 
interesting region for Raman spectroscopy of pigmented tissues because the use of a longer laser 
excitation wavelength significantly reduces the tissue auto-fluorescence backgrounds.1,2  
Laser diode sources in the 900-1000 nm range are not so much used in Raman spectroscopy and 
those with narrow and stable linewidth are expensive. Besides, edge-emitting laser diodes are 
characterized by their elliptical beam output and astigmatism.3,4 There are several requirements 
that a laser light source needs to fulfil to be used in Raman spectroscopy. It is essential to have a 
narrow and highly stable linewidth (typically better than 1 cm-1) to achieve high spectral resolution 
of the Raman spectrum and to avoid spectral shifts or spectral broadening.5-7 The laser must have 
stable laser power to enable subtraction of background signals from the Raman spectra. Another 
requirement can be fundamental transverse mode operation to obtain a diffraction-limited beam 
quality, particularly important for confocal Raman (micro)spectroscopy.5,7  
Recent developments in the vertical-external-cavity surface-emitting lasers (VECSEL) technology 
have brought their characteristics in the realm of Raman spectroscopy, with special interest for 
low-cost hand-held devices.7-12 VECSELs are semiconductor lasers based on a vertical-cavity 
surface-emitting (VCSEL) chip. Therefore, in a VECSEL the light is emitted perpendicularly to the 
top surface of the chip. An additional mirror is used to create an external cavity, allowing control of 
the transverse mode properties while enlarging the area of gain in the semiconductor laser. This 
achieves a combination of high continuous-wave (CW) output power, due to a large gain area, and 
a low-divergence near-diffraction-limited beam, due to the transverse mode control of the 
extended cavity. The advantages of VECSELs over edge-emitting semiconductor lasers are: circular 
output beam, easy array fabrication, small size, and low cost at mass production.4,13 Their cost 
advantages stem from their vertical nature, which allows on-wafer testing, easy extension to an 
extended cavity, and a better match with conventional semi-conductor equipment. However, a 
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disadvantage of extended cavities is the presence of multiple longitudinal modes, which can 
potentially lead to mode-hopping. In order to avoid mode hops the temperature and current need 
to be tightly controlled or, alternatively, volume Bragg reflectors could be introduced as an 
external mirror.  
In our previous work we tested the feasibility of an in-house built Raman spectroscopy device to 
acquire high-quality Raman spectra of pigmented skin lesions.2,14 The instrument comprised a 
near-infrared (NIR) 976 nm edge-emitting diode laser. The Raman signal was detected in the SWIR 
region, using a sensitive indium-gallium-arsenide (InGaAs) detector with extremely low detector 
noise. With this prototype we demonstrated high-quality, shot-noise-limited high-wavenumber 
(HWVN) Raman spectra of pigmented skin lesions with acquisition times sufficiently short to be 
compatible with application in a clinical setting.2 
In this study we have developed a 986 nm CW electrically pumped VECSEL and implemented this 
laser in the SWIR multi-channel Raman spectroscopy instrument to test the suitability of the 
VECSEL for Raman spectroscopy applications. We demonstrate that high quality Raman spectra 
from pigmented skin lesions in the SWIR region can be obtained.  
 
Materials and Methods 
VECSEL instrumentation. The developed CW electrically pumped VECSEL consists of a large oxide 
emission aperture (approximately 150 μm) semiconductor (GaAs/AlGaAs) cavity with a partial 
transmitting mirror on one side augmented with an external mirror for transverse mode control. A 
reduced reflectivity n-distributed Bragg reflector (DBR) structure was grown on a GaAs substrate. 
The active region consists of 3 quantum wells (QW) in one anti-node of the standing wave. The 
QWs contain indium and are separated by barriers containing phosphorus. Next to this active 
region was grown a thin layer with high aluminum content, which was oxidized to provide a 
current aperture. The growth was completed with a full reflectivity p-DBR structure. The device 
was processed with a full contact on the epitaxial side and therefore meant for flip-chip mounting 
i.e. substrate side emission. The backside of the substrate is anti-reflection coated. The external 
mirror with 90% reflectivity is a flat mirror as the lens developing in the substrate by temperature 
gradients (thermal-lens) is sufficient to define a stable resonator. 
The VECSEL chip size is 1.7 by 1.7 mm. Current was supplied by a current source (model Keithley 
2420, Tektronix, Beaverton, OR, USA). During operation the temperature of the VECSEL was kept 
stable within 21.05±0.05 °C using a thermal electric cooler with controller (model LDC 3744B, ILX 
Lightwave, Bozeman, MT, USA).  
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VECSEL beam profile and emission spectrum. The beam profile was measured with a beam 
profiling camera (Model WinCamD DataRay Inc., Redding, CA, USA) and corresponding stage. The 
ISO Standard 11146 describe test methods for laser beam widths, divergence and beam 
propagation ratios.15 Following this standard the M2 value of the beam was measured by focusing 
the laser with a lens (f= 19 mm focal length, Model C280-TMB, Thorlabs Inc., Newton, NJ, USA) and 
moving the camera through the focus region of the beam. The M2 value was then calculated from 
the second order moment of the beam profile. To measure the emission spectrum of the VECSEL 
we used an optical spectrum analyzer (resolution of 10 pm at high resolution mode, resolution of 
100 pm at low resolution mode, model Q8347, Advantest, Tokyo, Japan). 
 
Current versus VECSEL optical output power curve. In order to measure the current versus optical 
output power curve we used a current supplier (model Keithley 2420, Tektronix, Beaverton, OR, 
USA) and the optical output power was measured with an integrating sphere power meter (model 
S145C, Thorlabs Inc, Newton, NJ, USA). 
 
VECSEL wavelength stability. To determine the exact wavelength of the VECSEL we recorded the 
Raman spectrum of cyclohexane with well-defined Raman peaks at 2852.9, 2923.8 and 2938.3 cm-
1.16 Possible variations in laser wavelength are reflected in variations in the peak positions of the 
Raman spectra of cyclohexane. From the accurate wavelength position of each peak of 
cyclohexane and their Raman shifts follows the corresponding laser wavelength. The laser 
wavelength was calculated from the average of those three peaks. Peak positions were accurately 
calculated from the zero-crossing of the first derivative of Raman spectra. We have tested the 
VECSEL wavelength stability over a short-term interval at a high spectrum-sampling rate (40 
measurements within 30 minutes) for possible wavelength fluctuations and over an extended 
period of time, corresponding to a full-day of measurements at a low spectrum-sampling rate (one 
measurement every 20 minutes over approximately 5 hours) to identify possible wavelength drifts. 
The temperature of the VECSEL was kept constant to within 21.05±0.05˚C during all the 
experiments.  
 
VECSEL power stability. The VECSEL power stability was tested over a short-period of time at an 
acquisition sampling rate of 10Hz over 16 minutes and over a longer period of time, 
corresponding to a full-day of measurements (approximately 5 hours). An optical power meter (Ge 
photodiode, Model S132C, Thorlabs Inc, Newton, NJ, USA) was mounted on the optical table, 
behind the sample position. During the experiments, the stabilized temperature of the VECSEL 
was monitored.  
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Raman spectroscopy instrumentation. A SWIR multichannel Raman instrument was constructed 
in-house and has been described elsewhere 2. The collimated light from the VECSEL was focused in 
the sample to a Gaussian spot with a diameter of ~6 μm. The f/#2 spectrometer that was used 
(BaySpec Inc., San Jose, CA, USA), had an entrance slit with a width of 25 μm and had a 5 cm-1 
spectral resolution. The spectrometer has been customized to cover the spectral range between 
1300 and 1550 nm when using an excitation wavelength of 976 nm from the diode laser (IPS, 
Monmouth Junction, NJ, USA). The captured spectral range 1337.6-1532.4 nm corresponds to a 
Raman spectrum from 2659.0 cm-1 to 3609.7 cm-1 when using the 986 nm VECSEL.  
Raman spectroscopy measurement protocol on pigmented skin lesion. Six excised pigmented 
skin lesions from an on-going study (approved by the Medical Ethics Committee of the Leiden 
University Medical Center, C13.06) were measured with the Raman spectroscopy instrument and 
the VECSEL laser in the Leiden University Medical Center (LUMC). Immediately after surgery, the 
freshly excised skin samples were rinsed with NaCl solution (0.9%), wiped with gauze soaked in 
ethanol (70%), pressed between two fused silica windows and inserted into the sample cartridge 
for Raman measurements.2,14  
 
Pre-processing and calibration of Raman spectra. Raman spectra were corrected for the 
wavelength-dependent detection efficiency of the setup as described elsewhere, using an 
SRM2246 intensity standard (National Institute of Standards and Technology, Gaithersburg, 
Maryland, USA). The absolute wavenumber axis was calibrated using the spectral lines of a neon-
argon lamp and the Raman spectrum of cyclohexane. The Raman background that originates from 
the optics was subtracted from all spectra.2 
 
Results  
 
VECSEL beam profile and emission spectrum. The developed VECSEL operates with a circular 
beam (ellipticity 0.95:1). The beam 1/e2 diameter output is approximately 100 μm. Figure 1a shows 
the beam profile measured with the beam profiling camera. The determined M2 value is 1.5. Figure 
1b shows the VECSEL spectrum with the central wavelength of emission at 986 nm and spectral 
linewidth of 5.75 pm (full width at -3dB) which spectrally corresponds approximately to 0.03 cm-1 
in the detected Raman range (1350-1550 nm). The side mode suppression ratio is >30 dB. The 
temperature drift of the VECSEL is 0.03 nm/°C.  
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Current versus VECSEL wavelength and optical output power. Figure 2a shows the wavelength 
of the device versus current. As the current increases the device shows longitudinal mode hops, 
i.e., changes in the emitting central wavelength. The curve shows several ranges of 10 to 20 mA 
wide, on which the laser is stably operating in a single mode. For measurements on these stable 
plateaus the sensitivity of the wavelength with current is 0.01 nm/mA. However, when the current 
is set between 500 mA to 600 mA the laser operates in a higher order transverse mode regime and 
may be multimode. In this range the wavelength is no longer stable. Therefore, tight temperature 
control and current control are required to keep the VECSEL operating in a stable single mode 
with a constant wavelength. We have chosen to operate the VECSEL at 450 mA, which 
corresponds to an output power of approximately 100mW, for the Raman measurements in this 
study.  The optical output power versus current (LI) characteristic curve in figure 2b shows the 
output power of the VECSEL at a temperature of 21.05 ±0.05°C. At currents below 200 mA there is 
no emission. Above 200 mA the optical output power increases roughly proportionally to slightly 
above 100 mW at a current of 500 mA.  
 
VECSEL wavelength stability . Figure 3 shows the results for the wavelength stability tests. Figure 
3a shows the measured Raman spectra of cyclohexane and the peaks used to calculate the laser 
wavelength. The three peaks of cyclohexane Raman spectrum were detected at 1373.63 nm, 
1386.27 nm and 1389.20 nm, respectively. The results of the experiments carried out to detect 
possible laser wavelength changes in short and long-term are shown in figures 3b and 3c, 
respectively. The standard deviation of fluctuations in laser wavelength in the short-term 
measurement was ±0.01 nm. The maximum variation in the peak position was obtained during 
the long-term measurement (over period of 5 hours), corresponding to a SD of ±0.025 nm.  
 
Figure 1. a) Beam profile(fundamental transverse TEM00 mode) recorded with a CCD camera. b) Measured 
VECSEL spectrum centred at the wavelength of 986 nm. 
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Figure 2. a) Wavelength-current curve of the 986-nm tested VECSEL; b) Optical output power -current (LI) 
curve of the 986-nm tested VECSEL (at 21.05 °C). 
 
 
Figure 3. VECSEL wavelength stability. a) Cyclohexane was measured 40 times within 35 min for the short-
term wavelength stability test. b) VECSEL wavelength stability over a period of 35 min (40 measurements, 
average wavelength: 986.6726 nm, SD = 0.01 nm); c) VECSEL wavelength stability over a period of 5 h (16 
measurements, average wavelength: 986.5694 nm, SD = 0.025 nm). 
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VECSEL power stability The results for power stability tests of the VECSEL are presented in figure 
4. Figure 4a shows the power variation during a single measurement of 16 minutes at an 
acquisition rate of 10Hz. The average value is 79.85±0.01 mW (SD). Figure 4b shows the power 
variation during a period of approximately 5 hours. During this time the power was measured 16 
times, each time for 15 seconds at an acquisition rate of 10Hz. The average value is 79.95±0.01 mW 
(SD). The variation represents <0.02% of the average power. Raman spectra measured using the 
VECSEL showed laser light interference in the 1330-1530 nm spectral range (Figure 5). This 
interference could be sufficiently suppressed by insertion of an edge short-pass filter (OD>5.0, 
cutoff at 1000 nm, Model FESH1000, Thorlabs Inc., Newton, NJ, USA).  
 
Demonstration of Raman measurement on pigmented skin tissue Figure 6 shows typical 
Raman spectra measured on two different excised pigmented skin lesions using the 986nm 
VECSEL (Figure 6a) and the 976 nm edge-emitting diode laser (Figure 6b). This figure illustrates a 
qualitative comparison of a Raman spectrum obtained with the developed VECSEL and the 
commercial edge-emitting diode laser. Each spectrum was obtained in an integration time of 30 
seconds. Both spectra were intensity-normalized using the extended multiplicative scatter 
correction (EMSC) method.17  
 
 
 
Figure 4. VECSELpower over a) 16 min; b) a period of approximately 5h. 
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Figure 5. a) Background signal without additional filtering. b) After introduction of an edge short-pass filter 
(OD > 5.0, cutoff at 1000 nm) in the laser path this background signal was sufficiently suppressed. 
?
 
Figure 6. Examples of Raman spectra measured from two different excised pigmented skin lesions using the 
same in-house built Raman instrument. Acquisition time per spectrum: 30 s. The spectra are offset along the 
intensity axis for clarity. a) Using the developed 986-nm VECSEL (100 mW). b) Using a 976-nm edge-emitting 
diode laser (150 mW). 
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Discussion 
The findings of this study show the feasibility of a novel developed VECSEL for Raman 
spectroscopy. The design wavelength of the VECSEL in this study was optimized to enable for 
Raman spectroscopy on pigmented tissues. However, the design wavelength can be changed to 
accommodate other applications as well. The design wavelength of the VECSEL can be tuned from 
approximately 800 - 1200 nm by changing the bandgap of the quantum well. 
The tested VECSEL yields an excellent round beam profile with an ellipticity close to 1. In respect to 
beam spatial quality, the parameter M2 indicates how much stronger a laser beam diverges 
angularly in the two transverse directions as compared with a single-transverse mode diffraction-
limited beam, which is designated by M2 value of 1.4 In this tested VECSEL, the determined M2 
value was 1.5, which is close to a perfect Gaussian beam. This value is more than sufficient for the 
intended Raman application. In terms of spectral linewidth, the measured value is 5.75 pm (1.77 
GHz), which was the operational resolution of the optical spectrum analyzer. This linewidth is very 
good for Raman spectroscopy. The possibility that the linewidth of the laser was more narrow 
could not be confirmed due to the limit of resolution of the optical spectrum analyzer used. The 
commercial 976 nm diode laser linewidth was specified at better than 18 pm (value limited by the 
resolution of the optical spectrum analyzer). In respect to spectral purity, the side mode 
suppression ratio is better than 30 dB, which corresponds to an OD3. This value is sufficient for 
many Raman spectroscopy applications. However, additional filtering with a short-pass filter in the 
laser path can remove unwanted light emission. In this study light emission from the laser source 
around 1300-1500 nm caused an enhanced background radiation which limited the sensitivity for 
the Raman signal (Figure 5a). This was solved by inserting a short-pass filter (OD>5) in the laser 
light emission path, blocking all light above 1000 m (Figure 5b).  
The wavelength of the VECSEL is mainly dependent on the stabilization of its operating 
temperature and of the laser current. In figure 2a, we can see the effect on laser wavelength with 
increasing current. As the current increases the device shows longitudinal mode hops (in the order 
of 0.1 nm, which corresponds well with the expected mode spacing for a 4 mm extended cavity), 
in the region from 320 to 500 mA. In this range we can find plateaus of about 10 to 20 mA where 
the laser is operating in a single mode and the wavelength is stable. At higher currents (above 500 
mA) the VECSEL operates in a high order transversal mode (M2 value gets significantly higher) and 
multiple transverse modes can be lasing at the same time. Therefore, the drive current needs to be 
selected and kept constant to avoid longitudinal mode hops at currents in the fundamental mode 
region between 320 and 500 mA.  
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Temperature variations cause changes of the refractive index, and hence on the optical path 
length of the cavity. This induces changes in wavelength and output power. The temperature 
induced wavelength drift of the VECSEL semiconductor cavity is ~0.03 nm/°C. This means that the 
temperature needs to be stable at <0.1°C to limit wavelength changes to less than 3 pm. As 
mentioned before, to prevent mode-hopping the current should be chosen such, that the VECSEL 
operates in the middle of the single-mode stable plateaus of about 10 to 20 mA wide (Figure 2a). 
To limit the influence of current fluctuations on the wavelength of the VECSELs it is desired to 
make it 10 times smaller than the Raman sensitivity limit of 1 cm-1, corresponding to 1 pm. This 
would result in a current stability of 0.1 mA. To ensure the overall wavelength stability, a 
requirement on current of 0.1 mA and temperature of 0.1°C is desired. The tested VECSEL was in 
contact with a Peltier element to ensure constant heatsink temperature during the measurement 
period. During these experiments the VECSEL temperature was kept stable within 0.1°C using the 
laser controller temperature driver. Temperature and current stabilization are easy to achieve, but 
additional hardware and power dissipation are needed for temperature stabilization. Temperature 
stabilization can be achieved using conventional package technologies with thermo-electric 
cooling and would fit in a TO-Can package. 
A Raman spectrum provides a convenient and sensitive method to test laser wavelength stability 
by accurately monitoring small shifts in Raman peak positions. We did not observe noticeable 
fluctuations on a short time-scale of 30 minutes (SD=0.01 nm), nor did we see drifts over longer 
period of time of over 5 hours (SD=0.025 nm), which is a regular working period with the 
equipment. The short-term and long-term wavelength stability tests were performed on different 
days (Figures 3b and 3c, respectively). There is a slight wavelength difference (dλ = 0.1032 nm) 
between these days. The magnitude of this difference is comparable with mode hop differences 
shown in figure 2a, which suggests that the VECSEL was operating at a different longitudinal 
mode of the external cavity between those days. Nevertheless, long-term measurement within the 
same day, during which the VECSEL was not turned off, did not show these wavelength changes 
and the wavelength remained stable within ±0.025 nm. This is very good for most of Raman 
spectroscopy purposes. 
The laser is required to have stable power because the background signal, which originates from 
optical elements in the laser path, must be subtracted from the Raman signal. However, the 
background signal from optical elements is typically low in the HWVN region and the influence of 
power fluctuations up to 10% is negligible. In the power stability tests we did not observe 
significant fluctuations on a short time-scale nor did we notice significant drifts over a 5-hours 
superior (maximum variation is less than 0.5 % of average power). The short-term power stability 
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test and the long-term power test were performed on different days (Figures 4a and 4b, 
respectively), with power variations of 0.1 mW between these days. As before, this might be due to 
the VECSEL operating at a different mode of the external cavity between these days, which would 
be reflected to a slightly different output power. However, within the same day, the power is kept 
stable (SD= 0.01 mW). In summary, the results presented above show that the VECSEL fulfils the 
power and wavelength stability requirements of a laser source to be applied in Raman 
spectroscopy.  
We presented typical example of Raman spectra of pigmented human skin lesions measured in 30 
seconds (Figure 6). The presented spectra prove that high quality Raman signals can be obtained 
when using the tested VECSEL as the laser source.  
With this work we demonstrate the feasibility of using VECSELs, which offer circular output beam, 
easy array fabrication, low cost at mass production, and compactness, for Raman spectroscopy 
applications.  
 
Conclusion 
In this paper, we tested the feasibility of a novel VECSEL source for Raman spectroscopy 
applications. Our results show that the VECSEL fulfils the requirements as a light source for Raman 
spectroscopy and has the characteristics to be employed in a low-cost compact hand-held Raman 
instrument device.  
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melanoma and benign melanocytic lesions 
suspected of melanoma using high-
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Abstract 
Melanoma is a pigmented type of skin cancer, which has the highest mortality of all skin cancers. 
Because of the low clinical diagnostic accuracy for melanoma, an objective tool is needed to assist 
clinical assessment of skin lesions that are suspected of (early) melanoma. The aim of this study 
was to identify spectral differences in the CH region of HWVN (high-wavenumber) Raman spectra 
between melanoma and benign melanocytic lesions clinically suspected of melanoma. We used 
these spectral differences to explore preliminary classification models to distinguish melanoma 
from benign melanocytic lesions. Data from 82 freshly excised melanocytic lesions clinically 
suspected of melanoma were measured using an in-house built Raman spectrometer, which has 
been optimized for measurements on pigmented skin lesions (excitation wavelength 976 nm and 
a wavelength range of the Raman signal 1340−1540 nm). Clear spectral differences were observed 
between melanoma and benign melanocytic lesions. These differences can be assigned mainly to 
the symmetric CH2 stretching vibrations of lipids. Our results show that the Raman bands between 
2840 and 2930 cm−1 have increased intensity for melanoma when compared to benign 
melanocytic lesions, suggesting an increase in lipid content in melanoma. These results 
demonstrate that spectroscopic information in the CH-stretching region of HWVN Raman spectra 
can discriminate melanoma from benign melanocytic lesions that are often clinically 
misdiagnosed as melanoma and that Raman spectroscopy has the potential to provide an 
objective clinical tool to improve the clinical diagnostic accuracy of skin lesions suspected of 
melanoma. 
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Introduction 
Melanoma is a form of skin cancer derived from melanocytes; the pigment-producing cells of the 
skin. Melanoma cells have a propensity to disseminate to distant organs and once metastasis has 
occurred the prognosis of patients is very poor. Metastasis and mortality from melanoma depend 
to a large extent on the stage of the disease and the thickness of the primary tumor on diagnosis. 
When diagnosed at an early stage, melanomas can be treated and cured by surgical resection in 
most cases.1,2,3 When diagnosed at a later stage, melanomas have a considerable risk of 
progression to lethal metastatic disease. Improving the early diagnosis of melanoma therefore 
constitutes an important clinical objective. 
Clinical differentiation between melanoma and benign melanocytic lesions can be challenging, 
even for experienced dermatologists. The clinical examination and diagnosis of melanoma is 
based upon visual inspection and recognition of morphologic characteristics, usually supported 
by tools such as a dermoscope. The use of a dermoscope can improve the accuracy of melanoma 
diagnosis but only when used by trained clinicians.4,5,6,7 Even with the use of a dermoscope by an 
experienced clinician the sensitivity of diagnosing melanoma varies between only 68% and 
96%.8,9,10 Because the distinction between early-stage melanoma and benign pigmented lesions is 
difficult to make, many pigmented skin lesions are unnecessarily surgically removed. Literature 
reports clinical positive predictive values as low as 7% to 23% for melanoma diagnosis by 
dermatologists in a specialized pigmented lesion clinic.11 Despite the over-diagnosis and 
subsequent unnecessary excisions, a substantial number of early-stage melanomas is still missed 
at the first clinical presentation with severe risk to progress to a metastatic stage.7,12,13 It has been 
reported that there are up to 30% missed melanomas among general practitioners.12 Objective 
methods are needed to improve the clinical diagnostic accuracy of melanoma in general and early 
melanoma specifically. 
Various methods have been investigated to objectively diagnose melanoma, almost all of which 
rely on the detection of morphological differences between benign and malignant tumors. 
Examples of such methods are reflectance confocal microscopy,14 electrical impedance 
spectroscopy,15 confocal microscopy,16 multispectral imaging,17 and automated dermoscopy 
image analysis.18 Incremental improvements in diagnostic accuracy are feasible through 
optimization of these morphology-based methods. 
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A promising approach is the analysis based on biochemical differences. Biochemical differences 
are potentially much more specific than morphological characteristics.19,20 Besides the enhanced 
sensitivity, specificity and positive predictive value of diagnosis, these methods would have the 
advantage of facilitating accurate earlier diagnosis, which would enable improvement of 
treatment efficiency and survival rates.  
Raman spectroscopy is an excellent candidate technique to characterize in vivo biological tissue 
and to detect non-invasively the molecular changes associated with pathological processes, i.e. to 
successfully distinguish tumor from healthy tissue.21,22 Raman spectroscopy is an optical non-
destructive technique that uses light scattering to characterize non-invasively tissue at a molecular 
level. It does not require any labelling, reagents or preparation of the tissue to be analyzed, which 
facilitates translation to the clinic.  
Until now, the application of Raman spectroscopy in the analysis of highly pigmented biological 
samples presented a major hurdle. When using visible or near-infrared laser excitation 
wavelengths up to about 850 nm, the absorption of light by melanin in pigmented skin lesions 
leads to laser-induced tissue fluorescence. This is generally much more intense than the tissue 
Raman signal, to the point that it obscures the Raman spectral features.  
In our previous work we tested the feasibility of an in-house built Raman spectroscopy device to 
acquire high-quality Raman spectra of pigmented biological samples.23 We used infrared laser-
excitation at 976 nm in order to decrease the laser-induced tissue fluorescence. The Raman signal 
was detected in the short-wave infrared (SWIR) region, using a sensitive indium-gallium-arsenide 
(InGaAs) detector with extremely low detector noise. With this prototype we demonstrated high-
quality, shot-noise-limited high-wavenumber (HWVN) Raman spectra of pigmented skin lesions 
with acquisition times sufficiently short to be compatible with application in a clinical setting.23 
In this paper we identify the main spectral differences between melanoma and benign 
melanocytic lesion classes and explore whether there is spectroscopic information in the CH-
stretching region (2820-3040 cm-1) to discriminate melanoma from benign melanocytic lesions. 
 
Methods and materials 
Excised skin lesions. This study was approved by the Medical Ethics Committee of the LUMC 
(C13.06). After clinical assessment performed by a dermatologist, pigmented skin lesions 
suspected of melanoma were excised and submitted for histopathological diagnosis in the 
dermatology outpatient clinic of the Leiden University Medical Center (LUMC). These excisions 
were performed according to the national melanoma guideline and standard protocol of the 
4C h a r a c t e r i z a t i o n  o f  m e l a n o m a  a n d  b e n i g n  l e s i o n s  b y  R S | 73 
 
?
LUMC department of dermatology. The standard excision protocol was followed; prior to surgery, 
the excision margins of the lesions were delineated with a permanent marker. The entire surgical 
area was wiped with a gauzed soaked in antiseptic chlorhexidine solution (0.5% in 70% ethanol). 
Local anesthesia (Lidocaine hydrochloride 2% epinephrine 1:100,000 solution) was administered 
via intradermal injection close to the excision margins, circumferential to the lesions. 
 
Measurement protocol. Immediately after surgery, the excised skin samples were rinsed with 
NaCl solution (0.9%), wiped with a gauze soaked in ethanol (70%) to remove residual ink from pen 
marker, gently flattened between two fused silica windows and inserted into a custom-made 
sample cartridge for Raman measurements (Figure 1). The maximum time allowed for the 
experimental procedure described below was fixed at 30 minutes after surgery, to keep optimal 
tissue preservation and to avoid interference with the routine histopathological examination of 
the excised specimen. Multiple locations within the lesion were measured. Approximately 15 point 
measurements were performed per lesion. Each point measurement had an integration time of 30 
seconds. After the Raman spectroscopy measurements, the skin samples were put in a 
formaldehyde solution (4%) and sent to pathology for the routine diagnostic procedure. 
 
Histopathological diagnosis. All excised lesions suspected of melanoma that were measured 
with the Raman spectroscopy instrument were diagnosed by two dermopathologists. The final 
histopathological diagnosis, upon agreement, was used as the gold-standard reference for 
correlation with the Raman measurement.  
 
- 
Figure 1. Excised skin lesion inserted into the sample cartridge. 
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Sample inclusion criteria. In total, 149 freshly excised pigmented lesions clinically suspected of 
melanoma were measured with the Raman spectroscopy instrument. Only histologically 
homogenous melanocytic lesions were included in the study. Lesions that were 
histopathologically heterogeneous, i.e., that did not have a consistent histologic appearance 
throughout the entire lesion, were excluded from data analysis after evaluation by two 
dermopathologists based on histopathological findings only (n=42) before data analysis. This 
group of 42 excluded lesions contained 13 melanomas. Non melanocytic lesions (n=11) and 
lesions that present strong spectral artefacts (due to presence of fixed pattern noise or equipment 
failure) were excluded (n=14). 
 
Raman spectroscopy instrumentation. A SWIR multichannel Raman instrument was used to 
obtain Raman spectra.23 The excitation light source was a single-mode continuous wave diode 
laser with a wavelength of 976 nm and an output power of 150 mW (Model R-type, Innovative 
Photonic Solutions, Monmouth Junction, NJ, USA). The captured spectral range 1340-1540 nm 
corresponds to a Raman spectrum from 2780 to 3750 cm-1. The custom-made sample cartridge 
was used to hold the excised skin sample between two fused silica windows. For Raman 
measurements, the sample cartridge was inserted inside an anodized aluminium sample holder 
that was mounted perpendicular to the laser beam. The light was focused in the sample to a 
Gaussian spot with a diameter of ~6 μm. The sample holder was mounted on a 3-axis translation 
stage to enable measurements at a range of locations in the sample. The sample was placed in the 
laser beam with the focus position optimized on the Raman signal from the tissue. 
 
Pre-processing and calibration of Raman spectra. Raman spectra were corrected for the 
wavelength-dependent detection efficiency of the setup, using an SRM2246 intensity standard 
(National Institute of Standards and Technology, Gaithersburg, Maryland, USA). The absolute 
wavenumber axis was calibrated using the spectral lines of a neon-argon lamp and the Raman 
spectrum of cyclohexane. The Raman background that originates from the optics was subtracted 
from all spectra. The spectra presented were scaled to the average of all individual spectra using 
extended multiplicative signal correction (EMSC) with a first order polynomial background.24 Due 
to a presence of fixed interference in the Raman spectra generated by the detector response, we 
filtered the data with a 5th order spline function to remove the fixed interference. All spectra were 
cropped to the spectral range (2820-3040 cm-1), which corresponds to the CH-stretching band 
region. This is the spectral region that includes the main information about protein and lipid 
vibrations.  
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Data Analysis. Average Raman spectrum per histopathological class. For each pigmented lesion 
included in this study, the Raman spectra from multiple measurements within the lesion were 
averaged. For interpretation of the spectral features per histopathological class, an average Raman 
spectrum was calculated for each histopathological class. A first derivative of these class-average 
Raman spectra was calculated to emphasize the spectral differences between the classes.  
Spectral difference between melanoma and benign melanocytic nevus classes. Spectral 
differences between melanoma and the other histopathological classes were assessed by creating 
difference spectra. Difference spectra were calculated by sequentially (i) averaging all spectra 
within each histopathological class, (ii) normalizing intensity of each spectrum using extended 
multiplicative scatter correction (EMSC)24 with a first order polynomial background, (iii) subtracting 
each of the average Raman spectra from the average spectrum of melanoma.  
PCA-LDA model with averaged spectra per sample. Linear discriminant analysis (LDA) classification 
modelling was used to investigate the discriminatory power of Raman spectral information for 
distinguishing melanoma from common benign melanocytic nevi. LDA models were created using 
the averaged spectrum per lesion as input. Because some classes only contain few samples, 
histopathological classes represented by less than 5 different lesions were left out of the LDA 
classification model. Principal component analysis (PCA) was performed to reduce the 
dimensionality of the data prior to LDA modelling. The performance of LDA on lesion averaged 
spectra was assessed using leave-one-lesion-out cross validation. For each leave-one-lesion-out 
LDA model, the scores on the most significant principal components (determined by the highest 
confidence levels in a student t-test of group differences) were selected as input parameters. An 
ROC (Receiver Operator Characteristic) curve was made to assess the discriminative power and 
optimal discrimination thresholds. In this study, specificity was computed as the fraction of 
correctly predicted negatives (not melanoma) from the total number of benign melanocytic 
lesions in the analyzed sample set. Sensitivity was calculated as the fraction of correctly predicted 
positives (melanoma) from the total number of melanomas in the analyzed sample set.  
The software used for all computations was Matlab R2015b (Mathworks Inc., Natick, 
Massachusetts, United States). 
 
Results and discussion 
 
The purpose of this study was to investigate whether there is diagnostic information in the CH-
stretching region of HWVN Raman spectra and to identify the main spectral differences between 
melanoma and benign melanocytic lesions.  
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After application of the inclusion criteria, the final dataset contained Raman spectra from 82 
lesions of which 24 were melanomas (including melanoma in situ, superficial spreading and 
nodular), 10 dysplastic/atypical nevi and 48 benign melanocytic nevi (including compound 
melanocytic nevus, dermal melanocytic nevus, junctional melanocytic nevus, combined 
melanocytic nevus, blue nevus, Spitz nevus and lentigo simplex) (Table 1).  
For spectral analysis, we used the CH-stretching spectroscopic region (2820-3040 cm-1 range), 
which includes the main protein and lipid vibration information.  
The Raman spectra averaged by histopathological class are shown in Figure 2. The first derivative 
of each average Raman spectrum is shown to accentuate spectral differences between the classes.  
Figure 3 shows the spectral differences between melanoma and the other benign melanocytic 
classes. Each plot shows the residual of the spectrum of each of the classes indicated in the figure 
subtracted from spectrum of melanoma class.  
Analyzing the spectral differences between Raman spectra of the melanoma group and the Raman 
spectra from benign melanocytic lesions (Figure 3), we found that the melanoma group shows 
increased Raman signal intensities between 2840 cm-1 and 2930 cm-1.  
The peak visible in the residual spectra at 2854 cm-1 is assigned to the symmetric CH2 stretching 
vibrations of lipids,25,26,27 and implies that the Raman spectra of melanoma exhibit an increased 
lipid contribution when compared to the other histopathological classes (dysplastic/atypical 
melanocytic nevus, dermal melanocytic nevus, junctional nevus and blue nevus). An exception is 
seen for the Spitz nevus. The negative peak of the difference spectrum between melanoma and 
Spitz nevus corresponds to the position 2848 cm-1 and suggests that melanoma has less lipids 
than Spitz nevus. Whether this observed difference for the Spitz nevus is coincidental or reflects a 
characteristic of Spitz nevus could not be established due to the low number of Spitz nevi (n=2) in 
this study.  
 
Table 1. Summary of included homogenous melanocytic skin lesions clinically suspected of melanoma 
Histopathological diagnosis n 
Melanoma (inc. in situ) 24 
Benign melanocytic lesions 
dysplastic 10 
compound 23 
dermal 14 
junctional 4 
blue nevus 2 
lentigo simplex 2 
Spitz 2 
combined 1 
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Figure 2. a) Average HVWN Raman spectra per histopathological class ± standard deviation (gray). b) First 
derivative of the spectra shown in A. In both figures the spectra are offset along the intensity axis for clarity. 
 
In the same spectral region, we can identify another peak at 2896 cm-1 that is more intense in 
melanoma group compared to the other histopathological classes. This peak is assigned to 
asymmetric CH2 stretching vibrations of lipids.27,28 In the difference spectrum between melanoma 
and compound melanocytic nevi (figure 3), the peak is not as evident as in the other difference 
spectra, although it is still visible. Another peak, at 2876 cm-1, is visible in both residuals between 
melanoma-combined melanocytic nevi and melanoma-compound melanocytic nevi. This peak is 
assigned to the asymmetric CH2 stretching vibration of lipids.27,28 An extra band at 2922 - 2930 cm-1 
is visible at the residual spectrum between melanoma and combined melanocytic nevi. This band 
is assigned to the symmetric CH3 stretching vibration of lipids and proteins.27,29  
In contrast to lipid contributions, Raman spectra of melanoma show consistently lower intensity in 
the spectral range between 2930 and 3000 cm-1 compared to the other groups. The negative peak 
visible in the spectral residual at 2950 cm-1 is assigned to CH3 stretching vibration of proteins.30 As 
before, the Spitz nevus group is an exception. 
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Figure 3. Difference spectra between the average Raman spectrum of melanoma and the average Raman 
spectra of each of the other histopathological classes. The spectra are offset along the intensity axis for clarity. 
In summary, our results show that Raman spectra of melanoma have an increased contribution 
from lipids when compared to the other histopathological classes. The results presented above 
show that the most distinctive spectral feature between melanoma and the other classes in the 
spectral region assigned to CH2 -CH3 stretching vibrations is attributed to a higher lipid-protein 
ratio in melanoma. These findings are in agreement with the findings of Gniadecka et al. 31, in 
which the authors used Fourier-transform Raman spectroscopy and found that melanoma 
presents increased lipid-specific bands around 1310 cm-1 when compared to pigmented nevi 
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(benign melanocytic lesions) and basal cell carcinomas and seborrheic keratoses (non-melanocytic 
lesions).  
The authors also mentioned the fact that the range between 2840 - 3000 cm-1 was an important 
region for the differentiation between melanomas and pigmented nevi, basal cell carcinomas and 
seborrheic keratoses by neural network analysis.31 The observed increase in lipid content in 
melanomas is consistent with recent studies, which report that cancer cells present dysregulated 
lipid metabolism and intensified de novo lipogenesis.32,33,34,35 Innocenzii et al., show that there is an 
overexpression of fatty acid synthase in melanoma compared to the dermal and junctional 
melanocytic nevi examined as control group.36 In another study, Sumantran et al. report that 
melanomas have upregulated genes that lead to an increase in fatty acid synthesis, metabolism of 
specific lipid second messengers and ganglioside synthesis.37 Kwan et al. suggest from their study 
that adipocytes might be an exogenous supply of palmitic acid that promotes melanoma cell 
growth.38 Other studies using HWVN Raman spectroscopy to differentiate different types of 
tumors or pre-tumor states (dysplasia) from their respective normal tissue, like breast cancer, 
cervical tissue cancer and liver cancer have reported similar findings, with tumor tissue showing 
higher intensities in the CH band, attributed to stretching vibrations of lipids, than normal tissue.39-
42 
In this study PCA-LDA classification was used to investigate the discriminatory power of the CH 
region of HWVN Raman spectra in discriminating melanoma from all the other lesion classes 
included in this analysis. For this analysis, the histopathological classes represented by less than 
five lesions have been excluded (combined melanocytic lesion, Spitz nevus, lentigo simplex, blue 
nevus and junctional melanocytic nevus) because the low number of cases in each class could 
introduce undesired variability into the analysis. This resulted in PCA-LDA based on a final set of 71 
lesions (24 melanomas, 10 dysplastic/atypical melanocytic nevi, 23 compound melanocytic nevi 
and 14 dermal melanocytic nevi). The discriminating parameter used as input for LDA was a 
Boolean: melanoma or not-melanoma. Due to the small size of the database, only a leave-one 
sample-out cross validation was used. Figure 4 shows the Receiver-Operator Characteristic (ROC) 
curve generated from different discriminating threshold levels, showing the performance of the 
created LDA model for melanoma detection. Because we performed this experiment in a 
specialized pigmented lesion clinic, it follows that our study contained only benign pigmented 
lesions and melanoma that were difficult to distinguish even by trained dermatologists. The 
positive predictive value of the clinical diagnosis in the pigmented lesions clinic was 25%; i.e. only 
37 out of 149 excised lesions was a melanoma. Our preliminary classification model correctly  
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Figure 4. ROC curve of discrimination of melanoma using the PCA-LDA classification model with leave-one 
sample-out cross validation method. The area under the ROC curve is 0.77.  
classified all melanoma with a specificity of 45%. This suggests that in vivo application of Raman  
spectroscopy, prior to lesion excision, might lead to a threefold reduction of the ratio 
of unnecessary excisions to melanoma excisions from 3:1 to 1:1. These results bode well for the 
development of an objective Raman spectroscopy instrument for objective melanoma diagnosis. 
This is an encouraging result towards an application to help general practitioners and non-
experienced dermatologists to discriminate melanoma from suspicious lesions and reduce 
unnecessary surgical excisions of benign melanocytic lesions. We are exploring the possibilities to 
transfer this technology to in vivo clinical application. Various approaches are conceivable to use 
this method in vivo such as a flexible fiber-optic probe for easy access of various parts of the body. 
 
Conclusion 
In this study we used a novel in-house built HWVN Raman spectrometer to obtain high quality 
Raman spectra of pigmented skin lesions suspected of melanoma. From the Raman spectra, we 
were able to identify the main spectral differences between melanoma and benign melanocytic 
lesions as increased contribution from symmetric CH2 stretching vibrations of lipids in melanoma, 
when compared to the other lesions analyzed.  
The obtained results demonstrate the potential of Raman spectroscopy as an objective clinical 
tool to help distinguishing melanoma from benign melanocytic lesions, which are often clinically 
misdiagnosed as melanoma, based on the spectroscopic information in the CH-stretching band.  
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Abstract 
Clinical diagnosis of early melanoma is crucial to disease-free survival. When diagnosed early 
(Breslow-thickness less than 0.8 mm) melanoma can be cured by surgical excision, with a 5-
year survival rate of > 97%. However, the clinical diagnosis of thin melanoma is subjective and 
can be exceedingly difficult, leading to missed diagnosis, or unnecessary excision of benign 
pigmented skin lesions.  
It has been reported that among general practitioners, the sensitivity of diagnosing melanoma 
varies between 70-88% and among dermatologists between 82-100%. The number of benign 
pigmented lesions excised to diagnose one melanoma varies between 6-9 for dermatologists 
and between 20-30 for general practitioners. Obviously, an objective technique is needed to 
improve the diagnosis of early melanoma. In this study, we use Raman spectroscopy to assess 
freshly-excised melanocytic skin lesions that were clinically suspicious for melanoma.  
We have developed a method to improve diagnosis of (thin) melanoma. A diagnostic model 
was developed based on high-wavenumber Raman spectra, obtained at multiple locations 
within freshly excised cutaneous melanocytic lesions. Measurements were performed on 174 
lesions, clinically suspicious for melanoma, in a highly specialized out-patient clinic. The 
diagnostic model was validated on an independent data set of 96 lesions. 
Approximately 60% of the melanomas included in this study were melanomas in situ. The 
invasive melanomas had an average Breslow thickness of 0.89 mm. The diagnostic model 
correctly classified all melanomas with a specificity of 43.8%. The diagnostic model for 
melanoma showed in this study a potential improvement of the number needed to treat from 
6.0 to 2.7, at a sensitivity of 100%. 
We demonstrate that, based on Raman spectroscopy, an accurate diagnosis of melanoma with 
Breslow thickness <0.8 mm can be made. This work signifies an important step towards 
objective accurate diagnosis of melanoma.   
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Introduction 
Melanoma is a malignant tumor arising from melanocytes, the pigment-producing cells of the skin. 
It is the most aggressive and fatal form of skin malignancy. Its incidence has been steadily 
increasing in the last decades, with more than 232 000 new cases estimated worldwide in 2012.1  
Melanoma must be diagnosed at an early stage. One of the most important prognostic factors of 
melanoma is the vertical depth of growth (Breslow thickness). In a primary lesion, the Breslow 
thickness is significantly correlated with metastatic propensity. Lesions that have a Breslow 
thickness less than 0.8 mm can be treated surgically with a high cure rate (5-year survival rate of > 
97%).2 In advanced stages, the 5-year survival rate can drop to 32%.2  
The clinical diagnosis of melanoma is based on analysis of morphological criteria and is therefore, 
subjective and difficult. It is based on visual inspection of the lesion, aided by dermoscopy, by a 
dermatologist or a general practitioner. When a lesion is clinically suspected of melanoma, a 
diagnostic excision is indicated. 
It has been reported that among general practitioners, the sensitivity of diagnosing melanoma 
varies between 70-88% and among dermatologists between 82-100%.3 However, the number 
needed to treat (NNT, the number of benign pigmented lesions excised to detect one melanoma), 
varies between 6.3-8.7 by dermatologists,4,5 and between 20-30 for general practitioners.4-12 The 
NNT can be even higher in a population of patients < 30 years (NNT = 75) 6-10,12 or in high-risk 
populations (NNT = 34, e.g. multiple dysplastic nevi or familial melanoma)13. 
These numbers imply that melanomas can be clinically missed, with the risk of missing the 
opportunity to cure the patient, while many unnecessary excisions of benign lesions take place. An 
objective and easy-to-use technique that will support and improve the diagnosis of thin 
melanoma is needed to complement the still limited diagnostic toolbox in current clinical practice.  
The reported efforts to develop techniques to improve the clinical diagnosis of melanoma are 
promising. Nevertheless, detecting early-stage melanomas is still a challenge. Various methods 
have been investigated to diagnose melanoma, most of which rely on the detection of 
morphological differences between benign and malignant pigmented skin lesions.14 Examples of 
such methods are reflectance confocal microscopy,15-17 confocal microscopy,18,19 multispectral 
imaging,20,21 automated dermoscopy image analysis22 and electrical impedance spectroscopy.23-25 
The implementation of these non-invasive diagnostic technologies is currently still low but is 
expected to increase gradually.14-26 Several studies show improvement in diagnostic accuracy 
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when combining one or more of these morphology-based methods with dermoscopy, even 
though most of these techniques are operator dependent and subject to interpretation.15,16 Using 
confocal microscopy in an in vivo setting, Monheit et al. reported a sensitivity of 98.4% (detecting 
125 out of 127 melanomas from which 44% were in situ) and a specificity of 9.9% with an 
independent validation set.27 A recent pilot study conducted by Delpueyo et al. on multispectral 
imaging based on LEDs showed a sensitivity of 87.2% and specificity of 54.5% with an independent 
validation set.21 Using reflectance confocal microscopy in clinically suspicious lesions in an in vivo 
setting, Alarcon et al reported a sensitivity of 97.8% and a specificity of 92.4% (264 lesions 
suspected of which 92 were confirmed melanomas).15 The authors stated that 6 melanomas in situ 
were missed. The presented results are promising for reflectance confocal microscopy as an 
adjunct technique for melanoma diagnosis. The limitation of reflectance confocal microscopy is 
the dependence on the experience of the operator (sensitivity 91.0% vs 84.8% and specificity 
80.0% vs. 77.9% for experienced vs recent users, respectively).28 In a multicenter study, 1300 lesions 
were analyzed by electrical impedance spectroscopy for melanoma discrimination from benign 
lesions on suspected lesions: the observed sensitivity was 99.4% (161 out of 162 melanomas, with 
1 melanoma in situ missed), and the specificity was 35.5% for benign melanocytic lesions excluding 
dysplastic nevi or 23.9% including them.24 In another multicenter study, 2416 lesions were 
analyzed by electrical impedance spectroscopy for melanoma detection. Sensitivity of 96.6% and a 
specificity of 34.4% were reported.29 From the 9 missed melanomas, 7 were in situ, other two had a 
Breslow thickness of 0.4 mm and 0.6 mm.  
Compared to the morphology, biochemical tissue characteristics are more specific. Research in 
proteomics and genomics has shown that melanoma undergoes genomic alterations, such as 
deregulation of the MAPK signaling pathway and that melanoma have different gene expression 
from benign melanocytic lesions.30-34 Raman spectroscopy is an optical non-destructive technique 
that goes beyond morphology analysis and characterizes the tissue at a molecular level. Raman 
spectra can be used as a highly specific tissue fingerprint, on the basis of which tissues can be 
classified. This objective technique does not require any labeling, reagents, or preparation of the 
tissue to be analyzed, which facilitates translation to the clinic. It has been amply demonstrated 
that Raman spectra can be used to distinguish cancer from healthy tissue, including pigmented 
skin lesions.35-41  
Lui et al. developed a classification model to distinguish benign pigmented lesions from 
melanoma, using a large Raman measurement volume (200 μm core diameter single fiber that 
illuminates a 3.5 mm diameter skin area.40 In this study, the clinical diagnoses were established by 
dermatologists and dermoscopy was not used. Only 28% of the clinically benign lesions were 
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histopathologically confirmed.40 The authors included in vivo Raman measurements acquired in 44 
melanomas and 81 pigmented skin lesions. The validation of the model was not performed on an 
independent data set instead, leave-one-out cross-validation was used. The authors reported 
sensitivity of 99% and specificity of 15%. This system, Aura®-system (Verisante, Canada) for skin 
cancer detection was commercialized. In a more recent study, the same authors increased the 
number of lesions (only 9 melanomas were added) in the same clinical setting and performed an 
independent validation. The model discriminates between all skin cancers and pre-cancers 
(including melanomas, basal cell carcinomas, squamous cell carcinomas and actinic keratosis) from 
their benign counterparts.42 In this study, the presented sensitivity was 99% and the specificity was 
24%. In 2014, Lim et al. combined diffuse optical spectroscopy, laser-induced fluorescence 
spectroscopy and Raman spectroscopy to distinguish melanoma from non-melanoma pigmented 
lesions. The measurements were performed in vivo. They used a limited number of cases (12 
melanoma versus 17 pigmented benign lesions). Based on non-independent, leave-one-out cross-
validation, a sensitivity of 100% and specificity of 100% was found.41 The authors did not clarify 
whether dermatologists used dermoscopy nor whether the pigmented benign lesions were 
melanocytic and clinically suspected for melanoma.41  
Our group has previously demonstrated the feasibility to acquire high-quality Raman spectra of 
pigmented tissue samples in the short-wave infrared (SWIR) region.43 The study was performed in a 
tertiary referral center for high-risk patients (familial melanoma, previous melanoma). All lesions 
suspicious for melanoma after evaluation by specialized dermatologists aided by dermoscopy 
were surgically excised. All lesions were evaluated by two expert pathologists. In that study, we 
measured 124 freshly excised melanocytic lesions. Some of them (n = 42) were histopathologically 
heterogeneous, i.e., did not have an even distribution of histological components throughout the 
lesion, leading to the possible sampling of non-melanocytic tissue (e.g. collagen or skin 
appendages). Because for heterogeneous lesions no accurate point-to-point correlation between 
the locations of the Raman measurements on the lesion and individual histological components 
could be made, these were not used for the development of a classification model. Therefore, the 
model was limited to histopathologically homogeneous lesions, which resulted in a specificity of 
45% and a sensitivity of 100%.39 We have confirmed that there is spectroscopic information in the 
2820−3040 cm−1 region (assigned to CH2 −CH3 stretching vibrations), which can be used to 
discriminate melanoma from benign melanocytic lesions. The results showed that the most 
distinctive spectral feature between melanoma and benign melanocytic lesions is attributed to a 
higher lipid−protein ratio in melanoma.39  
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Next to heterogeneous aspect of melanocytic lesions, the thickness of the stratum corneum can 
also influence the representativeness of Raman measurements. Some lesions present a thick layer 
of keratinized layer on top, whereas others show a relatively thin stratum corneum (~10-20 μm), 
depending on the anatomical location of the lesion. This variance can influence the effective depth 
at which the tissue is sampled, and which could result in missing representative regions of the 
lesion, i.e. underlying melanocytic proliferation. Likewise, in benign lesions that do not present 
malignant melanocytes with the epidermis or papillary dermis, the Raman signal will have a 
significant contribution from collagen type I as the major extracellular matrix protein (reaching 
approximately 80–85% of the dry weight of the dermis).44,45  
After our first study,39 representative Raman sampling in heterogeneous melanocytic lesions 
remained a challenge. In this paper, we have developed a Raman spectroscopy method to 
distinguish melanoma from clinically suspicious benign melanocytic lesions irrespective of their 
histopathological heterogeneity. The fundamental requirement of the diagnostic model was to 
not miss any melanoma (100% sensitivity). In order to use representative Raman signals, we 
developed a filtering method to eliminate non-informative spectral contributions of keratin and 
collagen. The diagnostic model was validated on an independent data set. 
 
Materials and Methods  
1) Sample handling. This study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center (LUMC) (C13.06). After clinical assessment performed by a dermatologist, 
pigmented skin lesions clinically suspicious for melanoma were excised and submitted for 
histopathological diagnosis in the dermatology outpatient clinic of the LUMC. These excisions 
were performed according to the national melanoma guideline and standard protocol of the 
LUMC department of dermatology. Immediately after surgery, the specimens were prepared for 
Raman spectroscopy measurements. They were rinsed with NaCl solution (0.9%), wiped with a 
gauze soaked in ethanol (70%, to remove residual ink from pen marker), gently flattened between 
two fused silica windows and inserted into a custom-made sample cartridge for Raman 
measurements, as illustrated in Figure 1. For detailed description, see our previous study.39  
 
5C l i n i c a l  d i a g n o s i s  o f  e a r l y  m e l a n o m a  b y  R S | 91 
 
 
 
 
Figure 1. Sample handling. a) Clinical diagnosis was aided by dermoscopy (insert); b) Lesions suspicious 
for melanoma were excised; c) Specimen is inserted in the cartridge and multiple points were measured 
within the lesion (insert); d) Routine histopathological evaluation (image from H&E slide). 
 
2) Raman spectroscopy measurements. Raman measurements were performed on freshly 
excised skin specimens, using a SWIR multichannel Raman instrument, which records in the 
spectral range 2780 to 3750 cm-1. This instrument was constructed in-house and has been 
described previously.43 The light source was a diode laser with a wavelength of 976 nm (IPS, 
Monmouth Junction, NJ, USA). The light was focused on the skin lesion to a spot with a diameter of 
~6 μm. Per lesion, an average of 14 (range 9-19) point measurements were performed in the 
pigmented region of the excised lesion. Each point measurement had an integration time of 30 s. 
After the Raman spectroscopy measurements, the skin samples were emerged in a 4% 
formaldehyde solution and sent to pathology for the routine diagnostic procedure.  
2.1. Calibration. All Raman spectra were corrected for the wavelength-dependent detection 
efficiency of the instrument, using an SRM2246 intensity standard (National Institute of Standards 
and Technology, Gaithersburg, MD), as explained elsewhere.43 The absolute wavenumber axis was 
calibrated using the spectral lines of a neon−argon lamp and the Raman spectrum of cyclohexane. 
The Raman background that originates from the optics was subtracted from all spectra. Data were 
filtered by 5th order spline filter to remove fixed pattern noise.39 
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2.2. Reference spectra. As reference, Raman spectra were measured from collagen type I (Sigma-
Aldrich, C7774 - CAS Number 9007-34-5). For the keratin Raman spectra were measured in vivo 
from the thick stratum corneum on the sole of the foot of a healthy volunteer.  
Moreover, a set of reference spectra from tissue with low fluorescence background and high 
variance of Raman signal was created from the spectra of skin lesions used in this study, as follows. 
For each spectrum, the ratio between peak content and background content was calculated using 
the spectral region: 2830 cm-1 - 3020 cm-1 (CH3 stretching vibrations, which are abundantly present 
in all biological tissues). A first-order polynomial baseline was fitted through the spectral points at 
2830 cm-1 and 3020 cm-1. Peak content was calculated as the integrated area above this baseline. 
Background was calculated as the integrated area below the baseline. The spectra with the highest 
40% peak to background ratio values were selected and divided into 20 clusters using hierarchical 
cluster analysis. Only clusters that consisted of more than 5 spectra were selected, and the spectral 
average per cluster was calculated. The resulting 17 cluster average spectra were considered as an 
HWVN tissue reference spectral library.  
 
3) Pre-processing of Raman spectra. All Raman spectra were pre-processed in the way described 
below. The software used for all computations in this study was Matlab R2015b (Mathworks Inc., 
Natick, MA). 
3.1. Tissue background subtraction. A method described by Barroso et al. based on multiple 
regression fitting (MRF), was used for background correction.46 MRF is an unsupervised method 
that corrects fluorescence spectra independently of the shape and intensity of the Raman signal. 
Briefly, a set of background-free library spectra and a 2nd order polynomial were fitted to the data 
using a non-negative least squares method. As the library spectra describe all Raman variance 
present in the data with minimal background signal, the fitted polynomial is a good approximation 
of the fluorescence background present in the data. The approximated backgrounds were 
subtracted from the respective spectra.  
3.2. Correction for variations in the water signal. A similar procedure was performed to remove 
the influence of the water signal in the CH band. A reference spectrum of water was fitted to the 
data. The coefficient that better approximated the water reference spectrum for each one of the 
spectra measured was obtained. The water signal multiplied by the corresponding coefficient was 
subtracted from the correspondent data spectra.  
3.3. Scaling. All the spectra were scaled to the average of all individual spectra using an extended 
multiplicative signal correction (EMSC) with a zero-order polynomial background47 and cropped to 
the spectral range (2800−3050 cm−1), which corresponds to the CH-stretching band region.  
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3.4. Detect spectrally heterogeneous samples. The spectral variance within each lesion was 
calculated (in the complete range 2800−3050 cm−1). The spectra variance per lesion was then 
added in the spectral direction, to have a total spectral variance per sample. The variance of each 
sample was normalized with respect to the maximum variance. The lesions that present a high 
variance (in the top 10% of the ranked values) were considered spectrally heterogeneous and were 
added to the heterogeneous lesions group. 
3.5. Signal orthogonalization for keratin and collagen. A Raman spectrum obtained from a 
melanocytic lesion can include contributions from several skin constituents, e.g. collagen from 
dermis and keratin from stratum corneum. These contributions are not informative for the 
discrimination of melanoma and benign melanocytic lesions, which do not originate from the 
stratum corneum or from the dermis. A method described by Maquelin et al. 48 was used to 
estimate the Raman signal variance in the spectra from keratin or from collagen. The method is 
based on a mathematical projection of the lesion Raman spectrum on the Raman signal of keratin 
or collagen. The results yield the Raman signal that cannot be distinguished from keratin or 
collagen. Subsequent subtraction of this projection from the spectrum results in the desired non-
keratin or non-collagen related Raman lesion spectra (i.e. the vector component of the spectrum 
that is orthogonal to keratin or collagen).  
In a first step, Raman spectra were orthogonalized with keratin. After projection and subsequent 
subtraction, the total integrated intensity (absolute area) of the orthogonalized signal was 
calculated. Given the fact that the spectra that have a low AUC cannot be distinguished from the 
spectra of keratin, it was assumed that the measurement was performed in a region with a thick 
overlying stratum corneum. Spectra of which the integrated value was below a certain threshold 
(i.e. high presence of keratin) were discarded. These Raman spectra were dominated by keratin 
and considered not suitable for classification. Orthogonalized spectra on keratin that presented an 
integrated area lower than 68% (i.e. high presence of keratin) were labelled as “Not predicted”.  
In a second step, the Raman spectra were orthogonalized with collagen. Lesion spectra that 
presented a low integrated value after projection and subsequent subtraction (i.e. spectra with 
high contribution of collagen) were considered to come from a benign lesion and removed from 
the data set for model creation. Orthogonalized spectra on collagen that presented an integrated 
area lower than 56% (i.e. high presence of collagen) were immediately classified as benign.  
3.6. Outlier detection using PCA. A PCA model was used to identify outliers. The first 5 principal 
components, representing 99.9% of the variance in the data set, were used in the model. Outliers 
were detected by projecting the spectra on the model. The spectra that could not be explained by 
the model (i.e. the variance of the residual was larger than 1%) were marked as outliers.  
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4) Histopathological evaluation and exclusion criteria. After Raman measurements, 
histopathological samples were prepared as part of routine procedure and were evaluated by two 
expert pathologists dedicated to this study. The final histopathological diagnosis, upon 
agreement, was used as the gold-standard reference for correlation with the Raman measurement.  
All pigmented skin lesions clinically suspected of melanoma and surgically excised for diagnostic 
purpose were eligible for this study. Non-melanocytic lesions confirmed by histopathology were 
excluded. Benign melanocytic nevi classes of which less than 5 lesions were present in our data set, 
were excluded.  
 
5) Histopathological classification used in this study. For the purpose of this study, the samples 
were divided into two groups based on histopathology: (1) homogeneous melanocytic lesions and 
(2) heterogeneous melanocytic lesions (Figure 2). Heterogeneous lesions were defined as those 
that did not have an even distribution of histological components throughout the melanocytic 
lesion in the most representative H&E slide. E.g. an uneven distribution of melanocytic nests 
surrounded by variable amount of collagen or other non-melanocytic tissue was considered 
heterogeneous. Also, lesions with a stratum corneum thickness of more than 300 μm, or lesions 
located at a depth of > 300 μm, were included in the heterogeneous group. Moreover, descriptive 
details were provided, as the thickness of the lesion, depth of the lesion location in the 
epidermis/dermis and thickness of stratum corneum.  
 
6) Diagnostic model creation 
6.1. Creation of training sets for the diagnostic model. From the homogeneous lesions, a 
subset was randomly selected, referred to as Homogenous lesions set 1 (Figure 3). This set was used 
to create the PCA-LDA model (see below). Also, from the heterogeneous lesions a subset was 
randomly selected, referred to as Heterogeneous lesions set 1. This set was used to define the 
parameters for the diagnostic model. All histopathologically proven dysplastic nevi were excluded 
from model creation. 
6.2. PCA-LDA model. A linear discriminant analysis (LDA) model was developed to distinguish 
melanoma from benign melanocytic lesions. The PCA-LDA model was created based on averaged 
spectra of Homogeneous lesions set 1. Principal component analysis (PCA) was performed to reduce 
the dimensionality of the data prior to LDA modelling. The scores of the spectra on the first 3 
principal components were used as input parameter for the model. The discriminating parameter 
used as input for the PCA-LDA was a Boolean: “melanoma” or “not-melanoma”. 
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Figure 2. Flowchart of histopathological classification. 
 
 
6.3 Parameters for the diagnostic model. The PCA-LDA model was applied to each individual 
point measurement of Heterogeneous lesions set 1. The model yields a probability for each 
individual point for being melanoma. These probabilities were used to establish the parameters of 
the diagnostic model. A lesion is classified as melanoma: (1) if 2 or more individual point 
measurements within a lesion have a PCA-LDA score higher than 0.35 and/or (2) at least 1 
individual point measurement has a PCA-LDA score greater than 0.8. Otherwise, the lesion is 
classified as benign.  
 
7) Diagnostic model validation on independent data. The diagnostic model was validated on 
an independent data set. The independent validation set was comprised of remaining 
homogeneous and heterogeneous lesions, referred as Homogeneous lesions set 2 and 
Heterogeneous lesions set 2 (Figure 3). The outcome of the model was a Boolean, “melanoma” or 
“not-melanoma”. Specificity was defined as the fraction of correctly predicted negatives (not-
96 | C h a p t e r  5     
 
melanoma) from the total number of benign melanocytic lesions. Sensitivity was calculated as the 
fraction of correctly predicted positives (melanoma) from the total number of melanomas. 
 
8) Separate test on dysplastic nevi 
Because there is no agreement whether dysplastic nevi must be considered benign, dysplastic 
were not included either in the diagnostic model or in the independent validation set. The 
diagnostic model was separately tested on the dysplastic nevi.  
 
Results  
In total, 222 freshly excised pigmented skin lesions clinically suspected of melanoma were 
measured. From those, a total of 48 were excluded: 17 for technical reasons, 28 non-melanocytic 
lesions (basal cell carcinoma, seborrheic wart, lichenoid keratosis, dermatofibroma, hemangioma, 
scar) and histopathological classes that contained less than 5 lesions (Spitz nevi, n=2 and 
combined melanocytic nevus, n = 1).  
The characteristics of the remaining 174 lesions are summarized in Table 1. Of  the 37 melanomas, 
22 were in situ (59.4%) and 15 had an average Breslow thickness of 0.89 mm (range 0.2-3.0 mm).  
 
 
 
Figure 3. Lesions used for diagnostic model creation (left), lesions used for the independent validation 
(middle) and dysplastic nevi on which diagnostic model was separately applied (right). 
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Table 1. Summary of the lesions included.  
 
Diagnostic model creation. A total of 78 lesions were used for model creation (Homogeneous 
lesions set 1 and Heterogeneous lesions set 1). First, the Raman spectra of the Homogeneous lesions 
set 1 (55 lesions) were used to create the PCA-LDA model. The Raman spectra of the Heterogeneous 
lesions set 1 (23 lesions) were used to define the parameters for the diagnostic model. The 
histopathological diagnosis of the lesions included in the diagnostic model set are shown in Table 
2. Figure 4 shows the PCA-LDA model discriminant for melanoma versus benign melanocytic 
lesions. 
Histopathological 
diagnosis 
Average age  
(y, range) 
Sex 
Anatomical 
Location 
Number 
of 
lesions 
Average 
Breslow 
thickness 
 (mm, range)) 
Melanoma      
in situ 58.5 (41 – 82) 
10 female 
12 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
2 
5 
7 
8 
 
invasive 52.9 (29 – 73) 
10 female 
5 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
2 
1 
4 
8 
0.89 
 (0.20-3.00) 
Dermal nevi 
 
43.0 (16 – 68) 
14 female 
13 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
1 
2 
14 
11 
 
Compound nevi 46.6 (15 - 75) 
25 female 
18 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
Unspecified 
- 
4 
26 
12 
1 
 
Junctional nevi 
 
51.5 (25 - 82) 
10 female 
6 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
1 
2 
11 
2 
 
Blue nevi 45.8 (19 - 87) 
3 female 
2 male 
Head and neck  
Upper limb 
Trunk 
Lower limb 
1 
- 
4 
- 
 
Dysplastic nevi 47.9 (23 - 77) 
29 female 
17 male 
Head and neck 
Upper limb 
Trunk 
Lower limb 
Unspecified 
1 
4 
34 
6 
1 
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Table 2. Histopathological diagnosis of lesions included in the diagnostic model set and in the 
independent validation set.  
Histopathological diagnosis 
Number of lesions per set 
Diagnostic 
model set 
Independent 
validation set 
Total 
(in situ) Melanoma  20 17 37 
Benign 
melanocytic 
nevi 
Dermal 20 7 27 
Compound 27 16 43 
Junctional 9 7 16 
Blue 2 3 5 
Total 78 50 128 
 
 
Figure 4. PCA-LDA model discriminant for melanoma versus benign nevi. The PCA-LDA model 
discriminant is a spectral representation of the discriminating differences between groups. The peaks at 
2854 cm-1 (assigned to the symmetric CH2 stretching vibrations of lipids) and 2896 cm-1 (assigned to 
asymmetric CH2 stretching vibrations of lipids) show lipid features which are more pronounced in 
melanoma than in benign nevi. 
 
Diagnostic model validation on independent data. Homogeneous lesions set 2 (21 lesions) 
and Heterogeneous lesions set 2 (29 lesions) were used for the independent validation of the 
diagnostic model. Table 2 shows the histopathological diagnosis of the lesions included in the 
independent validation set, comprising 17 melanomas (10 in situ and 7 thin melanomas with 
an average Breslow thickness of 0.42 mm, range 0.2-0.8 mm). Table 3 shows the contingency 
table of the diagnostic model validation. A specificity of 43.8% at 100% sensitivity was 
obtained, specificity defined as the fraction of correctly predicted negatives (not melanoma) 
from the total number of benign nevi in the independent validation set.  
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Table 3. Contingency table of the diagnostic model validation. 
 Independent validation outcome 
 
Benign nevi Melanoma 
Not predicted 
(high keratin) 
Histopathological diagnosis 
Benign nevi 14 18 1 
Melanoma 0 16 1 
 
Eighteen benign melanocytic nevi were classified as melanoma, of which 7 were compound 
nevi, 5 junctional nevi, 4 dermal nevi and 2 blue nevi. None of the melanomas was 
misclassified. 
Two lesions were identified by the keratin filter, both with thick stratum corneum (1 melanoma 
in situ and 1 compound nevus, shown in Figure 5). The measurements obtained in these 
lesions were identified and labeled as “Not predicted”. 
 
Figure 5. H&E stained thin tissue sections; a) melanoma in situ with a thick stratum corneum (1.2 mm); b) 
combined melanocytic nevus with a thick stratum corneum (200 μm). N.B.: the Raman spectra of these 
lesions showed high similarity with keratin and were labeled “Not predicted” by the diagnostic model.  
 
Separate test on dysplastic nevi. The diagnostic model was separately tested on the 
dysplastic nevi. From the total 46 dysplastic nevi, 73.9% were classified as melanoma (Table 4). 
 
Table 4. Outcome of the diagnostic model applied on the set of dysplastic nevi. 
 Test outcome for dysplastic nevi 
 
Benign nevi Melanoma 
Not predicted 
(high keratin) 
Histopathological diagnosis Dysplastic nevi 12 34 0 
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Discussion 
Melanomas with a Breslow thickness of less than 0.8 mm are curable by surgical excision. In 
this study, a diagnostic model for melanoma based on Raman spectroscopy was developed 
and validated on an independent test set. All the included lesions had been excised because 
they were clinically suspicious for melanoma. The study was conducted on a specific patient 
population at high risk of developing melanoma. These patients frequently visit the 
specialized pigmented lesions clinic.  
In our previous study we showed that homogeneous melanocytic lesions (i.e. with an even 
distribution of histological components throughout the melanocytic lesion) could be 
distinguished from melanoma with a high diagnostic power of almost 80% using Raman 
spectroscopy.39 However, a substantial portion of melanocytic lesions is heterogeneous (i.e. 
without an even distribution of histological components throughout the melanocytic lesion). 
Clinical application requires that both homogeneous and heterogeneous melanocytic lesions 
can be classified. Therefore, in the current study, we included heterogeneous lesions in the 
development of the diagnostic model. 
We divided the samples into two groups based on histopathology (homogeneous and 
heterogeneous) and created a PCA-LDA model using only homogeneous lesions. This ensured 
that the PCA-LDA model was based on an optimal match between Raman measurements and 
the reference histopathological diagnosis.  
The PCA-LDA model discriminant visualizes discriminative spectral information between 
melanoma and benign nevi. A higher lipid content in melanoma is the strongest discriminative 
factor (Figure 4). The diagnostic model in this study was developed to distinguish melanoma 
from benign melanocytic lesions suspicious for melanoma. 
Dysplastic nevi are melanocytic lesions that present histologically architectural disorder and 
cytological atypia.50,51 Because there is no international consensus about whether dysplastic 
nevi must be considered benign49,51-60,64, dysplastic nevi were not included in the diagnostic 
model. However, in clinical practice a significant portion of the lesions suspicious for 
melanoma are dysplastic nevi. Although the dysplastic nevi were not included in the 
development of the diagnostic model, we have applied the diagnostic model on these lesions 
as well.  
This is the first Raman study addressing thin melanomas. The diagnostic model was optimized 
for highest possible specificity at a sensitivity of 100%. Nine to nineteen individual point 
measurements were obtained per lesion. A lesion was classified as melanoma if 2 or more 
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individual point measurements had a PCA-LDA score higher than 0.35, or if at least 1 individual 
point measurement had a PCA-LDA score greater than 0.8. These criteria reflect a melanoma 
diagnosis based on either a single point measurement with high probability of melanoma or 
multiple point measurements with moderate probability. A limitation of this study is the lack 
of accurate correlation between the individual Raman point measurements and 
histopathology. We are currently developing a method for reliable and reproducible matching 
between the origin of individual Raman spectra and histological structures. It is expected that, 
when applying this method, the accuracy of the diagnostic model that we have developed will 
be further improved.  
In this study, the NNT by dermatologists was 6.0 (222 excised lesions suspicious for melanoma, 
and 37 histopathologically confirmed melanomas). Twenty percent of the excised lesions 
suspicious for melanoma were dysplastic nevi. To calculate the NNT based on Raman 
diagnosis, 13 randomly selected dysplastic nevi were added to the validation set, so that this 
set also comprised 20% of dysplastic nevi. If the Raman instrument were used as an add-on to 
diagnose the dermatologist-selected lesions, the estimated NNT would be 2.7 (43 lesions 
tested positive by Raman spectroscopy and a total 16 histopathologically confirmed 
melanoma.  There are indications that dysplastic nevi are associated with an increased risk of 
developing melanoma,49, 61-63 which is suggestively supported by our results shown in Table 4. 
In this study, we demonstrate that, based on Raman spectroscopy, an accurate diagnosis of 
melanoma with Breslow thickness <0.8 mm can be made. This work signifies an important step 
towards objective accurate diagnosis of melanoma. 
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Abstract 
Oncological applications of Raman spectroscopy have been contemplated, pursued, and 
developed at academic level for at least 25 years. Published studies aim to detect pre-
malignant lesions, detect cancer in less invasive stages, reduce the number of unnecessary 
biopsies and guide surgery towards the complete removal of the tumor with adequate tumor 
resection margins. This review summarizes actual clinical needs in oncology that can be 
addressed by spontaneous Raman spectroscopy and it provides an overview over the results 
that have been published between 2007 and 2017. An analysis is made of the current status of 
translation of these results into clinical practice. Despite many promising results, most of the 
applications addressed in scientific studies are still far from clinical adoption and 
commercialization. The main hurdles are identified, which need to be overcome to ensure that 
in the near future we will see the first Raman spectroscopy-based solutions being used in 
routine oncologic diagnostic and surgical procedures. 
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General introduction 
In 2012 the World Health Organization (WHO) reported 14.1 million new cancer cases, 8.2 million 
cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis). These 
numbers are increasing, which motivates development of cancer treatment possibilities and 
technology for early detection of (pre-) malignancies.1 The high mortality rate of cancer can be 
reduced by early and accurate diagnosis, and by adequate surgical treatment.2 The reference 
standard for cancer diagnosis is histopathologic assessment of biopsies or diagnostic excisions of 
suspicious tissue. After biopsy/excision the tissue specimen is fixed, micro-sectioned and routinely 
stained with hematoxylin and eosin (H&E). The pathologist makes a diagnosis based on 
microscopic examination of the H&E stained section. Because only small portions of the lesional 
tissue are biopsied or excised for histopathological examination, there is the risk of sampling error 
and the pathology report remains a subjective assessment (with its inter and intra operator 
variability).3 Studies have demonstrated that most tumor types develop through pre-malignant 
stages.4,5 Therefore, the treatment of pre-malignant tissue can prevent the further development of 
cancer. Because the distinction between early-stage malignant, pre-malignant and benign tumors 
can be difficult to make, repeated biopsies/excisions are often taken. For sampling of tissue, 
literature reports positive predictive values as low as 22% for prostate cancer diagnosis,6 1.4% for 
breast cancer,7 18.5% in lung cancer screenings,8 and 7–23% for melanoma diagnosis.9 Despite the 
risk of these unnecessary biopsies/excisions, a substantial number of early stage tumors are still 
missed, which increases the risk of progression to a metastatic stage.  
Introduction – early diagnosis/guided biopsy 
A technique that helps to achieve representative biopsies and that would enable accurate and 
early in vivo diagnosis is needed. This tool should detect lesions in pre-malignant/early stages and 
assess large tissue areas in real-time to decrease sampling errors. Several techniques have been 
tested for biopsy guidance, such as optical coherence tomography (OCT), white light reflectance 
(WLR), auto-fluorescence and Raman spectroscopy.10–14 OCT and WLR rely on the visualization of 
changes in tissue structure. These techniques provide little or no information about the molecular 
tissue composition and, therefore, generally have a low specificity.10,12 Auto-fluorescence imaging 
is an optical technique that detects natural fluorescence emitted by fluorophores present in the 
tissues (e.g. flavins, collagen or hemoglobin), after excitation by a short-wavelength light source. 
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This emission can be captured in real-time, for example during endoscopy, and can be used for 
lesion detection or characterization.13,14 Auto-fluorescence imaging has shown to improve the 
sensitivity of detection of early cancer, like epithelial neoplasia in esophagus and colon 
(sensitivities are 90% and 99%, respectively).14 It also improves the diagnostic sensitivity (from 67% 
to 89%) for pre-malignant stages of lung cancer (e.g., dysplasia and carcinoma in situ). It also 
improves the diagnostic sensitivity compared to white-light endoscopic imaging (from 67% to 
89%) for pre-malignant stages of lung cancer. However, the specificity of this technique is low; a 
specificity of 64% for diagnosing pre-malignant stages of lung cancer, a specificity of 81% for 
detecting high-grade dysplasia and early cancer in Barrett’s esophagus and a specificity of 35% for 
detection of pre-malignant colon polyps were reported.14–16 Optical vibrational spectroscopic 
techniques, such as Raman spectroscopy, can provide high molecular specificity. The gradual 
changes from healthy tissue to tumor are reflected by their Raman spectra.2,17–19 Raman 
spectroscopy is a technique for characterizing biological tissue in vivo, ex vivo or in vitro and for 
non-invasive detection of the molecular differences between tumor and healthy tissue. It does not 
require any labelling, reagents or other preparation of the tissue, which facilitates translation to 
the clinic. With the use of optical fibers many anatomical locations can be assessed in vivo.20 
Raman spectroscopy-based biopsy guidance can reduce the number of false positive biopsies and 
increase the accuracy of cancer diagnosis, with reported overall sensitivities and specificities 
between 73%–100% and 66%–100%, respectively.18,21 
Introduction – guided surgery 
After diagnosis the primary treatment for solid tumors is often surgery. The objective of surgical 
treatment is resection of all malignant tissue with adequate resection margins while preserving 
important healthy structures. Achieving adequate surgical margins is important for disease control 
and survival. Residual tumor after surgery is associated with poor survival and the need for 
additional surgery, adjuvant chemotherapy, radiation therapy, or a combination of these.22–25 A 
number of studies have shown that the 5-year survival decreases significantly when tumor is not 
completely removed.22–25 Intraoperative guidance tools can help to achieve adequate surgery. 
However, there are no widely used intraoperative guidance tools available yet. Current surgical 
resection techniques are based on subjective methods, such as palpation and visual inspection, to 
judge the border between normal and cancerous tissue. In order to support the intraoperative 
assessment of resection margins, frozen sections can be used.26–28 A small piece of suspicious 
tissue is usually sampled from the wound bed (i.e. wound-driven assessment) by the surgeon. A 
microscopic evaluation of the frozen section is performed by the pathologist, directing operative 
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management.28 It has been reported that the frozen section procedure increases the rate of 
adequate resections and thereby decreases local recurrence and improves the survival rate.29 Even 
though this procedure is successful for intraoperative assessment of the resection margins, it has 
its limitations: (1) it is time consuming, extending the duration of surgery and anesthesia;30 (2) it is 
likely prone to sampling errors because only a small fraction of the resection margin can be 
investigated, and (3) it can introduce histologic disruption caused by rapid freezing, which makes 
the analysis more difficult.31 Rosenthal et al. reported that at most 5% to 10% of the wound bed 
can be sampled and assessed with frozen section.32 These limitations can lead to false negative 
results.23,27,33–35 Consequently, there is much room for improvement in performing intraoperative 
assessment of the resection margins. In order to guide oncological surgery, techniques like 
intraoperative real-time MRI, intraoperative ultrasound, intraoperative OCT, fluorescence and 
Raman spectroscopy have been investigated in operating room environments. Real-time 
intraoperative MRI has been tested during surgical resection of brain cancer (i.e. glioma). Several 
studies have demonstrated that this modality can be used for surgery guidance and improves the 
extent of the tumor resection without increasing neurological deficits. This also has a positive 
impact on survival.36–42 Some drawbacks of intraoperative MRI include: (1) operative defects that 
can affect the MRI image and decrease its accuracy;43 (2) interpretation of the image by the 
surgeon and his capability to correlate the location of the lesion to the brain anatomy;17,43 (3) 
significant surgical disruptions that prolong the operation time; (4) it requires a considerable 
investment to implement MRI-capable operating rooms; and (5) there is a need for contrast 
agents.43 Intraoperative ultrasound has been used to localize the tumor, guide the resection 
especially among highly vascular tumors (e.g. breast), using probes that enhance contrast.43,44 
However, it is less sensitive for tumor margins and has shown lower resolution and accuracy 
compared to intraoperative MRI. Besides, its accuracy is affected by previous surgery, as almost 
any imaging modality.43,45 A portable label-free optical coherent tomography (OCT) imaging 
system has been tested intraoperatively to assess breast resection margins and lymph nodes ex 
vivo.46 The study showed promising results for real-time microscopic image guide breast cancer 
surgery. Structural-based imaging techniques (like OCT and intraoperative MRI) show promising 
results. Unfortunately, they lack chemical disease-specific information, which is essential for 
adequate tumor removal. Fluorescence imaging is another technique that has been applied to 
assess surgical resection margins. The technique requires administration of fluorescence agents 
and is based on the detection of fluorescently labelled structures during surgery. Various studies 
have reported that complete resection was achieved in a significantly higher percentage when 
fluorescence imaging was used, as compared to only regular white light.47–50 The major 
112 | C h a p t e r  6    
 
disadvantages of fluorescence imaging are: (1) the need for fluorescence agents, and (2) the need 
to switch off the room lighting to maximize the detection of the weak fluorescence.46 In addition, 
translational problems have been identified, related to the need of consistent manufacturing, to 
costs related with toxicology studies, and to the strict procedures for submission of a new 
investigational drug.51 An interesting alternative would be a label-free imaging method, which 
avoids the risks associated with dye/drug reactions and the challenges associated with specific 
tumor targeting and non-specific binding Raman spectroscopy has also been implemented to 
guide oncological surgery. Several studies have demonstrated that this technique can be used for 
surgical guidance. For example, in brain cancer surgery, an intraoperative Raman system that 
measures directly brain tissue in the patient, has proven to distinguish dense and low-density 
cancer infiltration from benign brain tissue with a sensitivity of 93% and a specificity of 91%.52 In 
another study, a real-time Raman intraoperative system was used during breast cancer surgery for 
assessment of freshly resected specimens. This study has demonstrated that Raman spectroscopy 
could discriminate cancerous tissue from normal breast tissue with a sensitivity of 83% and a 
specificity of 93%.53 Implementing Raman spectroscopy in the clinical setting can have important 
benefits: (1) it can enable representative sampling for correct pathological diagnosis (biopsy 
guidance);(2) it can accurately assist in defining adequate resection margins during surgery; (3) it 
can reduce the sampling problem, during intraoperative assessment; (4) it can introduce a more 
objective assessment and (5) it can reduce the need for adjuvant therapies.20 In the last years, 
several review articles reported the advances of Raman spectroscopy with the ultimate goal the 
clinical application for cancer diagnosis in different anatomical locations.17,18,20,21,54–57 In these 
reviews the latest developments of technology adaptations for Raman cancer diagnostic 
applications are described. The latest clinical outcomes of Raman spectroscopy on (early) cancer 
detection at different sites in vitro, ex vivo and in vivo have been also reported. However, 
specifically the translation of Raman spectroscopic developments into oncological applications 
has not been addressed extensively before. The scope of this article is to provide an analysis of the 
translation of R&D results, obtained in oncological applications of Raman spectroscopy, into 
clinical practice. We discuss problems that still need to be solved in order to bring the technique 
successfully to the end-users in the hospital setting. The importance of defining the clinical needs 
and requirements, for different applications, is also explored in this review. We have limited our 
review to spontaneous Raman spectroscopy applications on ex vivo and/or in vivo human tissue 
samples. We refer to the other recent review articles for biomedical applications of non-linear 
Raman spectroscopy, such as coherent and surface-enhanced Raman scattering.55,58,59 
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Methods 
Literature search. A search was carried out using the Web of ScienceTM library. Web of ScienceTM 
comprises the following databases: Web of ScienceTM Core Collection, KCI-Korean Journal 
Database, MEDLINE, Russian Science Citation Index and SciELO Citation INdex. For research articles 
the included period was from 2006 to 2017. For review articles the included period was from 2011 
to 2017. The date of the final search was on 16th of January 2017. The search filter comprehended a 
combination of the keyword “Raman” with two of the following keywords: "tumo(u)r", "patient", 
"biopsy", "carcinoma", "assessment", "intraoperative", "cancer", "guidance", "surgery", "human", 
"diagnostics" and "translation". These keywords were searched as a topic in the article. Articles that 
had at least three of the topic words were considered for inclusion. Commentaries and opinion 
articles were excluded. Furthermore, studies on non-human samples and performed in vitro were 
not selected. Studies that used non-linear Raman spectroscopy were excluded. Cytological 
screening methods based on Raman spectroscopy are also being developed,60,61 however to limit 
the scope we have chosen not to include such studies in this review. Articles that were not written 
in English were also discarded. 
 
Definition of the clinical need. The clinical needs (clinical problems and their relevance) that 
could be solved by Raman spectroscopy applications were defined per cancer type as reported by 
the studies selected in this review. Furthermore, the information on clinical needs from current 
(inter)national guidelines and clinical articles (PubMed) were included. For clinical articles the 
included the period from 1990 to 2017 was regarded. Moreover, opinion from pathologists and 
surgeons was obtained based on personal interviews.  
During the interviews clinical needs for another types of cancer than those addressed in the 
included studies were identified and discussed. 
 
Raman spectroscopy applications. All the eligible Raman application studies were included, 
regardless the cancer type addressed. The included studies were divided considering two major 
oncological applications of Raman spectroscopy: (A) biopsy guidance/early diagnosis and (B) 
surgery guidance. 
 
Progress of the companies. To address the progress of the companies that are developing/ have 
developed commercial Raman spectroscopy oncological applications towards implementation in 
the clinics, we have contacted leading companies in Raman spectroscopy (Tokyo Instruments Inc., 
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Princeton Instruments Inc., Verisante Inc., ODS Medical Inc., Endofotonics Pte. Ltd., RiverD 
International B.V., EmVision LLC, Invenio Imaging Inc., Artphotonics GmbH., Carl Zeiss GmbH., 
Kaiser Optical systems Inc., Lambda solutions Inc., Horiba Jobin-Yvon Inc., B&W Tek Inc., Snowy 
Range instruments Inc., Wasatch Photonics Inc., Witec GmbH., Avantes B.V., Photonetc Inc. and 
Renishaw Plc.) to collect information. A questionnaire was sent to the companies with the 
following questions: 1) “Are you actively developing or collaborating in the development of 
oncological Raman in vivo and/or ex vivo tools for the clinics?”; 2) “Can you indicate what is the 
application?”; 3) “Do you have any scientific publication or can you share with us more information 
about the subject?”; 4) “When do you think that it will be available in the market? What is the 
prognosis?”, and 5) “About the translation to the clinics, what hurdles have you encountered?”. 
 
Technology readiness level (TRL) classification of the studies. In order to provide an overview 
of the current status of the technology towards clinical translation we classified all the included 
studies based on the Technology Readiness Level (TRL).  
The TRL is an index used to measure the maturity and usability of an evolving technology.62 There 
are 10 levels (TRL 0 to TRL 9): at TRL 0 there is just an idea, but the concept is not yet proven or not 
yet tested; TRL 1 is related to basic research, when the principles are observed and postulated, but 
not experimentally proven; TRL 2 is associated with technology development, when the concept 
and application have been formulated; TRL 3 consists of applied research/ proof of concept, when 
the first laboratory tests are completed; at TRL 4 a small scale prototype has been realized, which is 
still working in a laboratory environment; at TRL 5 the prototype has been tested in intended 
environment; at TRL 6 the prototype system has been tested in the intended environment close to 
the expected performance; at TRL 7 use of the system has been demonstrated in an operational 
environment at a pre-commercial scale; TRL 8 is characterized by the first version of a commercial 
system, when manufacturing issues are solved; finally, at TRL 9, the technology is available for end 
users.  
We have grouped the TRL levels of the Raman applications into 4 main categories: (A) the proof of 
concept has been tested in the laboratory (TLR 0-3), (B) first hardware and software have been 
developed, including the algorithms for detection of (pre-)malignant lesions, and experiments 
have been performed close to the intended environment (TLR 4), (C) the developed hardware and 
software were tested with an independent dataset in the intended environment and preferably at 
different centers (TLR 5-7), and (D) the first of a kind commercial system(s) are/will be available 
soon for end users (TLR 8-9). 
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Results 
Clinical need and Raman applications 
Definition of the clinical need. Prior to the development of technological tools aiming to improve 
diagnosis and/or treatment of cancer, it is important to define the actual clinical needs, because 
various clinical problems have different needs and solutions.  
Currently, two main oncological clinical needs, which could be fulfilled by Raman spectroscopy, 
have been identified: (A) diagnostic tools for biopsy guidance for early diagnosis of (pre-
)malignant, and (B) tools for surgery guidance, which can be used for intra-operative assessment 
of resection margins to achieve adequate tumor resection.  
In this section we review several clinical problems in the process of diagnosis and surgical 
treatment of cancer.  
Raman spectroscopy has been explored for oncological applications in numerous studies, 
employing various types of measurement systems, and targeting various types of cancers. This 
section also provides a review of the use of Raman spectroscopy ex vivo and in vivo for early 
diagnosis, biopsy guidance and surgery guidance of different types of cancer.  
Based on the search terms, 42 research papers on oncological applications of Raman spectroscopy 
were included. From those, 36 studies regarded early diagnosis and biopsy guidance applications 
and 6 studies regarded surgery guidance applications. 
 
Breast Cancer 
Clinical need: The second leading cause of cancer-related deaths in women worldwide is breast 
cancer with an incidence rate of more than 1,670,000 and a mortality rate of 522,000.1 Presently, 
screening mammography is used to identify breast lesions. When suspicious lesions are found 
histopathological diagnosis is the next step, based on fine-needle aspiration cytology (FNAC) 
and/or histological biopsy 63. High sensitivity for FNAC (82-99.7%) and for biopsy (90.1-93%) is 
reported.64–68 
The treatment of choice for ductal carcinoma in situ (DCIS) and early stage invasive cancer is breast 
conserving surgery. The surgery aims to preserve as much healthy tissue as possible while 
achieving negative resection margins.69 This procedure is performed in 58-70% of the patients.70,71 
As a standard of treatment, patients receive adjuvant radiotherapy after surgery. In the 
Netherlands, resection margins are considered adequate when ‘no tumor touches ink’.72 
Concerning pure DCIS resection margins of 2 mm are considered adequate. It is proven that 
patients with more than focal tumor positive resection margins have higher risk of developing 
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recurrent disease.73,74 When final histopathology shows a more than focal positive margin 
(concerning pure DCIS) an additional resection is performed. Re-resection rates varying between 
7%-73% have been reported by different institutes.73 Therefore, an intra-operative guidance with 
an objective and rapid tool is needed to achieve high adequate resection rates.  
Raman applications for early diagnosis/biopsy guidance: Saha et al. developed a Raman 
spectroscopic tool for detecting microcalcifications, as an adverse sign, in breast tissue. An ex vivo 
study was conducted and Raman spectra were acquired in fresh stereotactic breast needle 
biopsies from 33 patients using a portable compact clinical multi-fiber Raman spectroscopy probe 
system. This first study resulted in a positive predictive value of 97% for detecting 
microcalcifications, demonstrating potential of Raman spectroscopy as real-time feedback tool for 
radiologists and to reduce unnecessary biopsies.75  
Raman applications for surgery guidance: Barman et al. looked at the utility of Raman 
spectroscopy as a guidance tool for mastectomy procedures. Spectra were acquired ex vivo on 
freshly excised specimen from a total of 33 patients. The Raman instrument was a portable clinical 
fiber probe system. A classification algorithm was developed to differentiate breast cancer from 
healthy tissue. The reported sensitivity was 62.5% with a specificity of 100%. The accuracy 
obtained for differentiation between normal, fibrocystic change, fibroadenoma, and breast cancer 
was 82.2%.76 
Skin Cancer  
Clinical Need: The clinical diagnosis of skin cancer is conventionally based on visual inspection of 
morphologic characteristics of the lesions, usually supported by a dermoscope. This manner of 
diagnosing cancer is subjective and largely depends on the experience of the clinician.  
Keratinocytic cancers: Keratinocytic cancers, such as the basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC), are two of the most common cancers in fair-skinned populations.77 Only in 
the United Stated of America, about 3 million people are diagnosed with keratinocytic cancers per 
year. Although keratinocytic cancers are associated with low mortality rates both, BCC and SCC, 
can destruct surrounding tissue, recur and/or metastasize.78 
SCC can be locally aggressive, difficult to treat and it is associated with a 0.5% - 5% risk of 
metastasis. An effective management can be challenging in cases of patients with multiple lesions, 
or patients that in the past were diagnosed with keratinocytic cancers, demonstrating the need for 
early diagnosis.79 
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Standard type of treatment for keratinocytic cancers is complete removal of the lesion by (1) 
standard surgical excision or (2) Mohs micrographic surgery (MMS). In standard surgical excision, 
resection margins are examined by the pathologist after the procedure. In low risk BCC a tumor 
free resection margin of 3 mm is recommended, and in high risk BCC a margin of 5 mm is 
advised.78,80 
In MMS, complete resection margins are examined by the specifically trained dermatologist 
and/or pathologist during the procedure, aiming to spare healthy tissue while removing 
completely the cancer cells. MMS leads to fewer recurrences; however, this procedure is labor-
intensive and time consuming.81 
Therefore, a tool that could quickly detect the cancer cells at the resection margins, could guide 
the excision towards an adequate surgical margin and accelerate the surgical procedure.21,82 
Melanoma: Melanoma is the most commonly fatal form of skin cancer with a worldwide incidence 
of 232,130 and mortality rate as high as 55,488.1 Melanoma is preferably diagnosed at an early 
stage because of its metastatic disease. The vertical depth of growth in a primary melanoma, the 
Breslow thickness, is significantly correlated with metastatic propensity and thus prognosis. 
Melanoma with < 1mm thickness can be treated surgically with a high cure rate without reducing 
life expectancy (5-year survival is approximately 97%).83,84 Once the melanoma is diagnosed at an 
invasive stage, the survival rate decreases enormously to approximately 40% for melanomas with 
a Breslow thickness >4mm.83,85 Patients with thick melanomas and signs of distant metastasis are 
submitted to surgery and/or immunotherapy, which places a high burden on the patient’s quality 
of life. Moreover, the effect of current treatments on patient survival is very limited. 
Even with the use of a dermoscope by an experienced clinician, the sensitivity in diagnosing 
melanoma is between only 68% and 96% and it is very much depending on the clinician’s 
experience. 9,86,87 Despite the large number of excised benign pigmented lesions (false positive 
suspicious lesions), 30% of early stage melanomas is still missed at the first clinical presentation 
and thereby present a risk to progress to a metastatic stage.88 Because of the severe consequences 
when a melanoma is missed, many suspicious pigmented skin lesions are surgically removed. The 
clinical positive predictive values are as low as 7% to 23% for melanoma diagnosis by 
dermatologists in a specialized pigmented lesion clinic 9,89. Therefore, a rapid, objective, real-time 
tool for clinical diagnosis could reduce the number of unnecessary excisions and, at the same time, 
guarantee early detection of melanoma.  
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Raman applications for early diagnosis/biopsy guidance: Investigations of Raman spectroscopy for 
skin cancer focus primarily on (early) detection of skin cancer and discrimination of benign from 
malignant and pre-malignant skin tumors.2,18,79,90–95 
In 2008, Raman experiments were performed in vivo by Zhao et al. on 289 patients using a single 
fiber Raman probe; Raman spectra were measured from 9 different types of lesions, including BCC 
and SCC. The authors report a sensitivity of 91% and a specificity of 75% in differentiating 
malignant lesions from benign lesions. Malignant melanoma could be distinguished from 
pigmented benign lesions with reported sensitivity of 97% and specificity of 78%.96  
In the same year, Lieber et al. used a portable Raman system with handheld probe for non-
melanoma skin cancer diagnosis.97 Lieber et al. performed an in vivo study on 19 patients. Using 
the same handheld probe, Lieber et al. report classification of the BCC, SCC, inflamed scar tissues 
and normal tissues with sensitivity of 100% and specificity of 91%. The reported overall 
classification accuracy was 95%.98 
In 2012, Lui et al. measured 518 in vivo skin lesions from 453 patients. Malignant and pre-
malignant lesions could be separated from benign skin lesions using a single fiber Raman probe 
with a reported sensitivity of 90% and a specificity of 64%. Benign pigmented lesions could be 
distinguished from melanoma with reported sensitivity of 90% and specificity of 68%. Melanomas 
could be separated from seborrheic keratosis with a reported sensitivity of 90% and specificity of 
68%.90 The specificities were 15%, 17% and 25% for a sensitivity of 99%, when three distinct 
discrimination tasks were investigated: melanoma vs pigmented benign lesions, all cancers vs 
benign lesions and melanoma vs seborrheic keratosis, respectively.  
In 2012, Silveira et al reported an in vivo study using a Raman fiber probe in which they 
demonstrated differentiation of BCC from normal skin with an accuracy of 85%.99 
Lim et al. determined the diagnostic capability of a multimodal spectral diagnosis for in vivo non-
invasive disease diagnosis of melanoma and non-melanoma skin cancers. Measurements were 
performed with a custom-built clinical system that combines three fiber optic-based optical 
spectroscopy modalities: diffuse optical spectroscopy, laser-induced fluorescence spectroscopy, 
and Raman spectroscopy. Raman, fluorescence and reflectance spectra were acquired from 137 
lesions in 76 patients. From the measured set, the number of lesions considered for the study were 
100 (12 melanomas, 19 BCC, 38 SCC, 14 actinic keratosis and 17 non-melanoma pigmented 
lesions). When combining the three modalities, they reported a sensitivity of 100% and specificity 
of 100% for classifying melanoma vs non-melanoma pigmented lesions. BCC and SCC vs actinic 
keratosis were classified with a sensitivity of 95% and specificity of 71% also when combining the 
three modalities.100 
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In 2015, using a multi-fiber Raman probe, Schleusener et al. performed in vivo measurements on 
104 subjects with lesions clinically suspected of being skin cancer (36 melanomas, 39 BCC and 29 
SCC). Additionally, 67 measurements on benign pigmented nevi from 33 subjects were also 
included. Sensitivity and specificity for discriminating histopathologically confirmed melanoma 
from lesions clinically suspected of being melanoma (not histopathologically confirmed) were 
52% and 67%, respectively. For discriminating histopathologically confirmed BCC from lesions 
clinically suspected of being BCC (not histopathologically confirmed) the sensitivity was 54% and 
specificity was 48%. The results for discriminating histopathologically confirmed SCC from lesions 
clinically suspected of being SCC (not histopathologically confirmed) were sensitivity of 52% and 
specificity of 27%. Discriminating histopathologically confirmed malignant lesions from lesions 
clinically suspected of being skin cancer, but not histopathologically confirmed, was not 
successful.93 
Zhao et al., in 2015, performed an independent clinical test on a total of 645 lesions from 409 
patients. The sensitivity and specificity for discriminating skin cancers and precancers (including 
melanoma, BCC, SCC, and actinic keratoses) from benign skin disorders were 99% and 24%, 
respectively. This study provided an independent confirmation of in vivo skin cancer diagnosis by 
Raman spectroscopy.92 
Santos et al. measured 82 freshly excised melanocytic lesions suspected of melanoma.89 The 
measurements were performed using an in-house built Raman micro spectrometer optimized for 
measurements on pigmented skin lesions.101 All 24 melanomas were correctly identified with a 
specificity of 45%. The authors indicated that Raman spectroscopy might lead to a 3-fold 
reduction of the ratio of unnecessary skin excisions and that their results should encourage the 
use of Raman spectroscopy in vivo systems by general practitioners and non-experienced 
dermatologists to discriminate melanoma from suspicious lesions and reduce unnecessary skin 
excisions.89  
In 2017, Bratchenko et al. tested a combination of Raman spectroscopy with auto-fluorescence for 
melanoma and BCC diagnosis. They performed ex vivo measurements on 39 melanomas, 40 BCC’s 
and respective healthy skin within the excised samples. The authors show that the combination of 
Raman spectroscopy with auto-fluorescence has an accuracy of 97.3% in discriminating BCC’s 
from melanoma, whereas the determined accuracy for each modality separately is 79%.102 
Raman applications for surgery guidance: Kong et al. combined auto-fluorescence with Raman 
spectroscopy for intraoperative detection of BCC in skin. This approach was developed to reduce 
the measuring time of whole tissue sections during the Mohs surgery procedure. First, the auto-
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fluorescence images, which were taken at excitation wavelengths of 377 nm and 292 nm 
(corresponding to collagen and tryptophan excitation) were segmented. In this way, the normal 
dermis, which is dominated by collagen, was discarded and only the suspicious segments were 
sampled by Raman spectroscopy. Based on this approach, Kong et al., demonstrated that BCC 
could be automatically detected with a sensitivity of 95% and a specificity of 94%.94  
 
Lung Cancer 
Clinical need: Lung cancer is one of the leading causes of cancer-related deaths in the world, with 
an incidence of 1 824 701 and mortality rate of 1,589,925. Reasons for the high mortality rate are 
the fact that patients tend to be diagnosed at an advanced stage and a lack of effective 
treatments. Part of the diagnostic process is white light bronchoscopy (whether or not combined 
with auto-fluorescence) combined with tissue biopsy for definitive pathology. A problem with this 
technique is that it suffers from either low sensitivity or specificity 102 and it is mainly accessible for 
centrally located lesions. Morever, the representativeness and quality of the transbronchial and 
endobronchial biopsies is difficult to assess during the procedure.104 
Cytologic evaluation also plays an important role in the initial evaluation and diagnosis of patients 
with lung cancer, especially in the evaluation of suspicious lymph nodes.105 Sampling errors and 
numerous mimics are the main pitfalls of the technique.105 An objective optical tool that could be 
adapted to bronchoscopy or incorporated in a biopsy needle would be beneficial for biopsy 
guidance and early diagnosis of lung cancer. 
In early stage disease, surgical management is the treatment of choice. Several studies showed 
better 5-year survival rate for lobectomy (complete removal of the pulmonary lobe where the 
tumor is situated) than for sublobar resection, where less than an entire pulmonary lobe is 
removed.106–108 The sublobar resection procedure has been adopted in a number of centers. This 
procedure has been used for diagnosis and is considered sufficient for early stage disease and for 
non-cancerous lesions. Technical limitations that preclude negative surgical margins are a more 
challenging issue for sublobar resection than conventional lobectomy.108 Ideally, complete tumor 
resection with resection margins of ≥ 2 cm by sublobar resection would be favorable, maintaining 
lung volume and function108 while reducing the risk of local recurrence. Intraoperative frozen 
section has traditionally been the sole modality for achieving negative resection margins. 
However, in some cases, frozen sections are not representative enough to predict the final 
pathology. Thus, the histopathological evaluation of the frozen section is difficult, especially 
between non-invasive stage of the disease and minimally invasive stage.109 The difficulty to predict 
the predominant pattern based on frozen section has been reported to be due mostly to sampling 
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errors.110 Moreover, the intraoperative assessment of margins is challenging owing to an 
underestimation of the margin distance in lung tissue. If the tumor is peripheral, it is easier to 
guarantee a large resection margin. However, when the tumor is centrally located it is more 
challenging to assure that adequate resection margins are achieved. Improvement of 
intraoperative assessment of resection margins is essential to amend sublobar surgery and reduce 
the local recurrence rate. 
Raman applications for early diagnosis/biopsy guidance: The first study that demonstrated the 
technical feasibility of measuring in vivo lung lesions using Raman spectroscopy was conducted in 
2008 by Short et al.111 A multi-fiber Raman probe was implemented to complement white light 
and auto-fluorescence bronchoscopy for in vivo detection of lung cancer. Preliminary research on 
26 patients demonstrated that the combination of Raman spectroscopy with white light 
bronchoscopy and auto-fluorescence bronchoscopy can improve the diagnostic specificity of lung 
cancer (reducing the number of unnecessary biopsies). With these combined technologies, the 
sensitivity and specificity achieved were above 90% for detection of lung cancer and high-grade 
dysplasia lesions. The authors stated that the use of Raman spectroscopy has potential for 
substantially reducing the number of false-positive biopsies associated with white light 
bronchoscopy and auto-fluorescence bronchoscopy.112  
Recently, the same group used the bronchoscopic Raman spectroscopy in vivo in 80 patients (280 
samples), using signal acquisition times of 1s. The detection of high grade dysplasia and malignant 
lung lesions resulted in a reported sensitivity of 90% at a specificity of 65%.113 
 
Esophageal Cancer 
Clinical need: Esophageal cancer has an incidence rate of 455 784 and mortality rate of 400 169.114 
There are two main types of esophageal cancer: squamous cell carcinoma and adenocarcinoma. 
Diagnosis is established with endoscopic guided biopsy. Esophageal adenocarcinoma develops in 
sequential stages of change in the mucosa. Firstly, there is a change from a normal squamous 
epithelium to a columnar cell epithelium (i.e. intestinal metaplasia), known as "Barrett's 
esophagus". The "Barrett's esophagus" is considered a pre-malignant stage because it is associated 
with 100 times higher risk of developing esophageal cancer.115 Endoscopic identification of this 
pre-cancerous stage may enable early, minimally invasive therapeutic intervention (i.e. 
endomucosal resection). The greater the number of biopsies taken from the border of the lesion 
(at least six), the higher the diagnostic accuracy.116,117 However, the increase in the number of 
biopsies performed may cause an increased risk of complications, such as gastrointestinal 
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bleeding. Furthermore, still 11.3?% of upper gastrointestinal tract cancers are missed with this 
technique.118 Therefore, an objective, real-time tool for biopsy guidance could reduce the number 
of unnecessary biopsies and improve the diagnostic accuracy.  
Surgical resection is the treatment of choice in early staged esophageal cancer. The optimal extent 
of esophageal resections is still controversial, but completeness of surgical resection is an 
important determinant for a better outcome. There are recommendations for clearance of tumor 
from proximal and distal margins, but this may vary depending upon the type of tumor. 119,120 The 
presence of tumor at a distance ≤1 mm of the circumferential resection appears to be a significant 
cause of local tumor recurrence and decreased survival.121,122 An intraoperative assessment of the 
resection margins of esophageal excisions is essential to reduce the local recurrence rate and 
increase the survival rate. 
Raman applications for early diagnosis/biopsy guidance: Teh et al. studied 21 dysplastic gastric 
lesions and 44 normal samples from 44 patients using in vivo multi-fiber Raman probe system. A 
sensitivity of 95% and specificity of 91%, between dysplastic and healthy stomach tissue was 
found.123  
Bergholt et al. measured 924 Raman spectra in vivo from normal tissue and 111 from benign ulcers 
from 71 patients with an endoscopic multi-fiber Raman probe system. Malignant ulcers were 
correctly classified with a sensitivity of 82.1% and a specificity of 95.3%.124  
An endoscopic multi-fiber Raman probe system for in vivo and on-line diagnosis of gastric cancer 
was developed by the group of Huang.125 Using this system, they obtained a total of 2748 in vivo 
gastric tissue spectra from 305 patients: 2465 diagnosed as normal and 283 as cancer. The 
reported diagnostic accuracy for gastric cancer was 85.6% (sensitivity of 80.5% and specificity of 
86.2%). Gastric cancer detection algorithms were further applied on 10 patients undergoing 
gastroscopy (Figure 1). The authors report a predictive accuracy of 80.0% (sensitivity of 90.0% and 
specificity of 73.3%).125  
In 2014, Bergholt et al. performed an in vivo study for diagnosis of gastric dysplasia in Barrett’s 
esophagus. A total of 450 patients underwent endoscopy in the upper gastrointestinal tract, 
Raman measurements were performed, biopsies were taken and submitted for histopathological 
evaluation. High grade dysplasia in Barrett’s esophagus, non-dysplastic Barrett’s esophagus and 
normal columnar lined epithelium could be discriminated with a reported sensitivity of 87% and a 
specificity of 84.7%.126  
Wang et al. demonstrated that, using the in vivo endoscopic multi-fiber Raman probe system and 
acquisition times of 0.1-0.5s esophageal squamous cell carcinoma can be detected with sensitivity 
of 97% and specificity of 97%, based on the results from 48 patients.127  
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Figure 1. a) Photograph of Raman endoscopy system in clinic; b) insertion of the 1.8 mm Raman endoscopic 
probe into the working channel of an endoscope during gastroscopy; and c) routine Raman endoscopy 
procedure in clinic 123. From Duraipandian et al. 123. Reprinted with permission from SPIE. 
 
Ishigaki et al. used a micro Raman probe system to examine ex vivo early-stage (stages 0 and I) 
esophageal cancer samples from 15 patients. They demonstrated a sensitivity of 81% and a 
specificity of 94% using leave-one-out cross validation.128  
Using a Raman endoscopic multi-fiber probe during routine endoscopy examination, Lin et al. 
demonstrated in vivo that simultaneous use of the fingerprint and high-wavenumber part of the 
Raman spectrum can improve early diagnosis of gastric pre-cancers (sensitivity of 93% and 
specificity of 94%) in an independent dataset. A total of 48 patients were included. From this 
dataset, 80% of the spectra were used for training and 20% for testing. Using exclusively either the 
fingerprint or the high-wavenumber part, the area under the ROC curve was 0.972 and 0.928, 
respectively. When combining fingerprint and HWVN, the area under the ROC curve was 0.995.129 
 
Head and Neck Cancer  
Clinical need: Head and neck cancer includes cancer of the oral cavity, nasopharynx, oropharynx, 
hypopharynx, and the larynx. It has an incidence rate of 686 328 and a mortality rate of 375 665.114 
The most frequent type of cancer in head and neck region is the oral cavity squamous cell 
carcinoma (OCSCC). When a patient is suspected for a tumor in the head and neck region, all 
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subsites will be examined with a flexible fiber optic endoscope. Examination under anesthesia is 
performed and biopsies are taken for tissue diagnosis.  
Surgery is the mainstay of treatment, with adequate resection margins. Acceptable remaining 
function and physical appearance are the main goals. Inadequate resection margins influence 
negatively local control and prognosis.130,131 In head and neck cancer, clear resection margins of 
>5mm are decisive for disease control and survival.132,133 Achieving adequate resection margins is 
challenging. The lack of reliable intraoperative guidance and the proximity of tumors to vital 
structures are common causes of inadequate tumor resection. Recent studies show poor surgical 
success rates with inadequate tumor resection in oral cavity cancer surgery from 30% up to 
85%.23,33,134 Intraoperative assessment by means of frozen-section is the standard procedure. 
However, it can only be used for soft tissue and not for bone. Additionally, only a very small 
percentage of the resection margins can be investigated by this procedure and the selection of 
suspicious tissue depends on the surgeon’s and/ or the pathologist’s experience. These 
confounding factors also result in a high recurrence of oral cancer.21,135 The two primary clinical 
needs are early diagnosis of OCSCC and intraoperative assessment of the complete resection 
margins, not only for soft tissue but also when bone is involved. 
Raman applications for early diagnosis/biopsy guidance: In 2014, Krishna et al. created an in vivo 
multi-fiber Raman probe system and measured a total of 28 healthy volunteers and 171 patients 
with oral lesions. Spectra were annotated, based on histology or by clinical assessment, as oral 
squamous cell carcinoma (OSCC), oral submucosa fibrosis (OSMF), oral leukoplakia (OLK) and 
normal mucosa. Each group (OSCC, OSMF, OLK and normal) was correctly classified, when 
applying the developed diagnostic algorithm, in 89%, 85%, 82% and 85% of the cases, 
respectively.136  
In 2015, Guze et al. conducted an in vivo pilot study with a Raman probe and measured oral 
diseases from 18 patients. Benign and malignant oral lesions were classified correctly with 
sensitivity of 100% and specificity of 77% using a multi-fiber Raman probe. Although, a larger 
study group was preferable, the results indicate that Raman spectroscopy is a promising 
diagnostic tool.137  
Raman applications for surgery guidance: In 2015, the feasibility of identifying oral cancer tumor 
based on water concentration was demonstrated ex vivo, using high-wavenumber Raman spectra 
obtained from freshly excised resection specimens from oral cavity.135  
Barroso et al. investigated how the water concentration changes across the border between tumor 
and the healthy surrounding tissue on ex vivo specimens from patients that underwent surgery for 
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oral cavity squamous cell carcinoma. Measurements were performed on 20 patients using a 
confocal Raman microscope system. The results revealed consistent changes in the water 
concentration across the tumor border. Over distances of 4 to 6 mm across the tumor border, 
water concentrations changed from 76% ±8% in the tumor to 54%±24% in the healthy 
surrounding tissue.138  
 
Brain cancer  
Clinical need: The estimated incidence of brain cancer in the developed world is 7.1/100 000 with a 
high mortality of 5.3/100 000.1 Neuroradiology is usually sufficient as the initial diagnostic 
modality for brain cancer. In some cases, stereotactic biopsy is needed to decide for primary 
resection versus chemo- radiation. For accurate histopathological diagnosis multiple tissue 
samples are obtained.139 Brain biopsy may be complicated by sampling error and cerebral 
hemorrhage. 140,141 Therefore a rapid and objective tool is needed for optimal biopsy guidance to 
provide one representative brain tumor tissue sample, thus minimizing the risk of cerebral 
hemorrhage. 
Treatment of choice for most primary brain cancer is surgery 17. In low-grade gliomas the extent of 
tumor tissue resection is associated with improved patient outcome.141–143 Three-dimensional 
stereotactic navigation, 5-ALA-fluorescence and intraoperative magnetic resonance imaging (MRI) 
are currently used to achieve optimal surgical results.141,144 Unfortunately, distinguishing cancer 
from healthy tissue during surgery still is a challenge.140,145 Generally, postoperative MRI 
demonstrates residual tumor in 69.6% of the cases.145 The accuracy of navigation is influenced by 
the intent to preserve vital brain structures, inter-observer disagreement on the tumor 
transformation zone, and brain edema.146 In the current practice, adoption of navigation 
techniques is limited owing to high costs and hampered by low evidence of survival benefit.147 An 
optical, intra-operative tool to guide the surgeon towards tumor tissue in stereotactic biopsy and 
to identify adequate resections while preserving function brain structures with resection may 
improve patient outcome. 
Raman applications for surgery guidance: Jermyn et al. in Montreal have developed a Raman 
system with a hand-held probe for intraoperative use during brain tumor resection. In an in vivo 
study, spectra were obtained from 17 patients with 0.2s acquisition time (Figure 2). Patients with 
grade 2 to 4 gliomas were included (66 normal spectra and 92 cancer spectra). They reported a 
sensitivity of 93% and a specificity of 91% in distinguishing normal brain tissue from dense cancer 
and normal brain invaded by cancer cells.148  
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Figure 2. The handheld contact fiber-optic probe for Raman spectroscopy. The probe (Emvision, LLC) was used 
to interrogate brain tissue during surgery. A schematic diagram illustrated the excitation of different molecular 
species, such as cholesterol and DNA, to produce Raman spectra of cancer versus normal brain tissue 52. From 
Jermyn et al.52. Reprinted with permission from the authors and AAAS. 
Colorectal Cancer  
Clinical need: Colorectal cancer (CRC) has an incidence rate of 1 360 602 and mortality rate of 
almost 700 000.1 CRC is diagnosed after onset of symptoms or through screening by 
colonoscopy.149 Screening detects early-stage malignancies or premalignant polyps (adenomas) 
and improves prognosis for the patient.149 Colonoscopy miss rates are 2-6% for CRC and 20-26% 
for adenomas.150,151 Additionally, many polyps with minimal malignant potential are removed 
without benefit to the patient.149,152 
Despite its contribution to the effectiveness of colonoscopy, polypectomy is associated with 
increased risk of major complications (perforation, hemorrhage).153 An objective biopsy guidance 
tool is therefore of clinical importance to reduce these limitations.  
Surgery is the only curative modality for localized colon cancer. Proximal and distal resection 
margins should be at least 5 cm from the tumor.154 Satisfyingly, positive margins in colon cancer 
resections are rare.155 The most important indicator of outcome following resection of colon 
cancer is the tumor pathologic stage.156 
Raman applications for early diagnosis/biopsy guidance: In 2008, Widjaja et al. measured 105 
colon specimens ex vivo with an in-house built Raman probe 155. From the 105 colon specimens 41 
were normal, 18 were hyperplastic polyps and 46 were adenocarcinomas. In this study, the 
diagnostic accuracy was 98%.157  
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Short et al. conducted a study using Raman spectroscopy on ex vivo colon tissue from 18 patients, 
measuring both the fingerprint and high-wavenumber spectral regions. The results indicated that, 
using the high-wavenumber region, the non-malignant and the malignant groups could be 
classified correctly with a specificity of 89%. The authors referred that high-wavenumber region 
could be used in vivo to improve the identification of neoplastic lesions.158  
Bergholt et al. tested the same approach in vivo (combined fingerprint and high-wavenumber 
spectral regions) on adenomatous polyps measured from 50 patients using an endoscopic multi-
fiber Raman probe. Adenomatous polyps were separated from hyperplastic polyps with a 
sensitivity of 91% and specificity of 83%. The authors demonstrated that the analysis based on the 
combination of fingerprint and high-wavenumber spectral regions is superior to considering 
either region alone.12 
 
Cervical cancer  
Clinical need: Cervical cancer has a worldwide yearly incidence of 528 000 women and mortality of 
266 000.1 In recent years incidence and mortality rates have decreased because of the emergence 
of screening.159 The primary method of screening is by cervical cytology with the Papanicolaou 
test (PAP). This has a high specificity (95–98%) but a low sensitivity (<50%).160 This sensitivity of 
screening is increased by testing for Human Papilloma Virus (HPV) in the cervical swab.161 Final 
diagnosis of cervical cancer is based on histopathology. For this colposcopy guided biopsy is 
recommended, with a sensitivity of 92% and specificity of 67%.73 In low resource settings visual 
inspection of the cervix with biopsies is used with a specificity and sensitivity of 88-92% and 10-
84%.162,163 Treatment of cervical cancer is based on stage. Small tumors will be treated by surgery, 
and higher stages with chemotherapy. It is not to be expected that Raman spectroscopy has any 
value in the diagnostic or treatment of cervical cancer since the diagnostic accuracy of colposcopy 
guided biopsies will not be improved and precision treatment is not applicable for cervical cancer. 
Raman applications for early diagnosis/biopsy guidance: Mo et al. measured Raman spectra from 
46 patients in vivo with high-wavenumber Raman spectroscopy, to investigate cervical pre-cancer 
diagnosis. The Raman instrument used a ball-lens fiber-optic Raman probe. Cervical dysplasia 
could be distinguished from normal tissue with a reported sensitivity of 94% and specificity of 
98%.164  
Kanter et al. performed a clinical study on a total of 43 patients that underwent colposcopy-guided 
biopsy to investigate dysplasia. Using a portable Raman system with a fiber-optic probe, spectra 
were acquired of low grade squamous intraepithelial lesions, high grade squamous intraepithelial 
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lesions, metaplastic lesions and normal tissue. The classification accuracy for discriminating 
diseased from normal tissue was 88%, the sensitivity was 86% and the specificity was 97%.165 The 
same group reported, in 2011, a sensitivity of 70% and a specificity of 83% for cervical pre-cancer 
diagnosis. In this study a total of 29 patients were included. Measurement were done in vivo using 
fiber-optic Raman probe with a ball-lens.166 To improve diagnostic accuracy, Duraipandian et al. 
combined high-wavenumber and fingerprint Raman spectroscopy for cervical and pre-neoplasia 
detection. The obtained sensitivity and specificity were 85% and 81.7%, respectively.167  
Rubina et al. performed ex vivo Raman measurements on 49 abnormal cervical specimens and 45 
negative control cytology samples using a fiber-optic Raman microprobe system. Abnormal 
lesions were classified correctly in 84.5% of the cases. The authors suggested that presence of 
blood in abnormal specimens was a major cause of discrimination.168,169  
 
Vulvar cancer  
Clinical need: Vulvar cancer has an incidence of 1,300 women and mortality of 450 women per 
year.170 This malignancy has a high curability in early-stage disease, but a poor prognosis for 
advanced-stage disease and recurrent disease. Diagnosis is based on histopathology of a biopsy of 
the vulva at the peripheral edge of the lesion,171 whereby underlying stroma is included and 
possible necrotic tissue avoided.172 In vivo diagnosis and biopsy guidance can be of great value for 
accurate diagnosis. Surgery is the main choice of treatment. In recent years surgical management 
has changed, were large radical and disfiguring resections make place for conservative surgery.172 
Resection margins of ≥8 mm are considered clear margins. Resection margins less than 8 mm 
result in local recurrence rates of 23-50%.173,174 Surgical management of vulvar carcinoma aims to 
achieve a fine balance between adequate resection margins and preservation of sexual and 
urinary function.172,175 An intra-operative tool for surgery guidance is therefore needed. 
Raman applications for early diagnosis/biopsy guidance: During the literature search we have 
noticed that Raman applications have not been greatly developed for vulvar cancer. The most 
recent study, was developed by Frost et al.176 They have evaluated the diagnostic performance of 
Raman Spectroscopy for differentiating a pre-malignant vulvar lesion (lichen sclerosus, LS) from 
other inflammatory vulvar conditions in fresh vulvar biopsies from 27 women. Biopsies resulted in 
circular discs o skin 3-4 mm in diameter (full thickness of the epidermis with underlying dermal 
tissue). Spectra were measured with a Raman micro-spectrometer (modified Renishaw system 
1000 dispersion), which was coupled to a diode laser of 830 nm excitation wavelength and had a 
spot size of 15x17 μm. A classification model was created using principal components and 
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multivariate linear discriminant analysis. Leave one sample out cross validation was used to 
validate the model. The model was able to correctly differentiate LS from other inflammatory 
vulvar conditions with a sensitivity of 91% and specificity of 80%. The authors suggested that the 
study demonstrates that Raman spectroscopy has potential for in vivo non-invasive diagnosis of 
vulvar skin conditions and when applied in the clinical setting may reduce the need for invasive 
tissue biopsy.177 
 
Bladder Cancer 
Clinical need: The global incidence rate for bladder cancer is 430 000 and mortality is 165 000.1 The 
standard for diagnosis is cystoscopy, with biopsies of suspicious lesions, and transurethral 
resection (TUR) to confirm the diagnosis.178 Unfortunately, small papillary bladder tumors and flat 
urothelial tumors can easily be overlooked.179 This contributes to increased residual rates and a 
recurrence rate of 50% within 18 months. TUR is (also) the standard of treatment for small (Ta) 
bladder tumors. Incomplete resection results in a second operation and/or increased recurrence 
rate, resulting in poor long-term prognosis.180–183 Thereby, high risk tumors grow fast with a 
mortality rate of 50%, despite treatment. Also, bladder cancers have the tendency to recur 
frequently, leading to re-operations, loss of function and worse patient outcome. Urinary markers 
are emerging but not able to outperform cystoscopy. These findings suggest that in vivo biopsy, 
biopsy guidance and surgery guidance is needed for early detection, accurate diagnosis and 
adequate resections, to improve patient outcome. 
Raman applications for early diagnosis/biopsy guidance: The first in vivo Raman probe that was 
used in bladder was an Emvision® probe with a filtered six-around-one fiber configuration. The 
excitation wavelength was 785 nm. The probe used had a large measurement volume (~1 cm3) 
and did not have any lenses. As a result, the probe collected Raman spectra not only from the 
upper urothelium surface of the bladder (where transitional cell carcinoma has its origin) but also 
from deeper layers. During the procedure of transurethral resection of bladder tumors (TURBT), 
spectra were collected from suspicious and non-suspicious locations (collection times of 1 to 5 s). 
Bladder cancer could be distinguished from normal bladder with a reported sensitivity of 85% and 
a specificity of 79%. Even though the results show the possibility of discerning normal from 
malignant bladder tissue using Raman spectroscopy, the authors suggest that using a Raman 
probe that collects shallower signal from the urothelium surface of the bladder would be ideal for 
early diagnosis. Also, the combination of auto-fluorescence with Raman spectroscopy could 
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potentially improve the diagnostic capability, by using the sensitive auto-fluorescence modality to 
indicate suspicious regions for “optical biopsy” by the highly specific Raman spectroscopy 
modality.184,185  
In 2012, a confocal Raman probe was designed by Barman et al. and it was used ex vivo for bladder 
cancer diagnosis in 14 patients. The confocal probe had depth of field of approximately 280 μm. 
The result of the confocal system had a significantly higher specificity with respect to large-volume 
Raman spectral data, with a sensitivity that was comparable to the large-volume Raman 
system.60,177 
 
Prostate cancer  
Clinical need: Prostate cancer is among the most common cancers in men worldwide, with an 
incidence of 1 094 916 and mortality rate of 307 481.1 The diagnosis of prostate cancer is often 
made through transrectal ultrasound guided prostatic biopsy.186 Ten to twelve core biopsies are 
recommended, with > 12 biopsies not being significantly more conclusive.187,188 While the majority 
of prostate cancer patients is treated by radical prostatectomy or radiation therapy, an increasing 
number of men is actively surveyed for their disease without immediate treatment. In a significant 
number of men, radical prostatectomy is complicated by urinary and/ or erectile dysfunctions, 
which is related to eradication of the neurovascular bundles (NVB) localized in the dorsolateral 
peri-prostatic fat tissue. Operative removal of the prostate leaving the NBV intact can reduce post-
operative complications. Decision-making on nerve-sparing surgery can be optimized by intra-
operative assessment of the prostatic surgical margins. In practice, the urologist can only remove 
the prostate initially leaving the NVB in situ. In case intra-operative assessment of the prostatic 
surgical margin is negative, the NVB will remain intact; in case, the margin is positive the urologist 
can remove the NVB at a second term. Although intra-operative frozen-section assessment is able 
to increase nerve-sparing surgery from 81% to 97%, it is labor-intensive requiring an optimized 
work-flow for the fast throughput of a large number of frozen sections 189. Intra-operative 
assessment of surgical margins using Raman spectroscopy might be a good alternative for 
extensive pathologic frozen sections and could be implemented at large scale in operation 
theatres or departments of pathology. 
Raman spectroscopy applications: Spontaneous Raman spectroscopy has not been explored yet in 
vivo and/or ex vivo using human prostate cancer material. Raman-based studies were developed in 
the last years in vitro, using cell cultures and, more recently, ex vivo using peripheral nerves of 
rats.177,190,191 
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Instrumentation 
When developing instrumentation for in vivo and ex vivo applications, the main technical 
problems are: speed of measurement, adaptation in clinical workflow, interference of background 
from tissue auto-fluorescence and high instrumentation costs.  
In the last years we consider that the major technological advances in Raman spectroscopic 
systems for clinical applications have been in: (1) detector technology, (2) fiber-optic probe design, 
(3) combination with other techniques, and (4) new laser opportunities for low-cost systems.  
 
(1) InGaAs detectors for short-wave infrared Raman spectroscopy 
Until now the detection of Raman signals in the short-wave infrared (SWIR) region (>1100 nm) was 
constrained by limitations of the state-of-the-art detector technology for visible to NIR excitation 
(CCDs). An alternative in this spectral range is the Indium-Gallium-Arsenide (InGaAs) detector, 
which enables detection at wavelengths well above 1100 nm. Several companies have recently 
moved towards the SWIR range, and have introduced InGaAs-based Raman devices (e.g. Andor™, 
Anton Paar™, Horiba™, B&W Tek™). Xenics™ introduced an InGaAs camera that has a read-out noise 
at comparable levels as a CCD detector, and that consequently can achieve shot-noise limited 
Raman spectra in clinically acceptable integration times.101 This development in detector 
technology enabled the use of longer excitation wavelengths for clinical applications on tissues 
with would otherwise suffer from strong laser-induced fluorescence of fluorophore-containing 
tissues. Santos et al. could measure melanocytic skin lesions without overwhelming tissue auto-
fluorescence interference using a SWIR Raman system, with NIR 967 nm laser and an extreme low-
noise InGaAs detector (Figure 3).89  
Also Patil et al. and Pence et al. have reported dispersive Raman spectroscopy of tissues with 
strong auto-fluorescence (liver and kidney human tissues) using 1064 nm excitation in 
combination with an InGaAs detector array.192,193 Laser-induced tissue fluorescence was 
significantly reduced compared to excitation with lasers in the visible wavelength range.  
 
(2) Fiber-optic probes 
Fiber probes for early diagnosis: Fiber-optic probes have enabled the use of Raman spectroscopy 
for in vivo clinical applications. The integration of Raman spectroscopy with other diagnostic 
techniques has been a major step in the development towards improved efficiency in biopsy 
guidance and early cancer diagnosis. Fiber probes that could be inserted into endoscopic 
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Figure 3. Implementation of SWIR Raman system in the dermatology outpatient clinic of Leiden University 
Medical Center for in vivo measurements. a) Photograph of a pigmented skin lesion. b) This was measured 
using a 976 nm laser excitation, the SWIR Raman instrument and a single fiber probe. The corresponding 
Raman spectrum measured in vivo is shown in c). Exposure time: 30. 
?
channels enabled in vivo measurements in hollow organs or surface assessment of solid organs: 
oral cavity,136,137 lung,111,113 upper gastroinstestinal tract,123–127,129 colorectal,12,158 bladder,185 and 
cervical cancers.164–167,194 Also, handheld fiber-based systems have been used for in vivo assessment 
of skin cancer,88,90,91,94–96 and of brain cancers.148,195  
In the last years numerous Raman probe designs have been developed, optimized and tested for 
clinical purposes. There has been an increased effort to tailor Raman probes to clinical needs and 
constraints defined by the specific clinical targets, specific pathophysiology of diseases, and 
specific anatomies of the region of interest (e.g. accessibility of the tissue, sample size, sampling 
depth).  
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Stevens et al. and Wang et al. have reviewed Raman fiber-optic probe designs and construction 
concerns, considering different oncological applications and respective clinical needs.18,196  
Depth-selective fiber-optic Raman probes have been investigated for use in epithelial tissue 
associated with dysplasia.197 Wang et al. developed a confocal fiber-optic Raman probe coupled 
with a ball lens to enhance in vivo Raman measurements from gastric pre-malignant epithelial 
tissue during endoscopy.197,198 With a beveled fiber-optic probe coupled with a ball lens, the 
authors could limit their collection depth to 300 μm. Since gastric dysplasia initially evolves in the 
epithelial tissue layer (~300 μm), it is especially relevant for selective interrogation of the gastric 
epithelium. 
Further work from the same group, featured a fully automated real-time Raman spectral 
diagnostics framework integrated with a multimodal image-guided Raman technique that 
enabled real-time in vivo cancer detection at routine endoscopy procedure, as shown in Figure 
1.199 The same fingerprint/high-wavenumber fiber-optic Raman endoscopic system was 
developed further by Bergholt et al. for routine clinical colonoscopy diagnosis, making use of a 
foot pedal control switch and an auditory feedback to the gastroenterologist.199 
Using a similar probe in a hand-held confocal design, Duraipandian et al. measured in vivo 
fingerprint and HWVN Raman spectra during colposcopy.167 
Agenant et al. used a novel clinical Raman probe for sampling superficial tissue to improve in vivo 
diagnosis of (superficial) urothelial carcinoma. This probe had a measurement depth of 0-200μm, 
which corresponds to the average urothelium depth. The probe is comprehended by 7 collection 
fibers, 1 excitation fiber and two component front lens.200 
Fiber-optic probes for guided surgery 
In the field of brain cancer, Jermyn et al. preformed in vivo Raman measurements during human 
brain cancer surgery for real-time identification of invasive cancer, using a handheld contact 
Raman spectroscopy probe.52,195 Each measurement covered a 0.5mm diameter tissue area with a 
depth sampling up to ~1 mm in 0.2s. During the tumor resection, Raman signals were measured in 
the surgical cavity. The probe is comprehended by filters that were placed directly at the tip of the 
optical fibers. The spectra acquired with the handheld Raman probe (Figure 2) do indicate that 
there are still some challenges in developing probes and methods for correcting for spectral 
distortions mainly caused by the filter characteristics of the probes and subtraction of fluorescence 
signal backgrounds.201  
A Raman system comprehended by a single fiber needle probe is currently being tested ex vivo by 
Head and neck surgeons and pathologists from Erasmus University Medical Center Rotterdam, The 
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Netherlands. This probe aims intraoperative inspection of the entire resection margin of 
specimens from patients that underwent surgery for oral cavity SCC (Figure 4). 
 
(3) Combined Raman systems for guided surgery 
In the field of dermatology, Kong et al. developed a scanning device that combines auto-
fluorescence imaging and Raman spectroscopy to guide Mohs micrographic surgery (MMS) in the 
excision/treatment of high-risk skin basal cell carcinoma.94 Although MMS provides the highest 
cure rates, it is a time-consuming technique (1 - 3 hours) needing highly trained personnel. 
 
 
Figure 4. Single fiber needle probe for intraoperative assessment of the oral cavity SCC resection margins, 
developed by Artphotonics GmbH in collaboration with RiverD International B. V. and Erasmus University 
Medical Center, Rotterdam. a) Close up of the single fiber needle probe. b-c) Testing the single fiber needle 
probe for inspection of the freshly excised oral cavity specimens. 
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With the purpose of reducing the duration of scanning large areas of tissue, tissue auto-
fluorescence imaging is used to determine the main spatial histological features of the sample, 
and this information is used to select and prioritize the sampling points for Raman spectroscopy 
(Figure 5).94,202  
 
(4) New lasers  
Recent developments in vertical-external-cavity surface-emitting laser (VECSEL) technology have 
brought their characteristics in the realm of Raman spectroscopy, with special interest for low-cost 
hand-held devices.203 VECSELs are semiconductor lasers based on a vertical-cavity surface-emitting 
(VCSEL) geometry.  
These types of lasers achieve a combination of high continuous-wave (CW) output power, due to a 
large gain area, and a low- divergence near-diffraction-limited beam, due to the transverse 
mode control of the extended cavity. The advantages of VECSELs over edge-emitting 
semiconductor lasers are circular output beam, easy array fabrication, small size, and low cost at 
mass production.56,203–205 
Transferability 
The Raman applications described above demonstrate potential of Raman spectroscopy to affect  
 
Figure 5. Multimodal spectral histopathological diagnosis of BCC in unsectioned tissue blocks as received from 
surgery. H&E histopathology images for adjacent sections are included for comparison (Scale bars: 2 mm).94 
Reprinted with permission from the authors and PNAS. 
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patient care. The major requirements for translation of a Raman equipment into clinical practice 
are: (1) well defined clinical need, (2) patient benefit proven and/or cost benefit, (3) equipment 
changes clinical practice, (4) demonstrated safety, reproducibility, robustness, and reliability (e.g. 
large clinical trials) and (5) regulatory approval.  
First, it is important to verify beforehand that the developed Raman application addresses an 
actual clinical need and that the application can provide results of clinical relevance. This does not 
mean that the Raman instrument needs to give perfect results, as long as it can bring about 
measurable and cost effective improvements in patient care. Moreover, it is required that the 
instrument is introduced in the clinical workflow and is used/tested by clinicians. 
Second, it is essential to demonstrate the safety, reproducibility, robustness, and reliability of the 
developed application in large clinical trials, to the end-users. And finally, receive approval from 
regulatory agencies.  
Many of these aspects are now increasingly being addressed, which is a good sign of progress in 
the field towards clinical translation. However, for this translation continued effort is needed by 
searching for close collaboration and input from the medical community.  
Additionally, to gain the confidence of clinicians to the potential value of Raman-based 
applications, it is essential to expose the results of Raman technologies over or in line with existing 
medical devices.2,206 This should be done in large cohorts’ studies based on patient outcomes and 
in direct comparison with the current gold standards.  
Multidisciplinary networks are now being developed, such as the International Society for Clinical 
Spectroscopy (ClirSpec), European Photonics Industry Consortium (EPIC) and Raman4Clinics, 
which target especially these translational aspects. ClirSpec is a society, comprehended by 
spectroscopists and clinicians, that facilitates and promotes the translation of spectroscopy into 
the clinical environment, for the general benefit of patients (clirspec.org). Raman4Clinics is a 
platform for scientific communication, exchange, collaboration and for new research activities, 
combining the partners’ expertise in technology, component, system and methodology 
development and medical application (www.raman4clinics.eu). EPIC is a network that promotes 
awareness of opportunities for the European photonic industry in healthcare (www.epic-
assoc.com).  
To provide an overview of the current status of the technology towards clinical translation, we 
classified all reviewed R&D results, based on the TRL. Figure 6 (2008-2017) shows the result from 
the technology readiness classification of the different Raman studies mentioned in the Raman 
applications section. From this figure, it is immediately clear that the majority of the developed 
applications appears to get stuck in category B (TRL 4).  
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These studies presented results of algorithms for (pre-)malignant tissue detection with data either 
collected in vivo or ex vivo with prototype Raman systems. However, validation of algorithms with 
an independent large dataset has not been proven yet. Some of the systems used in the analyzed 
studies are already further towards actual clinical use, and were classified as C, such as Zhao et al., 
Wang et al., Kong et al., and Duraipandian et al.92,94,125,127 
 
Development of commercial instruments for oncological applications 
We realized that most of the studies do not report a fully commercial product (ready to be used in 
the clinic). We therefore contacted the companies that are collaborating directly with the research 
groups presented in the Raman applications section. We also investigated the progress/potential 
interest of the companies which are developing or have developed commercial Raman 
spectroscopic systems for oncological applications.  
We received information from the following leading companies in Raman spectroscopy: Avantes 
B.V., B&W Tek, EmVision LLC, Invenio B.V., Horiba Jobin-Yvon Inc. (HORIBA Scientific), ODS Medical 
Inc., Renishaw, RiverD International B.V., Verisante Technology Inc., and WITec B.V.. Based on the 
information received we have created a future perspective of clinical translation, which is 
presented in Figure 6 (2017-2021).  
Progress reported by companies: B&W Tek has developed a Raman spectroscopic system, for the 
identification and qualification of cytostatics (in-vitro). B&W Tek is a company that provides 
instruments looking for R&D partners. 
Invenio Imaging Inc. is developing a stimulated Raman scattering microscope for histological 
examination of fresh tissue. The most recent publication was in Nature Biomedical Engineering, 
early 2017.207 The perspective of the company is to have the equipment ready to be 
commercialized later this year. 
EmVision LLC does not manufacture or develop clinical systems, but the company is active in 
selling components, such as fiber-optic probes, to companies that are pursuing clinical systems.  
HORIBA Scientific is an active member of Raman4Clinics European project and provides research 
and analytical Raman instruments for all kind of applications, including oncology. 
ODS Medical Inc. is developing an in vivo Raman tool for surgical brain tumor resection.148,208–211 
The company predicts that the system will be commercialized within approximately 3 years (in 
2020) following approval by regulatory bodies, including FDA. 
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Figure 6. Illustration of the result from the technology readiness classification of the different Raman studies, 
mentioned in the Raman applications section. Verisante Technology Inc. is commercializing a device (Verisante 
Aura) for skin cancer detection [*]. In the graph is also plotted the prognosis (2017-2021) of further 
development/commercialization given by the companies RiverD International B.V. [**] and ODS Medical Inc. 
[***]. 
Renishaw has been actively developing a Raman system for ex vivo analysis of tissue cells and bio 
fluids for clinical use. The company is upgrading fiber-optic probe designs for clinical use during 
oncological surgery. This company has an ex vivo Raman spectroscopy platform (InVia series, 
Renishaw, Gloucestershire, U.K.) for a number of life-science and clinical applications including 
tissue pathology, neurobiology, stem cell research. Renishaw is currently developing a fast tissue 
imaging platform, which is based on the RA802 Pharmaceutical Analyser, for measuring uneven 
tissue surfaces with a minimum of sample preparation.212–214 The new fast tissue imaging platform 
should be available in the summer of 2017. 
RiverD International B.V. collaborates with the University of Nottingham in the development of an 
auto-fluorescence/Raman system for Mohs’ micrographic surgery of basal cell carcinoma. Two 
prototype systems are currently being tested at the University of Nottingham, in UK, and at 
Erasmus University Medical Center Rotterdam, in the Netherlands. The systems are based on the 
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concept described by the Nottingham group.94 RiverD International B.V. is developing a Raman 
tool for surgical guidance of Head and neck tumor resection, which they predict to be ready for 
clinical trials in 2019. Currently, an ex vivo fiber-optic probe system is being developed for 
intraoperative inspection of resection margins of excised tissue. The company is also collaborating 
in an R&D project that aims to the development of a Raman spectroscopic device for use by 
dermatologists and general practitioners for objective assessment of pigmented skin lesions 
clinically suspected of melanoma.89,101 
Verisante Technology Inc. is developing in vivo Raman technology for clinical oncology 
applications focused on: (1) in vivo non-invasive detection of skin cancers including melanoma and 
non-melanoma skin cancers; (2) endoscopy detection of cancers of internal organs such as lung 
cancers and gastro-intestinal cancers.88,111,113,215–217 Currently, Verisante Technology Inc. is 
commercializing a skin cancer detection device (Verisante Aura, Figure 7) in Canada, Europe and 
Australia. Aura systems are being in use in several clinics in Canada. In figure 6, Verisante Aura is 
identified by [*]. 
WITec B.V. develops and commercializes confocal Raman microscope systems. The company is not 
actively involved in development of applications in the clinical oncology field. However, various 
users of the confocal Raman microscopes have applied their instruments in oncology-relevant 
research.218–221  
Hurdles in translation reported by companies: Some of the companies have indicated what 
hurdles they have encountered when translating Raman systems into the clinics. One important 
issue can be assuring that high-quality data can be acquired consistently and robustly under 
intraoperative conditions, with minimal disruption of the surgical workflow.210 It is also important 
to ensure that real-time high-accuracy tissue classification is provided to surgeons in an intuitive 
way and by simple metrics (user-friendliness). 
 
Figure 7. Verisante Aura system for skin detection. Courtesy of Verisante Technology, Inc. 
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Another referred problem is to find funding/investors that can help to bring the product into the 
market. The fact that Raman spectroscopy is still a relatively unknown technique for most 
clinicians, was yet another hurdle mentioned. This can be partially explained by the fact that from 
all the scientific studies reviewed in this article only approximately 30% were published in medical 
oriented journals. Another explanation for Raman spectroscopy to be relatively unknown might 
be also partly due to this technique not being widely incorporated in the curriculum of clinicians 
or clinical researchers. To resolve this, more effort should be done towards publication of clinical 
Raman studies in medical oriented journals. Additionally, current academic leaders in the medical 
field, who have knowledge of clinical spectroscopy, should encourage the introduction of this 
subject in medical school curriculums alongside other medical imaging and diagnostic topics.  
 
Discussion 
In the last decade a strong effort has been made towards clinical implementation of Raman 
spectroscopy as an adjunct technique for early diagnosis, biopsy guidance and oncologic surgery 
guidance. The most recent studies aim to: (1) detect pre-malignant lesions,113,125,126,136,164,222 which is 
one of the most effective ways to reduce the number of cancer cases, (2) detect cancer in less-
invasive stages,101,113,125,157,157 (3) reduce the number of unnecessary biopsies,91,96,112,113 and (4) guide 
surgery towards complete removal of the tumor with adequate tumor resection margins, which 
reduces the need for post-operative treatment, decreases the aggressiveness of the post-
operative treatment and increases patient survival 76,94,138,148,206.This means that Raman 
spectroscopy is used to detect (pre-)malignant lesions for guidance of clinical procedures. A next 
step would be to use Raman spectroscopy in diagnosis of (pre-)malignant lesions; i.e. 
differentiating between different types of cancer and grading (pre-)malignant lesions (e.g. 
differentiating high-grade from low-grade dysplasia).12,111,126,127,136 
Raman spectroscopy may address all the clinical needs mentioned, because, in fact, all show the 
same fundamental problem: lack of pre- and intraoperative methods with sufficient or clinically 
relevant sensitivity and specificity. Raman spectroscopy is an objective technique that can add 
biochemical information, can be performed in vivo and can be used in real-time. Raman 
spectroscopy may, not only, address the need for rapid and objective intraoperative margin 
assessment, which is essential for surgical oncology. Raman spectroscopy could also help 
pathologists and surgeons to assure adequate resection margins intraoperatively.2,20,21,82,148 
Consequently, the use of this technique may help to improve the surgical outcome of the patients 
and to decrease the need for adjuvant therapy.  
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Additionally, Raman spectroscopy can also give an objective and reliable decision about 
malignancy and early malignant stages.2,20,21,82,223 This technique could help medical professionals 
in assessing with a clinically relevant specificity and sensitivity the location for most representative 
biopsies.2,21,223  
Many of the in vivo and ex vivo trials that aim for detection of malignant tissue have achieved 
sensitivities varying between 77% and 100% and specificities varying between 45% and 100%. 
Studies that aimed for detection of pre-malignant lesions presented generally lower specificities 
(ranging between 63% and 97.8%) and sensitivities (ranging between 70% and 93.5%). Although 
these numbers are not perfect they demonstrate that Raman spectroscopy can help improving the 
current clinical practice.  
In the past, a disadvantage of Raman spectroscopy was the low measurement speed. One way to 
overcome this is to complement Raman spectroscopy with other techniques, such as auto-
fluorescence imaging. For instance, Kong et al. and McGregor et al. 94,113,224 have used auto-
fluorescence imaging to quickly scan large areas of tissue for selection of the measurement 
locations for Raman spectroscopy, thereby reducing the time spent on redundant or non-relevant 
Raman measurements.94,202 
From the work published in the recent years, we consider that the most notable advances in 
instrumentation of Raman spectroscopy include: (1) advances in the detector technology, (2) in 
vivo miniature fiber-optic probes to be used as an adjunct device to conventional endoscopes for 
biopsy targeting or for surgery guidance, (3) combined fluorescence microscopy and Raman 
spectroscopy systems for guided surgery, and (4) new lasers for low-cost Raman devices.  
The number of scientific groups that are working towards implementation of Raman spectroscopy 
devices in clinical procedures is remarkable. Most of the studies (89%) still take place at the same 
technology readiness level (TRL-4, or class B). In these studies, algorithms have been developed for 
detection of (pre-)malignant tissue based on in vivo or ex vivo measurements, under conditions 
that approach the intended clinical environment. Validation of these algorithms based on large 
independent datasets obtained in the actual clinical workflow still needs to happen.  
We have observed that approximately 30% of the reviewed studies were published in medical 
journals. In order to raise awareness and increase acceptance of Raman technologies among 
clinicians and clinical researchers results of Raman cancer diagnostic studies should be presented 
at medical conferences and published in medical journals. Better communication between 
clinicians and spectroscopists will facilitate understanding of the clinical requirements and 
challenges. The gap between technology developers and clinicians is narrowing due to the 
contribution of multidisciplinary networks like ClirSpec, Raman4Clinics (EU COST Action BM1401) 
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and EPIC. These networks also actively pursue standardization of sample preparation, 
measurements, data analysis protocols, which will help to form a basis for transferability and 
thereby accelerate the developments discussed in this review. The networks can also have an 
important role in presenting Raman spectroscopy as a technology that can complement and 
facilitate the work of the clinicians and improve patient outcome.  
In summary, based on the expectation given by the companies, we believe that within 5 years 
Raman-based oncological products will advance into routine clinical settings. 
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Introduction 
In the previous chapters of this thesis, an in-house developed focused-beam Raman spectroscopy 
setup was presented. The setup was used to measure Raman spectra of excised skin lesions. In 
order to add the option to perform in vivo Raman measurements, the setup was adapted to accept 
a fiber-optic probe extension that can be easily inserted in the existing optical path. This enables 
switching between the two measurement layouts without the necessity to re-align the optical 
paths. The fiber-optic probe layout enables in vivo measurements on the skin on different parts of 
the body of the patient, which was not possible with the original configuration.  
A significant problem associated with fiber-optic probes is that the laser light generates a Raman 
signal in the fiber material (usually fused silica), which is reflected at the distal end of the probe 
and re-enters the probe together with the Raman signal generated in the tissue. Often the probe 
signal is more intense than the Raman signal of interest. Technically, this unwanted signal can be 
filtered out, but this requires the used of a separate emission fiber with an optical filter at the distal 
end that transmits the laser wavelength and blocks the Raman signal generated in the probe. One 
or more collection fibers are then required to deliver the Raman signal from the tissue to the 
spectrometer. This makes the fiber-probe configuration complicated and expensive. In the past, 
we have discovered that fused silica optical fibers show negligible Raman signal in the high-
wavenumber (HWVN) Raman spectral range. This means that filtering and separation of excitation 
and signal collection fibers can be omitted, and simple and cheap fiber-optical probes with a 
single optical fiber for excitation and collection can be used.1 
In order to detect melanoma in an early stage, the equipment must collect Raman signal from the 
epidermis and superficial dermis (first 200-300 μm from skin surface), which is the depth at which 
early-stage melanoma is located.  
In this study, we have implemented the simplest probe design, a single, unfiltered optical fiber. 
The purpose of this study is to test the feasibility of the single-fiber probe for in vivo early 
melanoma diagnosis. We characterize the sampling depth of this single-fiber probe to test its 
suitability for early melanoma diagnosis. We also compare the signal quality of Raman spectra 
obtained with the fiber configuration to the Raman spectra acquired with the focused beam 
configuration.  
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Materials and Methods 
1) Raman instrumentation and signal acquisition  
Focused beam configuration for ex vivo measurements. The laser light is focused on the tissue 
by an achromatic lens (f=35 mm, NA 0.36). The Raman scattered light is collected by the same lens 
and projected onto the entrance slit of the spectrometer, which records the Raman spectra in the 
spectral range 2780 to 3750 cm-1. This instrument is described in detail in chapter 2.  
Single-fiber configuration for in vivo measurements. A single multimode fiber with a silica core 
and silica cladding (customized FG050LGA, Thorlabs Inc, Germany, NA 0.22, core diameter 50 μm, 
polypropylene inner tubing, threaded Kevlar reinforcement and black PVC outer tubing) was 
implemented in the SWIR multichannel Raman instrument. A removable adapter that can be easily 
inserted and removed from the optical path allows changing from the focused beam 
configuration to the fiber-probe configuration without realignment or changes to the existing 
optical path. A right-angle mirror (12.5 mm, Silver, Thorlabs Inc, Germany) was used to fold the 976 
nm laser light (IPS, Monmouth Junction, NJ, USA) beam towards an achromatic lens (25mm FL, NIR 
II coated, Edmund Optics, Barrington NJ, USA), which focused the laser light on the fiber. The fiber 
was inserted in a stainless-steel fiber handle to facilitate cleaning and handling of the fiber (Figure 
1). No filters or extra lenses were used at the distal end of the probe.  
Calibration. Raman spectra were corrected for the wavelength-dependent detection efficiency of 
the setup using an SRM2246 intensity standard (National Institute of Standards and Technology, 
Gaithersburg, MD).2 The absolute wavenumber axis was calibrated using the spectral lines of a 
neon−argon lamp and the Raman spectrum of cyclohexane.  
 
2) Fiber-probe characterization 
Sampling depth. To estimate the sampling depth, the fiber-optic probe was mounted in a one-
axis (vertical) micrometer stage so that its tip was positioned on top of a fused silica glass plate. At 
the initial position, the fiber tip was placed in direct contact with the silica glass, with no space 
between the glass and the fiber. A few drops of 20% Intralipid® emulsion (Fresenius Kabi BV, 
Netherlands) were put on a fused silica glass plate, around the fiber probe (Figure 2a). Intralipid® 
20% is a phospholipid micelles emulsion often used as skin phantom, to simulate the optical 
properties of the skin, including melanocytic nevi and melanoma.3,4 The fiber probe was then 
translated upwards, moving away from fused the silica glass, in steps of 20 μm (Figure 2b). 
Measurements with an integration time of 30 s were done at each position from 0 to a 500 μm 
distance to the fused silica plate. The sampling depth was then estimated as the depth at which 
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the integrated Raman signal between 2770 and 3710 cm-1 stopped increasing, i.e. the signal 
reached 95% of its maximum intensity (Figure 2c), indicating that the measurement depth is 
shorter than the distance between the fiber and the fused silica plate. 
The integrated intensity over the 2770-3710 cm-1 range was used as a measure of the signal 
intensity. The signal intensity was plotted as a function of the distance between the fiber tip and 
the silica glass to determine the sampling depth. The same experiment was repeated using water 
(as a non-scattering medium), with a step size of 50 μm. 
 
3) Raman skin measurements  
In vivo Raman spectroscopy measurements. In vivo measurements were performed on volunteers 
with benign pigmented skin lesions and on patients with skin lesions clinically suspected of 
melanoma, before surgical excision. The skin was not pre-treated in any way. Room lights were 
turned off but a LED lamp without emission in the SWIR range was left turned on during the fiber 
measurements. The fiber probe was placed on the skin lesion and approximately 15 Raman 
measurements were performed in multiple locations within the lesion. At each point, an 
integration time of 30 s was used. The in vivo measurements were approved by the Medical Ethics 
Committee of the Leiden University Medical Center (P16.315). Informed consent was obtained 
from the patients prior to the procedure. 
Ex vivo Raman spectroscopy measurements. Immediately after surgical excision, Raman 
measurements were performed as described elsewhere.5 When using the focused beam 
configuration, the excised skin lesion was enclosed in a cartridge and inserted in the focus of the 
laser beam. The laser focus was a spot with a diameter of ~6 μm. For fiber-optic probe 
measurements, the probe was placed directly on the excised skin lesion and approximately 15 
measurements were performed on different points within the pigmented region of the lesion. 
Each point measurement had an integration time of 30 s.  
4) Tissue measurement spectral pre-processing  
Signal-to-noise ratio of Raman spectra In this study, the signal-to-noise ratio (SNR) is defined as 
the ratio between the integrated signal in the CH band (2310−2350 cm-1) and the square-root of 
the sum of the integrated signal and tissue background in the same range (2310−2350 cm-1). The 
calculation of the signal-to-noise ratio was performed before background subtraction and before 
scaling. 
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Figure 1. a) Picture of the SWIR Raman spectroscopy setup; b) The removable fiber adapter enables changing 
from the focused beam configuration to the fiber-probe configuration without realignment of the existing 
optical path; c) Picture of the single fiber-optic probe with an aluminum holder. 
 
 
 
Figure 2. Graphical representation of the sampling depth measurement. a) In the initial position the fiber tip 
touches the silica glass. The grayed part in the cone of light indicates the cone of unknown length that the 
spectrometer is able to get signal from; b) the fiber probe was then translated upwards, moving away from 
fused the silica glass, in steps of 20 μm; c) The cone is fully inside the liquid, which is the point where the 
intensity of the Raman signal stops increasing. 
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Tissue luminescent background signal subtraction. The presence of luminescence background 
signal in the Raman spectra acquired from pigmented skin lesions is low due to the NIR (976 nm) 
excitation wavelength. A method described by Barroso et al. based on multiple regression fitting 
(MRF), was used for background correction. This method has been described in detail elsewhere.6  
Correction for variations in the water signal. A scaling algorithm was used to remove the 
influence of the broad water OH signal on the CH band. A reference spectrum of water was fitted 
to the spectrum, and the coefficient that best scaled the water reference spectrum to the water 
signal in the measured spectrum was determined. The water signal multiplied by this coefficient 
was then subtracted from the measured spectrum (Figure 3).  
Scaling. Each spectrum was scaled on the average of all spectra using an extended multiplicative 
signal correction (EMSC) with a zero-order polynomial background 7 after background subtraction. 
Spectra were cropped to the spectral range (2800−3050 cm−1), which corresponds to the CH-
stretching band region.  
 
Results 
Sampling depth of the fiber-optic probe. Figure Figure 4 shows the integrated intensity of the CH 
band and OH band in intralipid emulsion as a function of the distance between the fiber tip and 
the fused silica plate. The sampling depth was determined as the depth at which the signal 
intensity reached 95% of its maximum intensity, which was at 245 μm. 
 
 
 
Figure 3. Example of correction for variation in water signal. The original spectrum is plotted in red. A 
reference spectrum of water was fitted to the spectrum, and the was determined. The water signal multiplied 
by the coefficient that best scaled the water reference spectrum to the water signal (plotted in black) is 
subtracted from the measured spectrum. The result of this subtraction (final spectrum) is plotted in green.  
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Figure 5 shows the integrated intensity of water as a function of the distance between the fiber tip 
and the fused silica plate. The sampling depth was determined as the depth at which the signal 
intensity showed reached 95% of its maximum intensity, which was at 570 μm.  
SNR comparison of tissue spectra acquired with open-air focused beam configuration and with 
fiber probe. In this study, 55 excised pigmented lesions clinically suspected of melanoma were 
measured with the Raman spectroscopy instrument with the focused beam configuration. With 
the fiber probe configuration, 39 lesions were measured (21 excised lesions clinically suspected of  
 
Figure 4. Sampling depth measurements of the fiber-optic probe in a 20% intralipid emulsion. a) Raman 
spectra measured at different distances between the fiber tip and the fused silica plate; b) Integrated intensity 
(2770-3710 cm-1) of the Raman spectra depicted in (a) as a function of the distance between the fiber tip and 
the fused silica plate. 
 
Figure 5. Sampling depth measurements of the fiber-optic probe in water. a) Raman spectra measured at 
different distances between the fiber tip and the fused silica plate; b) Integrated intensity (2770-3710 cm-1) of 
the Raman spectra depicted in (a) as a function of the distance between the fiber tip and the fused silica plate. 
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melanoma and 18 benign lesions from volunteers). Figure 6 shows the distribution of the SNR 
values for spectra measured with both configurations. The average SNR of spectra measured with 
the focused beam configuration was 132.0 (SD 49.3) and the average SNR of spectra measured 
with the fiber probe was 136.7 (SD 36.4). 
 Example of in vivo Raman spectra of pigmented skin lesion. A typical example of Raman 
spectra of a pigmented skin lesion measured in vivo with the single-fiber probe is shown in Figure 
7.  
 
 
Figure 6. Distribution of SNR values of Raman spectra acquired with open-air focused beam (grey) 
configuration and acquired with the fiber probe (red). 
 
 
 
Figure 7. a) Pigmented skin lesion measured in vivo with the single-fiber probe; b) Raman spectra acquired 
using the single-fiber probe on the pigmented skin lesion depicted in a). Each spectrum had an integration 
time of 30 s.  
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Discussion 
The objectives of this study were: (1) to characterize the sampling depth of the single-fiber probe 
for early melanoma diagnosis and (2) test the compatibility of signal quality and spectral variations 
of the Raman spectra obtained with the single-fiber probe on the ex vivo classification model 
created with Raman spectra obtained with the open-air focused beam configuration.  
To measure the sampling depth of the single-fiber probe on the skin, a 20% intralipid emulsion 
was used as skin model. The sampling depth is influenced by light absorption and scattering in the 
tissue. Intralipid emulsions are often used to simulate the absorbing and scattering properties of 
skin.8-11 From Figure 4, the integrated Raman signal of the intralipid emulsion stabilizes around 245 
μm. The same experiment in water shows an integrated signal intensity stabilizing around 570 μm 
(Figure 5). The much smaller sampling depth observed in intralipid is most likely caused by the 
strong scattering properties of intralipid, which limits the acquisition of Raman signal to a more 
superficial depth. The optical properties of the intralipid® emulsion, resembles better the optical 
properties of the human skin than water does. Therefore we expect that the sampling depth in 
tissue is closer to 245 μm than to 570 μm. With respect to the envisioned application, this 
sampling depth of about 200 μm relevant because malignant melanocytes in early melanoma are 
also located in the upper 200-300 μm of the skin.  
The SNR values for spectra measured with the focused-beam configuration and with the fiber 
configuration are largely comparable. More studies are missing to determine whether the in vivo 
Raman spectra acquired with the fiber-optic configuration can be predicted using the ex vivo 
classification model.  
 
Conclusion 
In this study, we show the feasibility to acquire high-quality Raman spectra from pigmented skin 
lesions using a single-fiber probe. We conclude that the fiber-probe collects Raman signal from 
the first 245 μm from the skin surface. This sampling depth is ideal for detection of malignant 
melanocytes in the epidermis as in early-stage melanoma. Finally, the quality of the spectra 
obtained using the single-fiber probe was comparable to the quality of the spectra obtained with 
the lens setup. 
 
Future work 
For the future, a multiple fiber probe with 7 fibers developed by RiverD and Avantes will be 
implemented in the Raman instrument (Figure 8). In this multi-fiber probe, all the fibers are used 
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to transmit laser light and to collect Raman signal. This enables that an area of ~200 μm2 is probed 
at the same time in 7 different spots. The orientation of the fibers is hexagonal (one in the center 
and six around) in one end (sample side) and a linear array in the other end (to connect to the 
entrance slit of the spectrometer). This will refine the multiple point measurements assessment, 
improving the Raman sampling of the lesions. In Chapter 5, it was presented a method that uses 
multiple point measurement analysis to improve diagnosis of thin melanomas. With the 
developed method, the diagnostic model correctly classified all melanomas with a specificity of 
43.8%. This demonstrates that, based on Raman spectroscopy, an accurate diagnosis of thin 
melanomas can be made. 
 
 
Figure 8. Multifiber probe. 
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This thesis presents Raman spectroscopy as a method to characterize the molecular composition 
of cutaneous melanocytic lesions with the purpose of improving the clinical diagnosis of 
melanoma, especially thin melanomas which can be cured by surgical excision.  
Raman spectroscopy has two strong characteristics: (1) it provides discriminating information 
based on the molecular composition of the lesion and (2) it provides objective results, which are 
not influenced by the clinician’s interpretation. In the last decade a strong effort has been made 
towards clinical implementation of Raman spectroscopy (described in Chapter 6) as an adjunct 
technique for early diagnosis, biopsy guidance and oncologic surgery guidance. The most recent 
studies aim to: (1) detect pre-malignant lesions,1-6 which is one of the most effective ways to 
reduce the number of cancer cases, (2) detect cancer in less-invasive stages,1,2,7-8 (3) reduce the 
number of unnecessary biopsies,9-12 and (4) guide surgery towards complete removal of the tumor 
with adequate tumor resection margins, which reduces the need for post-operative treatment, 
decreases the aggressiveness of the post-operative treatment and increases patient survival.13-17 
However, until recent years, the application of Raman spectroscopy for the analysis of pigmented  
lesions was a major hurdle. When using visible or near-infrared laser excitation wavelengths the 
absorption of light by melanin pigment results in strong laser-induced tissue fluorescence. 
Because of this, it was difficult to obtain high-quality Raman spectra from pigmented tissues.  
The work described in this thesis shows the development of a Raman instrument that enabled the 
assessment of melanocytic lesions and the development of a method to distinguish melanoma 
from benign melanocytic nevi. The obtained results reflect the potential of Raman spectroscopy as 
an adjunct tool for the clinical diagnosis of cutaneous melanocytic lesions. Although histology is 
considered the gold standard for the diagnosis of melanoma, a recent study demonstrated that 
the accuracy and reproducibility among pathologists is far from perfect. Therefore, the 
introduction of adjuvant techniques such as Raman spectroscopy should be evaluated in an ex 
vivo setting to assist pathologist in optimal diagnosis of melanocytic lesions, especially in 
dysplastic and thin (in situ) melanoma’s.18 
For now, the intended target-users for the Raman tool are dermatologists and general 
practitioners. In the same way that dermoscopy provides detailed morphological information that 
can be used by the clinician in the decision for diagnostic excision, Raman spectroscopy provides 
information on the biochemical composition of tissue. Therefore, a Raman tool can bring added 
value after visual inspection of the lesion (including dermoscopy), as an objective, second-level 
examination tool. This thesis is divided in two parts. In the first part (Chapters 2 and 3) 
technological advances and development of instrumentation required to obtain high-quality 
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Raman signals from pigmented skin lesions are described. The second part (Chapters 4 and 5) 
describes the implementation of the developed Raman instrument in the clinic, for ex vivo 
measurements on freshly excised skin lesions that were clinically suspicious for melanoma. 
A crucial step was the shift of the excitation wavelength to the near-infrared (976 nm) and 
consequently, to detect the Raman signal in the short-wave infrared (1340-1540 cm-1) (Chapter 2). 
This shift of excitation wavelength was necessary to obtain high-quality Raman spectra from 
pigmented biological samples in short integration times compatible with clinical applications, and 
has proven successful. In measurements on over 300 lesions, tissue auto-fluorescence did not pose 
a problem even in cases of high presence of melanin. Because tissue auto-fluorescence has been a 
major technological hurdle, this opens new possibilities for Raman spectroscopy of highly 
pigmented samples in oncological applications for skin and other types of tissues (e.g. liver, 
kidney, lung). In a wider perspective, also other fields could benefit from this technology, for 
example the food industry. 
In the studies presented, we have limited the analysis of the Raman spectra to the CH stretching 
bands of the high-wavenumber spectral region (2800-3050 cm-1). The main reason was to avoid 
spectral interference by absorption bands of water, which happens to overlap with the OH-band 
of water in the Raman spectra recorded by our instrument. This thesis demonstrates that the CH 
stretching bands used in the analysis contain spectral information to discriminate melanoma from 
benign melanocytic lesions. This offers possibilities for development of a much simplified Raman 
device, which detects only a small part of the high-wavenumber spectral range. A simplified 
Raman device would promote the implementation of this technique in clinical practice 
considerably because the current settings are too costly and the measurements too cumbersome.  
Another important technological development presented in this thesis is the demonstration of 
the feasibility of a novel vertical-external-cavity surface-emitting laser (VECSEL) for Raman 
spectroscopy (Chapter 3). VECSELs offer interesting characteristics as low-cost laser sources: small 
size, narrow linewidth, high power stability, good power efficiency and a circular beam profile 
which facilitates focusing of the laser beam. Moreover, the wavelength of a VECSEL can be 
engineered over a broad range in the near-infrared, which gives flexibility for different 
requirements from specific applications. We implemented the VECSEL in the Raman instrument 
and showed, for the first time, Raman spectra of pigmented skin lesions in the SWIR region using a 
VECSEL as laser source. This demonstrated that the VECSEL fulfills the requirements of a laser 
source in a Raman application, which could eventually lead to the choice of VECSELs as the source 
of light in low-cost compact hand-held Raman devices in various applications.  
The second part of this thesis (Chapters 4 and 5) demonstrates the application of the 
developed technology for measurements on pigmented skin lesions. The lesions clinically 
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suspicious for melanoma were excised for diagnostic purpose and measured directly after 
excision. The prototype instrument was placed in a tertiary referral clinic for pigmented skin 
lesions at the Leiden University Medical Center (LUMC). In a first application study (Chapter 4), a 
total of 82 melanocytic lesions were included and the results from Raman spectroscopy were 
correlated with the histopathological diagnosis. For the purpose of this study, the samples were 
divided into histopathologically homogeneous and heterogeneous lesions. Heterogeneous 
lesions were defined as those that did not have an even distribution of histological components. In 
this study, only homogeneous lesions were included. Clear spectral differences were observed 
between melanoma and benign nevi. We discovered that melanoma had higher lipid content. The 
preliminary model resulted in a specificity of 45% at a sensitivity of 100% for melanoma, which 
was determined by leave-one sample-out cross-validation.  
However, a clinical application requires that both homogeneous and heterogeneous melanocytic 
lesions can be classified. In the next study (Chapter 5), we included heterogeneous lesions in the 
development of the diagnostic model (Chapter 5). Decision strategies were explored to diagnose a 
lesion based on multiple measurements within the lesion. The results showed that the lipid 
content was the main spectral difference between melanoma and benign nevi, which is in 
agreement with the findings from Chapter 4. The diagnostic model was validated on an 
independent data set of 50 lesions. The validation set was comprised of 10 in situ melanomas and 
7 with an average Breslow thickness of 0.42 mm. The results showed that all melanomas were 
detected (sensitivity of 100%) at a specificity of 43.8%. Because there is no international consensus 
about whether dysplastic nevi must be considered benign,18-29 dysplastic nevi were not included in 
the diagnostic model, but were separately tested. From the total 46 dysplastic nevi, 73.9% were 
classified as melanoma.  
Even though high-grade dysplastic nevi are associated to an increased melanoma risk, 19 there is 
debate about the management of this type of lesions, mainly due to lack of knowledge regarding 
dysplastic nevi epidemiology and evolution.30 A statement signed by the members of the 
Pigmented Lesion Subcommittee of the Melanoma Prevention Working Group in the United 
States of America, recommends that: (1) pigmented lesions clinically and/or dermoscopically 
suspicious for melanoma should be surgically excised; (2) clinically atypical nevi stable in 
appearance should be followed-up; (3) histologically confirmed mild and moderate dysplastic nevi 
with clear margin do not need to be re-excised, whereas in the case of positive margins, a close 
follow-up is recommended. 30 The same management is followed by the majority of Canadian 
dermatologists.31 A survey of Australian dermatologists reported that all dermatologists would re-
excise an incompletely removed severely dysplastic nevus, even though their opinion was divided 
whether to treat such a lesion as a melanoma in situ or a mild dysplastic nevus.32  
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There are indications that dysplastic nevi are associated with an increased risk of developing 
melanoma,19, 33-35 which is suggestively supported by the results shown in Chapter 5. We 
demonstrate that, based on Raman spectroscopy, an accurate diagnosis of melanoma with 
Breslow thickness <0.8 mm can be made. This work signifies an important step towards objective 
diagnosis of melanoma.  
 
Prospects 
The Raman instrument presented in this thesis was an experimental prototype. A necessary next 
step is the development of an in vivo Raman spectroscopic device which is compatible with the 
clinical workflow. This will require several technological developments, in particular with respect 
to the detector, in vivo miniature fiber-optic probes, and the lasers source.  
One of the critical aspects that needs to be solved in the field of detector technology is to decrease 
the cost of short-wave infrared (SWIR) detectors. The InGaAs imaging camera implemented in the 
instrument described in this thesis was a high-end imaging camera which had not been 
developed for spectroscopic applications. The high-end device was necessary to provide 
sensitivity and extremely low-noise characteristics required to enable high-quality Raman spectra 
in the SWIR region. At the start of the RASKIN project this detector was the only one of a few in the 
market, with sufficient specifications to meet our requirements, in particular with such interesting 
noise characteristics. However, this camera was not designed for biomedical or even spectroscopic 
applications. The fact that it needed cooling with liquid nitrogen is one illustrative example of the 
differences between the intended use and the envisioned use, as described in this thesis. Also, the 
cost of this type of detector technology is out of reach for most biomedical applications. Currently, 
cheaper solutions in the detector technology for the SWIR region with better noise characteristics 
are appearing in the market. 
The heterogeneity at a histopathological level of the melanocytic lesions presented initially as a 
major hurdle. An obvious limitation of this study is the lack of correlation between the location of 
the individual Raman measurements in the lesion with histopathology. We are currently 
developing a method for a reliable and reproducible correlation. It is expected that, when 
applying this method, the accuracy of the Raman tool for clinical diagnosis can be improved.  
To ensure the transferability into a clinical application, it is important that the Raman 
measurement volume is representative of the entire lesion and that the diagnostic result from 
Raman spectroscopy correlates with the gold standard histopathological evaluation. For further 
improvement an interesting future development would be the combination of Raman 
spectroscopy with an image-based technique. In this way, the entire lesion could be quickly 
scanned by an image-based technique to identify the most suspicious regions, which would then 
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guide the selection of locations for Raman measurements. This would help to reduce the time 
spent on Raman measurements on non-representative locations.  
The experimental prototype and the diagnostic model were developed based on melanocytic skin 
lesions suspicious for melanoma. With this model, this instrument could be used in a specialized 
dermatology clinic. To optimize the diagnostic model for different settings the current model 
needs to be expanded to include more types of suspicious skin lesions, considering the multitude 
of skin lesions that dermatologists and general practitioners can possibly encounter. In order to 
create algorithms to distinguish melanoma from many different types of skin lesions, deep-
learning algorithms would be preferable. Deep-learning algorithms for melanoma detection have 
been flourishing in the last years.36-38 Artificial intelligence algorithms require huge amounts of 
data but are strong at extracting patterns. An interesting future possibility is the use of deep-
learning algorithms to integrate Raman spectroscopic instruments with morphology-based 
techniques, in order to create powerful diagnostic models for melanoma.  
In order to validate the current instrument, it is important to be able to collect in vivo Raman data 
of pigmented skin lesions in a large clinical study. After achieving sufficient evidence to introduce 
the modality into the clinical diagnostic decision process, commercial developments can be 
initiated.  
Raman spectroscopy has proved to be a versatile and interesting technique with inherent 
advantageous characteristics that promote clinical applications. Raman spectroscopy has proven 
to be an answer to the need of an easy-to-use, real-time objective tool to improve the clinical 
diagnosis of melanocytic lesions. I believe that, in the near future, the implementation of Raman 
devices in the routine clinical diagnosis will become a reality.  
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Summary  
Cutaneous melanoma is the most aggressive and fatal form of skin malignancy. Its incidence has 
been steadily increasing in the last decades, with more than 232 000 new cases estimated 
worldwide in 2012.  
The earliest possible clinical diagnosis of melanoma is of foremost importance for a good 
prognosis for the patient. When melanoma is diagnosed at an early stage it can be cured by 
surgical excision. When diagnosed at a later stage melanoma has a considerable risk of 
progression to lethal metastatic disease. The clinical examination and diagnosis of melanoma is 
based upon visual inspection and recognition of the morphologic characteristics. This method is 
subjective and open to the interpretation of the clinicians. The clinical differentiation between 
melanoma and benign melanocytic lesions can be challenging, even for experienced 
dermatologists. Because of the low clinical diagnostic accuracy for melanoma, an objective tool is 
needed to assist the clinical assessment of skin lesions that are suspected of melanoma. Improving 
the early diagnosis of melanoma constitutes therefore an important clinical objective. 
Raman spectroscopy has shown to be a successful method to distinguish cancer from healthy 
tissue based on the analysis of the biochemical composition of tissues. However, until recent 
years, the application of Raman spectroscopy for the analysis of pigmented lesions was a major 
hurdle. When using visible or near-infrared laser excitation wavelengths, the absorption of light by 
melanin in pigmented skin lesions results in strong laser-induced tissue fluorescence. Because of 
this, it was difficult to obtain high-quality Raman spectra from pigmented tissues. The objective of 
the research described in this thesis was to develop a Raman spectroscopic instrument that 
enables the assessment of melanocytic skin lesions and to develop a method based on Raman 
spectroscopy as a non-invasive objective technique to improve the clinical diagnosis of 
melanoma.  
Chapter 2 describes the development of a multi-channel short-wave infrared (SWIR) Raman 
instrument that enables the collection of Raman signal from pigmented tissue with low 
fluorescence background. In this study, we described the implementation of a novel low-noise 
InGaAs imaging camera as a detector for Raman spectroscopy. The results show that this 
instrument could obtain high-quality high-wavenumber (HWVN) Raman spectra with low 
fluorescence background of pigmented samples, which would not be possible with CCD-based 
instruments. The feasibility of using this detector for Raman spectroscopy was demonstrated by 
fast shot-noise limited measurements of pigmented biological samples. 
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In Chapter 3 a study that investigates the feasibility of an alternative low-cost and small laser 
source developed within the RASKIN project in relation to the requirements set by this biomedical 
application is described. The vertical external-cavity surface-emitting laser (VECSEL) is 
characterized and implemented in the SWIR Raman spectroscopy instrument. VECSELs are an 
interesting alternative laser source for Raman spectroscopy. They offer a narrow linewidth, high 
power stability, good power efficiency and circular beam profile characteristics, and their 
wavelength can be engineered over a broad range in the near-infrared. In addition, they offer the 
potential of low-cost mass production, and they are small in size. For the first time, Raman spectra 
of pigmented skin lesions with a VECSEL in the SWIR region were demonstrated. The results show 
that the VECSEL fulfills the requirements of a laser source to be applied in Raman spectroscopy, 
opening the possibility of using VECSELs for low-cost compact hand-held Raman spectroscopy 
applications. 
Chapter 4 describes how the developed instrument was employed to obtain Raman 
measurements of freshly excised skin lesions clinically suspected of melanoma in the clinic. The 
main objective was to explore whether there was spectroscopic information in the high-
wavenumber range of the Raman spectra (2800−3050 cm-1) to discriminate melanoma from 
benign melanocytic lesions and what would be the main spectral differences between melanoma 
and benign melanocytic lesions. Only histopathologically homogeneous lesions were included (82 
lesions). The results showed that melanomas present increased lipid content compared to the 
benign lesions. In this study, a classification model was developed using PCA-LDA to investigate 
the discriminatory power of the CH region of HWVN Raman spectra. The model was optimized to 
discriminate melanoma from benign nevi, with a leave-one sample-out cross-validation. Our 
preliminary classification model correctly classified all melanomas (sensitivity of 100%) with a 
specificity of 45%. 
Chapter 5 describes a development of a Raman spectroscopy method to distinguish melanoma 
from clinically suspicious benign melanocytic lesions, irrespective of their histopathologically 
heterogeneity. An important aspect of the study was that the diagnostic model was validated on 
an independent data set, with both histopathologically homogeneous and heterogeneous lesions. 
The independent validation set comprised 17 melanomas (10 in situ and 7 with an average 
Breslow thickness of 0.89 mm). The diagnostic model correctly classified all melanomas (sensitivity 
of 100%) at a specificity of 43.8%. The diagnostic model for melanoma showed in this study a 
potential improvement of the number needed to treat from 6.0 to 2.7, at a sensitivity of 100%. We 
demonstrate that, based on Raman spectroscopy, an accurate diagnosis of thin melanomas can be 
made. This work signifies an important step towards an objective accurate diagnosis of melanoma.  
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Chapter 6 provides an analysis of the status of translation of Raman spectroscopy oncological 
applications into the clinics. In this chapter we defined the clinical needs and requirements, for 
different cancer types, from the clinical point of view. The problems that need to be solved in 
order to bring the technique successfully to the end-users in the hospital setting are also 
discussed.   
In Chapter 7 the first steps towards the adaptation of the SWIR multi-channel Raman 
spectroscopy instrument for in vivo measurements are presented. The feasibility of the simplest 
possible probe design, which is a single-fiber probe, for melanoma diagnosis was tested. The 
sampling depth of the fiber-optic probe was characterized. 
Finally, in Chapter 8 a general conclusion is drawn from the work developed and described in this 
thesis, as well as a discussion about the prospects of the implementation of Raman spectroscopy 
to improve the clinical diagnosis of melanoma. 
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Nederlandse samenvatting 
Het melanoom is de meest agressieve en dodelijke vorm van huidkanker. De incidentie is de 
afgelopen decennia geleidelijk toegenomen, met wereldwijd meer dan 232.000 nieuwe gevallen 
geschat in 2012. Wanneer het melanoom in een vroeg stadium wordt gediagnosticeerd, kan het 
curatief behandeld worden door middel van een chirurgische resectie. Als het melanoom in latere 
stadia gediagnosticeerd wordt, heeft het een grotere kans op metastatische ziekte met de dood 
tot gevolg. Klinisch onderzoek en de diagnose zijn gebaseerd op visuele inspectie en herkenning 
van de morfologische kenmerken. Deze methode is echter subjectief en is afhankelijk van de 
interpretatie van artsen. Daarom kan de klinische differentiatie tussen een melanoom en een 
goedaardige melanocytaire laesie uitdagend zijn, zelfs voor ervaren dermatologen. Vanwege de 
lage klinische diagnostische nauwkeurigheid van het melanoom is objectief hulpmiddel nodig om 
te assisteren bij de klinische beoordeling van voor melanoom verdachte huidlaesies is. Een 
belangrijk klinisch doel is dan ook het optimaliseren van de vroege diagnose van het melanoom. 
Raman spectroscopie blijkt een succesvolle methode te zijn om kanker te onderscheiden van 
gezond weefsel op basis van de biochemische samenstelling van een weefsel. Echter, bij het 
toepassen van Raman spectroscopie bij de analyse van gepigmenteerde biologische weefsels, 
zoals melanocytaire huidlaesies, worden enkele problemen ondervonden. Bij gebruik van 
zichtbare of kortegolf-infrarode laserexcitatiegolflengten resulteert de absorptie van licht door 
melanine in gepigmenteerde huidlaesies in een sterke, door laser geïnduceerde, 
weefselfluorescentie. Dit sterke fluorescentiesignaal maskeert het zwakkere Raman signaal, 
waardoor het moeilijk, zo niet onmogelijk, is om kwalitatief goede Raman spectra uit 
gepigmenteerde weefsels te verkrijgen. 
Het doel van het in dit proefschrift beschreven onderzoek was om een op Raman spectroscopie 
gebaseerd instrument te ontwikkelen, voor het beoordelen van melanocytaire huidlaesies. Tevens 
was het doel een methode te ontwikkelen op basis van een niet-invasieve, objectieve, op Raman 
gebaseerde techniek, de klinische diagnose van het melanoom te verbeteren. 
Hoofdstuk 2 beschrijft het ontwikkelen van een meerkanaals kortegolf-infrarood (short-wave 
infrared, SWIR)  Raman instrument, waarmee Raman signalen uit gepigmenteerde weefsels met 
een lage fluorescentie-achtergrond verzameld kunnen worden. In deze studie beschreven we de 
implementatie van een nieuwe geluidsarme InGaAs-beeldcamera die werd gebruikt als een 
spectroscopische detector. De resultaten tonen aan dat dit instrument hoogwaardige HWVN 
Raman spectra met een lage fluorescentie-achtergrond van gepigmenteerde weefsels kon 
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verkrijgen, wat niet mogelijk zou zijn met op CCD gebaseerde instrumenten. De bruikbaarheid van 
deze detector voor Raman spectroscopie werd gedemonstreerd met snelle, door schrootruis 
gelimiteerde metingen, aan gepigmenteerde biologische weefsels. 
In hoofdstuk 3 wordt een studie beschreven dat onderzoek doet naar het gebruik van een 
alternatieve goedkope en kleine laserbron die ontwikkeld is binnen het RASKIN project op basis 
van de eisen die door de toepassing gesteld werden. De karakteristieken van een vertical external-
cavity surface-emitting laser (VECSEL) zijn in kaart gebracht en vervolgens geïmplementeerd in het 
SWIR Raman spectroscopie-instrument. VECSEL's kunnen fungeren als een alternatieve laserbron 
in Raman spectroscopie. Ze bieden een smalle lijnbreedte, een hoge vermogens-stabiliteit, goede 
efficiëntie, ronde bundel profiel karakteristieken, en de golflengte kan in het kortegolf-infrarood 
spectrum over een breed bereik worden aangepast. Daarnaast zijn ze geschikt voor goedkope 
massaproductie, en zijn ze klein van formaat. Voor het eerste werd met een VECSEL Raman spectra 
van gepigmenteerde huidlaesies in het kortegolf-infrarood spectrum aangetoond. De resultaten 
van deze studie tonen aan dat de VECSEL voldoet aan de eisen van een laserbron die kan worden 
toegepast in Raman spectroscopie, waardoor er de mogelijkheid wordt gecreëerd om VECSEL's te 
gebruiken voor goedkope, compacte, draagbare Raman spectroscopische toepassingen. 
In Hoofdstuk 4 wordt omschreven hoe het reeds ontwikkelde instrument werd gebruikt om in de 
kliniek Raman metingen te verkrijgen van vers uitgesneden, op melanoom verdachte huidlaesies. 
Het voornaamste doel was om te onderzoeken of op basis van spectroscopische informatie in het 
HWN bereik van de Raman spectra (2800-3050 cm-1), het melanoom onderscheiden kon worden 
van goedaardige melanocytaire laesies. Daarnaast wilden we de belangrijkste spectrale verschillen 
tussen een melanoom en goedaardige melanocytaire laesies weergeven. In deze studie werden 
alleen de histopathologisch homogene laesies geanalyseerd. Er werden in totaal 82 met chirurgie 
verkregen laesies gemeten. De resultaten toonden aan dat de lipiden concentratie in een 
melanoom hoger is in vergelijking met de lipiden concentratie in goedaardige laesies. In deze 
studie werd een classificatiemodel ontwikkeld met behulp van PCA-LDA om het discriminerend 
vermogen van de CH-regio in HWVN Raman spectra te onderzoeken. Het model werd 
geoptimaliseerd om melanoom te onderscheiden van alle andere laesies met een leave-one-
sample-out-kruisvalidatie. Ons voorlopig classificatiemodel classificeerde alle melanomen correct 
(sensitiviteit van 100%) met een specificiteit van 45%. 
Hoofdstuk 5 beschrijft de ontwikkeling van een nauwkeurige methode om een melanoom te 
onderscheiden van goedaardige melanocytaire laesies (die aanvankelijk klinisch verdacht werden 
voor melanoom). Een belangrijk aspect van deze studie is dat het classificatiemodel werd 
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gevalideerd op een onafhankelijke dataset, met daarin zowel histopathologisch homogene als 
heterogene laesies.  
De onafhankelijke validatie set bevatte 17 melanomen (10 in situ en 7 met een gemiddelde 
Breslow dikte van 0.89 mm). Alle melanomen werden correct geclassificeerd door het diagnostisch 
model (sensitiviteit 100%) met een specificiteit van 43.8%. Bij een sensitiviteit van 100% toonde 
het diagnostisch model een verbetering van het ‘number needed to treat’ van 6 naar 2.7%. Met 
deze studie hebben we aangetoond dat we op basis van Raman spectroscopie een accurate 
diagnose kunnen stellen van melanomen met een kleine Breslow dikte. Deze studie is dan ook een 
belangrijke stap in de ontwikkeling van het stellen van een accurate diagnose van het melanoom.  
Hoofdstuk 6 biedt een analyse van de status van de translatie van Raman spectroscopie naar de 
kliniek. In dit hoofdstuk hebben we de klinische behoeften en vereisten voor verschillende 
kankertypen gedefinieerd vanuit klinisch oogpunt. De problemen die moeten worden opgelost 
om de techniek met succes naar de eindgebruikers in de ziekenhuisomgeving te vertalen, worden 
ook besproken in dit hoofdstuk. 
In hoofdstuk 7 worden de eerste aanpassing gepresenteerd die nodig zijn om het SWIR 
meerkanaals Raman spectroscopie instrument te gebruiken voor in vivo metingen. Tevens werd 
het meest eenvoudige ontwerp voor een probe (een single-fiber probe) voor melanoom diagnose 
getest. Ten slotte werd de meet-diepte van fiber-optische probe bepaald. 
Tot slot wordt in Hoofdstuk 8 de algemene conclusie van dit proefschrift omschreven en de 
discussie over de vooruitzichten voor de realisatie van Raman spectroscopie voor klinische 
diagnose van melanomen in de dermatologie uitgezet. 
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Sumário 
Melanoma é o tipo de cancro cutâneo mais agressivo e letal. A sua incidência tem vindo a 
aumentar consistentemente nas últimas décadas, com mais de 232 000 novos casos a nível 
mundial em 2012.  
O diagnóstico clínico de melanoma mais precocemente possível é da maior importância para um 
prognóstico favorável para o paciente. Quando o melanoma é diagnosticado numa fase inicial, a 
cura pode ser assegurada através de excisão cirúrgica. Contudo, se diagnosticado numa fase tardia 
há um risco considerável de progressão para uma fase metastática. O exame e o diagnóstico 
clínico de melanoma são baseados na avaliação visual da lesão e no reconhecimento das suas 
características morfológicas. Este é um método subjectivo e sujeito a interpretação por parte dos 
médicos. Desta forma, a diferenciação clínica entre melanoma e lesões melanocíticas benignas 
pode ser bastante difícil, mesmo para dermatologistas experientes. Devido à limitada precisão de 
diagnóstico clínico, existe necessidade de um equipamento objectivo que possa auxiliar a 
avaliação clinica de lesões suspeitas de melanoma. Um objectivo clínico importante é, portanto, 
melhorar o diagnóstico precoce de melanoma.   
A espectroscopia de Raman tem demonstrado ser um método bem sucedido para discriminar 
tecidos cancerosos de tecidos saudáveis, através da análise da composição bioquímica dos 
mesmos. Contudo, existe um obstáculo à aplicação da espectroscopia de Raman na análise de 
amostras biológicas pigmentadas. Ao usar lasers com emissão de comprimento de onda na gama 
visível ou infravermelho próximo em lesões cutâneas pigmentadas, a absorção de luz pelo 
pigmento melanina origina uma forte auto-fluorescência no tecido. Essa fluorescência é intensa e 
dissimula o ténue sinal de Raman tornando difícil, senão impossível, obter espectros Raman de 
alta qualidade a partir de tecidos pigmentados.  
O objetivo do trabalho descrito nesta tese foi desenvolver um instrumento de espectroscopia de 
Raman que permitisse a avaliação de lesões cutâneas melanocíticas e desenvolver um método 
baseado na espectroscopia de Raman como técnica objetiva e não-invasiva para melhorar o 
diagnóstico clínico de melanoma. 
O Capítulo 2 descreve o desenvolvimento de um equipamento de espectroscopia de Raman 
multicanal que opera na região de infravermelho e que permite a aquisição de sinal Raman a partir 
de tecidos pigmentados com baixo nível de fluorescência. Neste estudo, descrevemos a 
implementação de uma câmara de imagem InGaAs de baixo ruído como um detector para 
espectroscopia de Raman. Os resultados mostram que com este instrumento é possível adquirir 
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espectros de amostras pigmentadas com elevada qualidade e com um baixo nível de 
fluorescência, o que não seria possível com instrumentos com detectores CCD (charge-coupled 
devices). A viabilidade de utilizar este detector para espectroscopia de Raman foi demonstrada 
pela capacidade em adquirir sinais limitados apenas por ruído shot em amostras biológicas 
pigmentadas e num curto tempo de aquisição. 
No Capítulo 3 é descrito um estudo que investiga a viabilidade de uma alternativa fonte laser de 
baixo-custo e compacta desenvolvida no âmbito do projeto RASKIN tendo em conta os requisitos 
estabelecidos pela nossa aplicação biomédica. Um laser Vertical External-cavity Surface-emitting 
laser (VECSEL) foi caracterizado e implementado no instrumento de espectroscopia de Raman 
desenvolvido. Os VECSELs são uma fonte laser alternativa interessante para a espectroscopia de 
Raman. Eles oferecem uma largura espectral estreita, elevada estabilidade de potência, boa 
eficiência energética e características de perfil de feixe circular. O seu comprimento de onda pode 
ser seleccionado numa ampla faixa de comprimentos de onda na região do infravermelho. Além 
disso, eles oferecem o potencial de baixo custo quando produzidos em larga escala, e são de 
tamanho compacto. Foram demonstrados, pela primeira vez, espectros Raman de lesões de pele 
pigmentadas obtidos a partir de um VECSEL. Os resultados mostram que o VECSEL cumpre os 
requisitos de uma fonte laser a ser aplicada em espectroscopia de Raman, abrindo a possibilidade 
de implementar VECSELs em aplicações de espectroscopia de Raman portáveis e de baixo custo. 
O Capítulo 4 descreve como este instrumento de espectroscopia de Raman desenvolvido foi 
utilizado numa clínica dermatológica para obter medições Raman de lesões de pele recém 
excisadas, clinicamente suspeitas de melanoma. O principal objetivo foi explorar a existência de 
informação espectroscópica na gama high-wavenumber (HWVN) do sinal Raman (2800-3050 cm-1) 
para discriminar melanoma de lesões melanocíticas benignas e quais seriam as principais 
diferenças espectrais. Apenas lesões homogéneas a nível histopatológico foram incluídas neste 
estudo (82 lesões). Os resultados mostraram que os melanomas apresentam uma maior 
contribuição de lípidos em comparação com as lesões benignas. Neste estudo, um modelo de 
classificação usando principal component analysis- linear discriminant analysis (PCA-LDA) foi 
desenvolvido para investigar o poder discriminatório da região CH da gama HWVN dos espectros 
Raman. O modelo foi optimizado para discriminar melanoma das lesões benignas incluídas na 
análise. O nosso modelo preliminar classificou correctamente todos os melanomas (sensibilidade 
de 100%) com uma especificidade de 45%, obtido através de uma validação cruzada leave-one-
sample-out. 
O Capítulo 5 descreve o desenvolvimento de um método para a discriminação entre melanomas 
e lesões melanocíticas benignas clinicamente suspeitas, irrespectivamente da sua 
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heterogeneidade a nível histopatológico. Um aspecto importante deste estudo é que o modelo de 
classificação foi validado num conjunto de dados independente, tanto com lesões homogéneas 
como heterogéneas a nível histopatológico. O conjunto de dados independente conteve 17 
melanomas (10 in situ e 7 com uma espessura média de 0.89 mm). O modelo de diagnóstico 
classificou correctamente todos os melanomas (100% de sensibilidade) para uma especificidade 
de 43.8%.  O modelo de diagnóstico mostrou uma potencial melhoria do número necessário para 
tratar de 6.0 para 2.7, com uma sensibilidade de 100%. Foi demonstrado que, através de 
espectroscopia de Raman, é possível realizar um diagnóstico preciso de melanomas em estágio 
inicial. Este trabalho representa um importante passo com vista a um diagnóstico objectivo e 
preciso de melanoma. 
O capítulo 6 fornece uma análise do estado da transferência de aplicações oncológicas baseadas 
em espectroscopia de Raman para a prática clínica. Neste capítulo, definimos as necessidades 
clínicas e os requisitos, para diferentes tipos de cancro, do ponto de vista clínico. Também são 
discutidos os problemas que precisam ser ultrapassados para levar a técnica com sucesso aos 
utilizadores finais em ambiente hospitalar.  
No Capítulo 7, são apresentados os primeiros passos para a adaptação do instrumento de 
espectroscopia Raman SWIR para medições in vivo. Foi testada a viabilidade para o diagnóstico de 
melanoma de uma sonda de fibra óptica mais simples possível, uma sonda de fibra única. A 
profundidade de amostragem da sonda de fibra óptica foi caracterizada. 
Finalmente, no Capítulo 8, é extraída uma conclusão geral do trabalho desenvolvido e descrito 
nesta tese, bem como uma discussão sobre as perspectivas futuras para a implementação da 
espectroscopia de Raman com vista a melhoria do diagnóstico clínico de melanoma. 
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List of Abbreviations 
AUC area under the curve 
ADU analog-to-digital converter units 
BCC basal cell carcinoma 
CCD charge coupled device 
CH carbon-hydrogen 
CRC colorectal cancer 
CSD chronic sun damage 
CW continuous wave 
DBR distributed Bragg reflector 
DCIS ductal carcinoma in situ 
DNA deoxyribonucleic acid 
EMSC extended multiplicative signal correction 
EPIC European Photonics Industry Consortium 
FDA Food and Drug Administration 
FN false negatives 
FNAC fine-needle aspiration cytology 
FP false positives 
FT Fourier-transform 
H&E hematoxylin and eosin stain 
HWVN high-wavenumber  
InGaAs indium gallium arsenide 
LDA Linear discriminant analysis 
LED light-emitting diode 
LUMC Leiden University Medical Center 
OH oxygen-hydrogen 
MAPK mitogen-activated protein kinase 
MMS Mohs micrographic surgery 
MRF multiple regression fitting 
MRI magnetic resonance imaging 
NA numerical aperture 
NaCl sodium chloride 
NH nitrogen-hydrogen 
NIR near-infrared 
NIST National Institute of Standards and Technology 
NNT  number needed to treat 
NVB neurovascular bundles 
OCSCC oral cavity squamous cell carcinoma 
OCT optical coherence tomography 
OD optical density 
OLK oral leukoplakia 
OSCC oral squamous cell carcinoma 
OSMF oral submucosa fibrosis 
PAP Papanicolau test 
PCA principal component analysis 
QW quantum well 
R&D research and development 
ROC receiver operator characteristic 
RNA ribonucleic acid 
RR resonance Raman 
RS Raman spectroscopy 
RWI read-while-integrate 
SCC squamous cell carcinoma 
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SD standard deviation 
SERS surface enhanced Raman spectroscopy 
SNR signal-to-noise ratio 
SRM standard reference material 
SSM superficial spreading melanoma 
SWIR short-wave infrared 
TEM transverse electromagnetic  
TP true positives 
TRL technology readiness levels 
TUR transurethral resection 
TURBT transurethral resection of bladder tumors 
UV ultraviolet 
VCSEL vertical-cavity surface-emitting laser 
VECSEL vertical-external-cavity surface emitting laser 
WHO World Health Organization 
WLR white light reflectance 
 
 

